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Epilepsy is especially prevalent in low- and middle-income countries, including those in 
sub-Saharan Africa (SSA).  There are few case-controlled data on epilepsy from SSA, where 
epilepsy remains largely untreated and highly stigmatized. 
Aims 
To determine the prevalence of active epilepsy among adults in a rural population in 
northern Tanzania.  To describe the pattern of disease and quantify the epilepsy 
treatment gap (ETG) in this population. 
Methods 
People with epilepsy (PWE) were identified through door-to-door screening of the adult 
study population (n=103,026) using a previously validated screening questionnaire.  
Controls were recruited from the background population.  Odds ratios for risk factors and 
impacts of epilepsy were calculated using logistic regression.  The burden of 
neurocysticercosis (NCC) was assessed using neuro-imaging in cases and serology.  The 
ETG was estimated according to self-reported antiepileptic drug use. 
Results 
We identified 291 PWE along with 182 controls.  The age-standardised prevalence of 
active epilepsy was 2.91/1,000.  All PWE had convulsive epilepsy, 71.5% being of focal 
onset.  Risk factors for epilepsy were a positive family history (OR 29.0), febrile 
convulsions in childhood (OR 20.4) and obstetric complications (OR 3.4).  Eight cases had 
NCC; six cases and no controls had antibodies to Taenia solium (p=0.036).  PWE were less 
likely to have completed primary education (OR 0.3) and were more likely to be divorced 
or separated (OR 7.7).  The ETG was 68.4%. 
Conclusions 
This is one of the largest community-based studies of epilepsy from SSA to date.  The large 
proportion of focal-onset epilepsy suggests a considerable burden of acquired epilepsy.  
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Chapter 1.  Introduction 
1.1 Introduction to the thesis 
This thesis describes a large community-based epidemiological study of epilepsy 
conducted in a rural district of northern Tanzania, East Africa.  The study consists of two 
main components: a door-to-door screening survey to establish the prevalence of active 
epilepsy within the study population, and the comparison of cases with controls to 
identify the clinical and socio-economic associations with epilepsy in this population.  
Complementary studies of adult and paediatric populations were conducted in parallel.  
This thesis describes the adult study; details of the paediatric study can be found in the 
published literature (Mushi et al., 2012, Burton et al., 2012a, Burton et al., 2012b, Burton 
et al., 2011).  To the best of our knowledge, these are the first studies to have specifically 
investigated the problem of epilepsy in this population. 
The various elements of the adult study are presented here in nine chapters which 
collectively provide the background, methods, results and discussion of the different 
research activities.  Each chapter has been written, as far as possible, to be self-
explanatory within the context of the thesis as a whole. 
After briefly summarising the contents of the thesis the remainder of this introductory 
chapter will define the key terms and concepts which are used throughout and describe 
the epidemiological context and historical background to the study.  As this study is 
concerned with the prevalence of epilepsy in a Tanzanian population, along with 
associated findings on phenotype, risk factors and  epilepsy treatment gap (ETG), these 
aspects are explored with reference to other work done in sub-Saharan Africa (SSA) in 
general, and Tanzania in particular.  As the literature from this region remains relatively 
limited in quantity, and yet heterogeneous in scope, a narrative rather than systematic 
approach was adopted in writing this review.  Initial literature searches using Medline 
were conducted using the following search terms: epilepsy, epidemiology, prevalence, 
treatment gap, Africa, sub Saharan Africa, Tanzania.  Citations published in English were 
retrieved and reference lists were scrutinised for any further relevant or useful citations.  
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Initial searches were repeated following completion of data collection and analysis in 
order to bring the review up to date at the time of writing the final thesis. 
The second chapter, on methods, gives an overview of the general approaches employed 
in the study.  More specific details, where appropriate, are given in the individual chapters 
which follow.  The principal objective of the methods chapter is to provide details of the 
demographic surveillance site (DSS) in which the study was conducted.   
The third and fourth chapters describe in more detail the screening methodology and its 
development, the pilot study, and the results of the main prevalence survey.  The clinical, 
demographic and socio-economic features of the cases identified during the screening 
survey are presented in Chapter Five. 
Chapter Six describes the recruitment of controls, and the results of comparisons with 
cases of epilepsy; data collected from cases and controls to specifically examine the issue 
of neurocysticercosis (NCC) in this population are presented in Chapter Seven. 
Details of the current situation with regards to treatment of epilepsy in this population 
along with an estimate of the ETG are presented in Chapter Eight. 
A final brief summary chapter reprises the key findings of the study and presents 
suggestions for future work. 
Details of questionnaires used during field work, ethical approval, consent forms and 
related publications are given in the appendices.  References and are provided at the end 




1.2 Context of the study: epilepsy in low income countries 
Epilepsy is one of the commonest neurological disorders.  It affects up to 65 million people 
worldwide(Ngugi et al., 2010) and accounts for up to 1% of the global burden of disease 
(WHO, 2005).  An estimated 80% of people with epilepsy (PWE) live in low- or middle-
income countries (LMICs)(Diop et al., 2003).  While it is generally believed that the 
incidence, prevalence and mortality associated with epilepsy are higher in LMICs 
compared with high-income countries (HICs), there have been relatively few large, cross-
sectional community-based studies to verify this (Ngugi et al., 2010).  Estimates have 
varied widely and it is often difficult to compare findings from different studies due to 
differing inclusion criteria, clinical definitions and the difficulties associated with 
establishing reliable baseline demographic data in resource-limited settings.  This is 
especially true of countries in SSA, including Tanzania. 
While the risk factors for developing epilepsy will vary from region to region, detailed 
observations from populations in LMICs, including data derived from case-control studies, 
are lacking (Edwards et al., 2008, Preux and Druet-Cabanac, 2005).  It is postulated that in 
SSA acquired brain injuries, through trauma, infections of the central nervous system 
(CNS) and perinatal or intrauterine insults, are likely to contribute to the increased burden 
of epilepsy observed in this region (Preux and Druet-Cabanac, 2005). 
With regards to incidence, a recent meta-analysis identified nine studies from LMICs, out 
of 33 studies in total, in which the incidence of epilepsy ranged from 49 to 
215/100,000/year (Ngugi et al., 2011).  The incidence in LMICs was estimated to be 
approximately twice that in HICs (81.7 vs. 45.0/100,000/year), reproducing findings from a 
systematic review of almost a decade previously (Kotsopoulos et al., 2002).  In this review 
of 40 studies, the median incidence in LMICs was 68.7/100,000/year compared to 
43.4/100,000/year in HICs.  Both studies postulate that higher incidences of head injury 
and CNS infection may explain these differences, and the latter of these reviews 
comments that the observed heterogeneity between studies was not explained by 
methodology and sampling variation alone, and that differences between risk factors 
locally were likely to play a significant role. 
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The costs and logistical challenges associated with collecting the longitudinal data 
required to estimate the incidence of a condition within a population are considerable.  
For rare conditions there will also be a lack of familiarity with clinical features among 
health providers to whom new cases may present.  In resource-limited settings a paucity 
of such services and of data-collection systems will make reliable data capture highly 
problematic.  In populations where a demographic surveillance system (DSS) is 
established, repeated point prevalence estimates over time, coupled with longitudinal 
tracking of immigration and emigration into and out of the surveillance area along with 
reliable birth and mortality data would be required.  Such undertakings have major cost 
and human resource implications, hence incidence data being relatively scarce from such 
settings (Ngugi et al., 2011). 
There are considerably more data on the prevalence of epilepsy from all regions of the 
world, including SSA, although the number of large-scale community-based studies that 
benefit from reliable baseline demographic data from this region is more limited.  A recent 
meta-analysis of the burden of epilepsy in terms of lifetime prevalence and active 
prevalence identified 34 studies from LMICs, of which only six were from SSA (Ngugi et al., 
2010).  The median lifetime prevalence (i.e. ever having suffered from epilepsy) in LMICs 
was 15.4/1,000 in rural areas and 10.3/1,000 in urban studies.  These figures are 
comparable to the median prevalence of 15/1,000 reported in a review of studies 
specifically from SSA (Preux and Druet-Cabanac, 2005),and higher than the median 
prevalence of 5.8/1,000 in studies from HICs.  As with incidence, the issue of 
heterogeneity between studies was addressed, and the higher prevalence of both lifetime 
and active epilepsy in LMICs was associated with studies conducted in rural populations 
and smaller study populations (Ngugi et al., 2011). 
While the prevalence of epilepsy is higher in LMICs than HICs, estimates available for 
incidence suggest that it should be higher still (Scott RA et al., 2001, Tomson, 2006).  This 
discrepancy may be due to excess mortality or to spontaneous remission.  The mortality 
rate suffered by PWE in developed countries is two to three times higher than in the 
general population, with standardised mortality ratios (SMRs) for epilepsy reported at 
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between 1.6 and 3.0 (Forsgren et al., 2005b).  These figures are higher in people with 
symptomatic epilepsy (i.e. epilepsy secondary to an acquired brain lesion, SMR 2.2 to 6.5), 
and are highest in people with neurological deficits present from birth (SMR 7.0 to 50.0).  
Such data are generated through longitudinal studies, which are particularly difficult to 
perform in LMICs, where the necessary infrastructure is often lacking; death certificates 
are unreliable or often unavailable altogether, rendering the cause of death difficult to 
ascertain (Carpio et al., 2005).  While there is consequently a general paucity of data on 
mortality in epilepsy from these regions, the data that do exist support the assumption 
that mortality is higher than in HICs.  In rural China, for example, the SMR for people with 
convulsive epilepsy has been estimated at 3.9 to 4.9, with seizure-related accidents and 
drowning being particularly implicated (Mu et al., 2011, Ding et al., 2006).  Data on 
mortality are particularly lacking from SSA (Diop et al., 2003).  Only one study, from 
Uganda, has formally reported SMRs, providing an estimate of 7.2 based on 18 deaths 
among 51 PWE who were followed up over a period of seven years (Kaiser et al., 2007).  A 
retrospective follow-up of 164 PWE in Tanzania initially identified 30 years previously 
found that 67.1% had died, which was approximately twice the expected number based 
on contemporaneous actuarial estimates (Jilek-Aall and Rwiza, 1992).  As with more 
recent data from China, more than 50% of these deaths were considered to be epilepsy-
related, including status epilepticus (SE), drowning, burns, and dying during or 
immediately after a seizure. 
Ascertaining the influence of remission, either spontaneous or treatment-induced, on the 
prevalence of epilepsy in a given population is difficult.  Recurrent remissions and relapses 
may occur within the same individual, and quantification with standard survival 
techniques is not possible (Berg et al., 2004).  It is also difficult to discern whether cases 
who remain seizure-free after withdrawal of anti-epileptic medication would actually have 
entered remission spontaneously (Kwan and Sander, 2004).  Longitudinal follow-up of an 
untreated population of PWE in Bolivia over a 10 year period suggested that up to 40% of 
cases may enter spontaneous remission, with generalised tonic-clonic seizures being a 
favourable prognostic factor (Nicoletti et al., 2009).  To the best of our knowledge, similar 
formal longitudinal data from SSA are not currently available. 
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With regards to aetiology, epilepsy may broadly speaking be genetic or acquired 
(symptomatic).  The risk factors of traumatic brain injury and CNS infection, which have a 
higher incidence in LMICs, are likely to account for the higher incidence and prevalence of 
epilepsy seen in these countries, particularly in SSA (Preux and Druet-Cabanac, 2005).  The 
particular role of these factors may also explain the differences in age of onset observed 
between HICs and LMICs, with the bi-modal curve (higher incidences in childhood and in 
later life) seen in HICs being replaced by a generally higher incidence and prevalence in 
older children and young adults in LMICs (Hesdorffer et al., 2011, Edwards et al., 2008, 
Ngugi et al., 2010, Ngugi et al., 2011). 
While seizures are recognised as an acute presentation complicating febrile illnesses in 
children in all populations, the high incidence and sub-optimal management of febrile 
seizures in early childhood in SSA have been postulated as risk factors in early life 
contributing to higher rates of epilepsy in this region (Newton, 2009).  High rates of 
obstetric complications have also been implicated (Burton et al., 2012a).  With regards to 
infectious risk factors in later life, epilepsy as a sequela of a variety of specific CNS 
infections has been extensively studied in LMIC populations, including neurocysticercosis 
(NCC), cerebral malaria secondary to Plasmodium falciparum, bacterial meningitis and 
encephalitis (Singh and Prabhakar, 2008, Garcia and Del Brutto, 2005, Birbeck et al., 2010, 
Singhi, 2011). 
Epilepsy can carry a good prognosis, given access to appropriate anti-epileptic drug (AED) 
therapy, with up to 78% of cases becoming seizure-free for two years within five years of 
initiating treatment (Perucca et al., 2000).  This finding holds true of epilepsy due to 
acquired brain insults, which is considered to account for a considerable amount of the 
burden of epilepsy in LMICs; it is also true with regards to treatment with older (and 
cheaper) AEDs, including phenobarbital (PB), phenytoin (PHT), carbamazepine (CBZ) and 
sodium valproate (SV), some or all of which are generally available in LMICs.  The annual 
cost of treatment with PB for an adult with epilepsy may be as low as five US dollars 
(USD), and mathematical modelling has suggested that if availability of AEDs such as PB 
could be increased to 50% of active cases, 1,360 disability-adjusted life years (DALYs) per 
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million population in SSA could be saved (Chisholm and Saxena, 2012).  In many parts of 
the developing world, however, a low degree of awareness regarding correct 
management coupled with high levels of poverty, illiteracy and stigma mean that the 
epilepsy remains largely untreated (Radhakrishnan, 2009), and while up to four-fifths of 
the potential market for AEDs is in LMICs, 90% or more of PWE in these countries may 
receive no treatment at all (Kale, 2002, Scott et al., 2001, Meinardi et al., 2001).  The 
proportion of cases requiring treatment but who are not receiving it is known as the 
epilepsy treatment gap (ETG), and this has frequently been estimated at above 80 to 90% 
in SSA (Meyer et al., 2010). 
Epilepsy also remains a highly stigmatised condition worldwide with this being particularly 
the case in SSA (Baskind and Birbeck, 2005b).  PWE in these countries may be excluded 
from school, work and marriage, with both felt and enacted stigma serving as barriers to 
treatment above and beyond any social or financial constraints (Mushi et al., 2010). 
1.3 Fundamental concepts and definitions 
Epilepsy is one of the oldest diseases known to Man, with descriptions of phenomena 
corresponding to epilepsy or epileptic seizures appearing in Babylonian, Chinese and 
Indian texts dating as far back as 1,000 years BC (Eadie and Bladin, 2001, Temkin, 1994).  
While medical historians argue that clear descriptions of distinct seizure types appear in 
some of these ancient writings, our current understanding of epilepsy rests on concepts 
first articulated by Hughlings Jackson in the late 19th Century which distinguish isolated 
epileptic seizures from the abnormal state of the brain and body that gives rise to 
recurrent epileptic episodes (Eadie and Bladin, 2001). 
1.3.1 Epileptic seizures 
An epileptic seizure is the clinically recognisable manifestation of a paroxysmal 
disturbance of brain function originating either in the grey matter of the cerebral cortex or 
in certain parts of the thalamus and upper brain stem.  The electro-chemical events which 
initiate epileptic seizures arise in or near neurones in these structures; seizures develop 
when groups of structurally and functionally interconnected neurones act collectively, 
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suddenly, briefly, excessively, and in a way that serves to disrupt the overall functioning of 
localised groups of neurones or of the brain as a whole (Fisher et al., 2005).  Depending on 
the normal functions of the neurones involved, a seizure will therefore be manifested as 
some involuntary alteration in brain function in the affected individual.  This alteration 
may involve any one aspect of normal brain function, including consciousness, behaviour, 
thought, speech, movement, sensation, or any combination of these (Eadie and Bladin, 
2001, Commission on Epidemiology and Prognosis, 1993).  Epileptic discharges may arise 
de novo, within particular groups of neurones because of an inherited abnormality present 
in them(Gutierrez-Delicado E, 2004) or because their biochemical environment is altered 
by acute systemic illness, toxicity or neurological insults (Banerjeea et al., 2009). 
1.3.2 Epilepsy 
The diagnosis of epilepsy is reserved for the state characterised by the spontaneous 
recurrence of epileptic seizures, as opposed to provoked seizures or psychogenic attacks 
(Sander and Shorvon, 1996, Banerjeea et al., 2009).  Distinguishing isolated from 
spontaneously recurrent seizures is important on clinical grounds, when considering 
aetiology and treatment, and on epidemiological grounds, when considering the incidence 
and prevalence of seizure disorders.  Up to 5% of individuals in the general population will 
experience an epileptic seizure at some point during their life, but only a small proportion 
of these will go on to have recurrent seizures (Sander, 2003, Bell GS and Sander JW, 2001).  
Similarly, provoked epileptic seizures may be seen in various clinical contexts, including 
metabolic and biochemical disturbances (e.g. hypoglycaemia or hyponatraemia), acute 
neurological insults (e.g. traumatic brain injury, brain ischaemia or infarct) and 
inflammatory processes affecting the brain (e.g. vasculitides, infective processes 
associated with local inflammation and swelling, or generalised encephalitis).  In such 
cases the risk of spontaneous recurrence of seizures in the future, and hence a diagnosis 
of epilepsy, will depend on the site and nature of the acute pathology. 
The diagnosis of epilepsy therefore remains essentially clinical, and should be based on a 
thorough history of the clinical episodes in question supported by an eye-witness account 
wherever possible.  While the measurement of various blood markers may be important 
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in identifying when seizures are due to acute biochemical or metabolic disturbances, and 
neuro-imaging with computed tomography (CT) or magnetic resonance imaging (MRI) may 
play a role in diagnosing or excluding intracerebral pathology that may trigger seizures 
acutely, electroencephalography (EEG) should only be used to support or further 
characterise a clinical diagnosis of epilepsy (Smith, 2002).  Once a clinical diagnosis is 
made, EEG recording and neuro-imaging may offer useful information when classifying 
seizures according to seizure type or epilepsy syndrome (Berg et al., 2010). 
1.3.3 Classification of seizures and epilepsies 
Various schemes for the diagnosis and classification of epileptic seizures and epileptic 
syndromes have been proposed over the past four decades.  These have been developed 
largely under the auspices of the International League Against Epilepsy (ILAE) in 
consultation with the international community of practitioners of clinical epileptology 
(Gastaut, 1970, Commission on Classification and Terminology of the International League 
Against Epilepsy, 1981, Commission on Classification and Terminology of the International 
League Against Epilepsy, 1989, Engel, 2001, Engel, 2006, Berg et al., 2010).  When 
considering seizure type, the primary criterion used in these schemes has been the site of 
epileptogenesis, the secondary criterion being a phenomenological description of the 
clinical manifestations of seizures.  According to the primary criterion, there are three 
main groups of seizure types: generalised seizures, focal seizures, and seizures of 
unknown origin. 
The most recently revised classification encompasses both seizure types and epileptic 
syndromes (Berg et al., 2010).  With regards to partial seizures, it is now recommended 
that these are no longer described as either complex or simple (i.e. with or without 
impairment of consciousness), but simply as ‘focal’, with an accompanying description of 
seizure features drawn from the ILAE-endorsed glossary of descriptive terminology for 
seizures (Blume et al., 2001).  This resource encompasses suggestions made by Luders et 
al who provided a scheme for a purely semiological classification (Lüders et al., 1998), with 
seizures being described according to their interference with four “spheres”: sensorial, 
consciousness, autonomic and motor. 
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Frequently occurring patterns of seizure disorder in persons who suffer recurrent epileptic 
seizures are designated as epileptic syndromes or ‘epilepsies’.  As with its classification of 
seizures, the ILAE has also developed and refined a classification of the epilepsies 
(Commission on Classification and Terminology of the International League Against 
Epilepsy, 1989, Engel, 2001, Engel, 2006, Berg et al., 2010).  This syndromic classification 
was initially built upon the concept of the clinical seizure type, with localisation-related 
epilepsies (i.e. focal seizure types) and generalised epilepsies being divided into idiopathic, 
symptomatic and cryptogenic varieties (Commission on Classification and Terminology of 
the International League Against Epilepsy, 1989).  Under this classification idiopathic 
epilepsies were synonymous with inherited syndromes and cryptogenic epilepsies were 
presumed, although not proven, to be symptomatic of some acquired pathology.  In 
addition to focal and generalised epilepsies a further category of situation-related seizures 
was proposed; this included febrile convulsions, isolated seizures, and seizures 
precipitated by acute metabolic or toxic disturbances.  The most recent revision of this 
system replaces the terms “idiopathic”,” symptomatic” and “cryptogenic” with “genetic”, 
“structural/metabolic”, and “unknown cause”(Berg et al., 2010).  Genetic epilepsies are 
the direct result of known or presumed genetic defects in which seizures are one of the 
symptoms of the disorder.  Epilepsies previously described as “idiopathic” are now 
included in this group.  “Structural/metabolic” epilepsies arise where there is a distinct 
structural or metabolic disease which is associated with recurrent seizures.  Structural 
lesions may be acquired (e.g. stroke, trauma, infection), or genetic or congenital in origin 
(e.g. tuberous sclerosis, anomalies of cortical development).  Epilepsies previously 
described as “symptomatic” are now included in this group.  The term “unknown cause” is 
intended to be viewed neutrally, encompassing epilepsies that may ultimately fall under 
either “genetic” or “structural/metabolic”; epilepsies previously termed “cryptogenic” are 




1.3.4 Classification of epilepsy in low income countries 
The classification of seizure disorders encountered in LMICs is difficult.  In many of these 
countries the diagnostic tools of cerebral imaging and EEG are simply not available in most 
clinical settings.  For this reason there has been recent interest in developing alternative 
systems of classification that may be of more pragmatic use in settings where clinical 
resources are limited (Birbeck, 2012).  Winkler et al have developed a pragmatically 
adjusted clinical classification of seizures for use in rural Africa (Winkler et al., 2008b).  
This scheme proposes that patients with no obvious focal onset and no evidence of diffuse 
brain damage should be classified according to age at presentation, with those presenting 
before six years or after 25 years warranting further investigation where available.  For the 
remainder, those with seizures of clear focal onset or with focal neurology should similarly 
be investigated further if possible.  The authors argue that this approach will help to focus 
any further investigations on those patients most likely to have underlying brain pathology 
which may be progressive and which may therefore benefit from specific management 
beyond controlling seizures with AEDs.  Similarly, those patients with diffuse, fixed brain 
damage are known to present special challenges with regards to treatment and follow-up 
and may be accorded special attention when planning their management.  This system has 




1.3.5 Summary of basic concepts 
Any meaningful discussion of literature pertaining to epilepsy will depend on a clear and 
concise application of the concepts summarised above.  When comparing populations and 
study findings it is important to clearly define which definitions are being used, and 
difficulties may arise when considering clinical and epidemiological studies which may 
have been performed at different times, using differing descriptive terms and inclusion 




Any clinical event, provoked or spontaneous, that results from a 
paroxysmal disturbance of brain function originating in the grey 
matter of the cerebral cortex or related structures. 
 
Epilepsy The tendency to suffer recurrent spontaneous (i.e. unprovoked) 





A seizure in which both cerebral hemispheres are involved from 
the onset of each seizure.  Primary generalised seizures are largely 




A seizure arising in a localised neuronal group in one cerebral 
hemisphere.  This definition includes seizures previously referred 
to as simple partial and complex partial.  Epilepsy characterised by 
focal seizures often arises as a result of an acquired brain insult, 





A seizure which has a focal origin, but which then progresses to 
involve both cerebral hemispheres as a whole.  Epilepsy 
characterised by secondarily generalised seizures would still be 
considered as focal. 
 
Ref: Thurman et al., 2011, Berg et al., 2010 
 





1.4 Epidemiology of the epilepsies 
Epidemiology is the study of the dynamics of health and disease in terms of their 
distribution, determinants and effects in any given population.  The epidemiology of any 
particular condition will take into account clinical data on its presentation and natural 
history along with the socio-demographic context of the disease within the study 
population.  The epidemiology of epilepsy is based largely on descriptive and analytical 
studies, comprised either purely of clinical observations in PWE, or of attempts to 
establish associations and determinants of the disease through comparison between 
individuals with epilepsy and those without (Sander, 2003). 
As discussed above, epilepsy is a heterogeneous set of disorders: aetiologies and risk 
factors vary with age and geographic location, and the differential diagnosis of epilepsy 
encompasses all causes of transient alteration or impairment of consciousness.  
Consequently, case ascertainment and diagnostic accuracy represent major challenges to 
the epidemiology of epilepsy.  The majority of PWE do not have permanent physical signs 
and can be diagnosed only by taking a clinical history.  The extent of investigation that is 
possible in different settings varies widely, and the use of terms such as idiopathic, 
cryptogenic and generalised are often confused (Sander, 2003, Winkler et al., 2008b).  All 
these factors should be borne in mind when comparing findings from different studies and 
study populations. 
1.4.1 Methods used in low-income countries for studies of epilepsy 
In HICs the most common published method of case ascertainment is a review of medical 
records, usually supplemented by interviews with positively identified cases (Shorvon and 
Farmer, 1988).  Medical records in LMICs are generally much less complete, and this 
method is generally not appropriate for any comprehensive surveys in regions such as 
SSA.  Other inherent disadvantages of this approach are that those who are incorrectly 
diagnosed, those who have not sought medical attention for their symptoms and those 
whose records are not retrieved may be excluded from epidemiological estimates. 
Door-to-door studies involve either the direct or indirect contact of all subjects in a 
sample population, with assessment of all subjects for the relevant disorder.  The main 
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advantage of this approach is the identification of cases that have yet to seek medical 
attention, and in the case of epilepsy such individuals may represent a significant 
proportion of the affected population, particularly in LMICs (Mbuba and Newton, 2009, 
Mbuba et al., 2012b, Mbuba CK et al., 2008, Ngugi et al., 2013a, Mushi D et al., 2010, 
Birbeck, 2000c, Meinardi H et al., 2001). 
Studies of this type in LMICs may be hampered by a lack of accurate diagnostic data, 
however, with the number of physicians with expertise in clinical neurology working in 
these countries being limited (Schoenberg, 1982).  According to the World Health 
Organisation (WHO), there are as few as 0.03 neurologists per 100,000 population 
working in SSA (WHO, 2004).  It must also be borne in mind that epilepsy remains a highly 
stigmatised condition in many countries; PWE are often marginalised or socially excluded, 
and hence less likely to come forward to be included in studies.  With these limitations in 
mind, the shortcomings of community-based studies of epilepsy may include the exclusion 
of minor or more subtle seizure types, such as absence or partial seizures, and 
underreporting because of the stigma associated with epilepsy (Giel, 1970, Senanayake 
and Roman, 1993).  Door-to-door studies are also logistically difficult and expensive to 
conduct. 
These problems notwithstanding, the community-based approach is considered the 
optimum method to detect cases of active epilepsy in prevalence studies in LMICs 
(Senanayake and Roman, 1993).  It has been suggested that studies of this design require 
a population of 25 to 50,000 to render age-, sex-, and race-specific prevalence ratios 
meaningful (Schoenberg, 1982, WHO, 1981). 
To maximise efficiency and minimise cost, door-to-door studies for the purposes of neuro-
epidemiology are generally conducted using a two-phase approach; lay personnel conduct 
a screening phase and clinicians with specific expertise make the final diagnoses 
(Schoenberg, 1982, World Health Organisation Neurosciences Programme, 1981, Ottman 
R et al., 2010).  This approach has been employed successfully in a number of regions 
around the world including Europe, the United States, Latin America, Africa and Asia 
(Ottman R et al., 2010). 
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1.4.2 Screening tools 
Any door-to-door population-based study must employ a screening tool with adequate 
sensitivity and specificity.  If the sensitivity of the screening instrument is low, many true 
positives will be missed: i.e. affected individuals will not be detected.  Conversely, a low 
specificity will lead to the inclusion of large numbers of false positives: i.e. individuals 
without the disease in question), leading to substantial logistical problems in a survey of 
any size.  Even where validated tools are used, door-to-door studies are likely to have a 
higher sensitivity for convulsive epilepsies, and more subtle forms of epilepsy will tend to 
be underestimated (Ngugi et al., 2010).  It is also generally the case that the more 
sensitive a screening questionnaire the less specific it will be (Shorvon and Farmer, 1988).  
Questionnaires that target symptoms that may represent the presence of a convulsive 
seizure disorder will therefore tend to have a high sensitivity but at the cost of a lower 
specificity, with many false positives being identified (Ottman R et al., 2010).  This has 
been seen in practice when screening questionnaires have been used in resource-limited 
settings; sensitivities in excess of 95% have been reported, but with lower specificities 
leading to the inclusion of large numbers of false positives among those who have 
screened positive (Osuntokun et al., 1982, Placencia et al., 1992a). 
The positive predictive value (PPV) of a screening test is defined as the proportion of 
individuals who screen positive who are subsequently confirmed to be affected.  Where 
the background prevalence of a condition being studied is low screening instruments with 
a low specificity will have a low PPV.  In a review of screening questionnaires used in 
community-based surveys PPVs were as low as 20% due to this effect (Placencia et al., 
1992a). 
Community-based door-to-door studies conducted in SSA over the past three decades 
have made use either of screening instruments devised specifically for the individual study 
or one of a number of validated screening tools, used in whole or in part.  These are 
reviewed in more detail in Section 1.5.2. 
The WHO has developed a two-stage protocol for the detection of neurological disability 
in LMICs (World Health Organisation Neurosciences Programme, 1981).  This comprises of 
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a screening tool, to be used during a population census, followed by individual 
assessments of positive responders to detect symptoms and signs of a range of 
neurological diseases.  The screening questionnaire contains fifteen questions, of which 
three relate to epilepsy (Box 2), combined with seven simple tasks.  Other conditions that 
this instrument was designed to detect include cerebrovascular disease, extrapyramidal 
disorders, peripheral neuropathy, intracranial neoplasia and migraine.  Based on 
contemporary prevalence figures for neurological disorders from HICs it was 
recommended that a study population of 50,000 or more would be necessary to obtain 
meaningful rates in four or five age bands across the two sexes (WHO, 1981).  Although 
widely used previously, including in studies from SSA (Tekle-Haimanot et al., 1990a, 
Osuntokun et al., 1982, Osuntokun et al., 1987, Almu et al., 2006), this instrument is now 
less favoured, focusing as it does on specific diseases rather than disability, and having 
been designed without due consideration as to which disease(s) may be of greatest public 
health importance in LMICs (Bower et al., 2009). 
For subjects of seven years of age and older: 
1.  Have you ever lost consciousness? 
2.  Have you ever had episodes where you lost contact with your 
surroundings? 
3.  Have you ever had any shaking of your arms and legs which you could not 
control? 
 
For children under seven years of age: 
1.  Has this child ever lost consciousness 
2.  Does this child have episodes characterised by vagueness and unawareness 
of surroundings? 
3.  Have you ever seen this child shaking and unable to control the arms and 
legs? 




More recently a new screening instrument specifically designed for the detection of 
neurological disability in resource-poor settings has been developed with the aim of 
improving on the sensitivity and specificity of the original WHO protocol (Bower et al., 
2009).  A hospital-based pilot study of this tool was conducted in 128 participants in 
Tanzania; there was a non-significant increase in sensitivity from 98.4% to 100% compared 
with the WHO protocol, but specificity improved significantly from 29.2 to 62.0% 
(p=0.001).  This represents a considerable improvement when contemplating large-scale 
community-based studies, and initial validation of this instrument in Tanzanian and 
Ethiopian populations has been promising (Bower et al., 2012) 
With regards specifically to epilepsy, it has been argued that the WHO questionnaire was 
likely to have a poor sensitivity for partial seizures, that its specificity was too low to be 
logistically acceptable in any large scale epidemiological study, and that for these reasons 
composite neuro-epidemiological screening questionnaires to detect specific disease 
entities should be avoided (Placencia et al., 1992a).  With this in mind, and for the 
purposes of a large epidemiologic study of epilepsy in Ecuador, a nine-item screening 
questionnaire designed specifically to detect partial and generalised seizures was 
developed (Placencia et al., 1992a).  An initial bank of twenty questions derived from the 
authors’ clinical experience was found to have a sensitivity of 100% and specificity of 
50.8% when applied to eighty-seven patients and sixty-three controls.  After cluster 
analysis of responses this was refined to a combination of nine questions which 
collectively had a sensitivity and specificity of 92% and 98% respectively (Box 3).  Following 
comprehensive field-based validation during a population survey of 72,121 people the 
instrument was found to have a sensitivity of 79.3%, specificity of 92.9%, PPV of 18.8%, 
and negative predictive value (NPV) of 99.6%.  While the final nine questions did not 
include any that would readily identify absences or myoclonic seizures, this instrument did 
include a disease-specific question intended to easily detect individuals who may already 
be aware of their diagnosis; this was not a feature of the WHO questionnaire. 
Screening instruments based on modified forms of the Ecuador questionnaire have 
subsequently been used in community-based studies conducted in SSA.  In a study from 
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Zambia three additional questions were included to exclude individuals that would 
otherwise screen positive due to febrile or malaria-associated seizures in early childhood 
(Birbeck and Kalichi, 2004).  More recently a large door-to-door study from Tanzania also 
used a screening questionnaire derived from the Ecuador questionnaire, but with an 
extended number of questions informed by the work of Birbeck et al in Zambia(Birbeck 
and Kalichi, 2004) coupled with the authors’ own clinical experience of diagnosing and 
treating epilepsy in Tanzania (Winkler et al., 2009c). 
1. Have you ever had attacks of shaking of the arms or legs which you 
could not control? 
 
2. Have you ever had attacks in which you fall? 
Affirmative answers to questions 1 and 2 together render the subject positive. 
3. Have you ever lost consciousness? 
 
4. Have you ever had attacks in which you fall with loss of consciousness? 
 
5. Have you ever had attacks in which you fall and bite your tongue? 
 
6. Have you ever had attack in which you fall and lose control of your 
bladder? 
 
7. Have you ever had brief attacks of shaking or trembling in one arm or 
leg or in the face? 
 
8. Have you ever had attacks in which you lose contact with the 
surroundings and experience abnormal smells? 
 
9. Have you ever been told that you have or have had epilepsy or 
epileptic fits? 
Affirmative answers to any of questions 3 to 9 render the subject positive. 
Box 3: Nine-item epilepsy screening questionnaire developed in Ecuador 




A number of other screening tools have also been used in studies from countries in SSA.  
Investigators at the Institute of Neuroepidemiology and Tropical Neurology at the 
University of Limoges in France, recognising the need for comparable epidemiologic data 
on epilepsy from tropical countries, have developed a detailed pro-forma designed to 
collect standardised data when investigating epilepsy in tropical LMICs (Quet et al., 2011).  
Designed as a comprehensive protocol to be used in two-stage surveys the pro-forma 
includes a screening questionnaire, consisting of five questions, which has been shown to 
having a sensitivity and specificity of 95.1% and 65.6% respectively.  The full document is 
available on-line in various translations (Institute of Neurological Epidemiology and 
Tropical Neurology, 2012).  To date this instrument has been employed, in whole or in 
part, in thirteen epidemiological surveys in twelve African countries (Quet et al., 2011). 
The Ten Questions tool is a composite instrument designed to detect severe neurological 
impairment in children living in resource-poor countries (Mung'ala-Odera et al., 2006).  In 
a study in a rural Kenyan population this questionnaire had a sensitivity of 100% for the 
detection of active epilepsy in children (Mung'ala-Odera et al., 2004).  In a larger 
community-based study in the same population two questions derived from the Ten 
Questions Questionnaire were used to detect the presence of seizures with convulsions in 
all age groups (Edwards et al., 2008).  In the latter study children under the age of six years 
were excluded due to the difficulties in differentiating between febrile seizures and 
epilepsy in infants. 
Finally, in Rwanda, a standardised seven-item tool for the detection of musculoskeletal 
disorders that included a single question on convulsions was used in a cross sectional 
community-based survey (Simms et al., 2008).  In a validation study conducted in 179 
individuals the screening tool performed with a sensitivity of 97.8%, a specificity of 98.8% 
and had a PPV of 99%, although these were composite scores for all musculoskeletal 
impairments and no specific discussion of how many individuals with epilepsy were 
included is offered (Atijosan et al., 2007). 
Demonstration projects established by the ILAE to develop models for the management of 
epilepsy in LMICs have also included community-based screening surveys (Sander, 2002).  
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These have made use of questionnaires based on the WHO instrument described above 
(Wang et al., 2003b), include work done in SSA (Ndoye NF et al., 2005), although to the 
best of our knowledge specific details of the instruments have not been published. 
1.4.3 Key informants 
Key informants (KI) are defined as long-term residents within a population who occupy 
positions of trust and respect in their communities (Pal et al., 1998).  While KI have been 
used extensively in LMICs for community health assessments the major criticism of this 
method has been its lack of sensitivity: in a Jamaican study of childhood disability the 
sensitivity of KI-based screening for epilepsy was found to be less than 12% (Thorburn et 
al., 1991), in a Kenyan study of the prevalence of epilepsy KI-based screening yielded a 
prevalence of 3.6/1,000 compared with 18.2/1,000 estimated by a random cluster sample 
survey in the same population (Kaamugisha and Feksi, 1988), and a door-to-door 
screening study conducted in a rural district of West Bengal in India had a sensitivity for 
the detection of epilepsy of 59% utilising questionnaires compared with 17% when 
utilising KIs (Pal et al., 1998).  The authors of this latter study were however able to 
demonstrate that when the KI method was used alongside the door-to-door method a 
number of additional cases of epilepsy were detected that would have been missed by the 
door-to-door approach alone.  While the PPV for seizures was similar for the two 
methods, the slightly higher value for the KI approach (40% vs. 36%) suggests that this is a 
useful adjunct to any community-based screening methods.  The KI approach has been 
used in SSA in community-based prevalence surveys of epilepsy (Snow et al., 1994, 
Debrock et al., 2000), and more recently as an adjunct to a questionnaire-based approach 
to screening for Parkinson’s Disease in Tanzania (Dotchin et al., 2008). 
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1.4.4 Data-linkage and capture-recapture techniques 
Given the limitations and relative costliness of the two-stage screening approach, other 
methods of estimating the burden of disease in resource-limited settings have been 
explored. 
The technique of electronic data linkage constructs a local register for a given condition 
using as many data sources as possible (Morris et al., 1997).  The capture-recapture 
technique is a statistical method which analyses multiple patient lists to identify the 
degree of overlap and allows estimates of the total population, counted and uncounted, 
to be made (International Working Group for Disease Monitoring and Forecasting, 1995).  
This technique has been used to assess the undercount of a data linkage approach when 
attempting to enumerate the number of people with a variety of non-communicable 
diseases (NCDs), including hypertension, diabetes, asthma and epilepsy, in a rural district 
of South Africa (Gill et al., 2001).  Records from a weekly NCD clinic, satellite health clinics 
and repeat prescription cards were available for data linkage, with a comparator list being 
available from the NCD clinic of the local central hospital.  There was only overlap 
between the lists for the hypertension and diabetes groups, however, and consequently 
little or no adjustment was possible.  The authors cite the complex spelling of duplicate 
names along with duplicate attendances at the same clinic as factors that may complicate 
data analysis, and also acknowledge the limitation that only enumeration of known, 
diagnosed disease under healthcare treatment is possible using this approach.  The 
difficulties associated with matching names from different lists have also previously been 
observed when attempting to use capture-recapture to correct estimates of mortality as 
part of a long-term study of causes and rates of death in three areas of Tanzania (Kitange 
HM et al., 1996).  Use of capture-recapture in this study was hampered not only by 
variations in the spelling of names, but also by individuals using completely different 
names at different times and for different purposes for social, religious and cultural 




1.5 Prevalence of epilepsy 
1.5.1 Estimates of prevalence from regions outside sub-Saharan Africa 
In systematic review of epidemiological studies of epilepsy from Europe population-based 
studies came largely from the UK and the Nordic, Baltic and western Mediterranean 
countries (Forsgren et al., 2005a).  Twenty-three sufficiently comparable studies from 
twelve countries were identified, with active epilepsy being defined as seizures within the 
previous five years.  The median estimated prevalence in these studies was 5.2 /1,000 
(range 3.3 to 7.8).  Prevalence rates were often higher in males than females, but this was 
rarely of statistical significance.  The overall prevalence was estimated at 4.5 to 5.0 per 
1,000. 
A review of multiple data sources from the Russian Federation, including records from 
hospitals, outpatient departments and emergency care units, estimated the prevalence of 
active epilepsy in the adult population (aged fourteen years or older), with a denominator 
population of 517,624 people (Guekht A et al., 2010).  The prevalence was 3.4/1,000 (95% 
CI 3.26 to 3.55); epilepsy was significantly more common in men than in women 
(4.5/1,000 vs. 2.52/1,000; p<0.0001), and significantly higher in the Eastern than the 
Western population of the Federation (4.12/1,000 vs. 2.82/1,000; p<0.0001). 
A similar review of studies conducted in Latin American countries identified thirty-two 
studies that provided prevalence estimates (Burneo et al., 2005).  Only eleven of these 
studies made a clear distinction between lifetime and active prevalence, with the median 
estimated prevalence of active epilepsy being 12.4/1,000 (range 5.1 to 57.0).  The majority 
of the studies utilised a questionnaire plus clinical examination, with additional 
information from EEG or neuro-imaging being available in seven studies.  No overall 
differences in prevalence were identified between rural and urban studies, or between 
the males and females. 
A systematic review of studies from Asian countries identified twenty-one studies from 
eleven countries, the majority of which were community-based door-to-door studies (Mac 
et al., 2007).  The median estimated lifetime prevalence was 6/1,000 (range 1.5 to 14.0), 
with no significant difference between men and women. 
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The median prevalence of epilepsy in Arab countries, based on five studies from four 
countries, was 2.3/1,000 (range 0.9 to 6.5) (Benamer and Grosset, 2009).  Four of these 
studies were community-based, with a definition of active epilepsy being provided in 
three studies and acute symptomatic seizures being specifically excluded in only one. 
1.5.2 Prevalence of epilepsy in sub-Saharan Africa 
Of the community-based studies that have been performed in Africa over the past two 
decades, many reflect a model in which lay investigators administer questionnaires and 
conduct examinations followed by confirmation of cases by neurologists or other trained 
doctors.  As discussed above, while it has been suggested that studies of this design 
require a population of twenty-five to fifty thousand to render age-, sex-, and race-specific 
prevalence ratios meaningful (Schoenberg, 1982, World Health Organisation 
Neurosciences Programme, 1981), and many of the published studies from SSA fall far 
short of this figure (Bondestam et al., 1990, Dumas et al., 1989, Goudsmit et al., 1983, 
Osuntokun et al., 1982, Osuntokun et al., 1987, Longe and Osuntokun, 1988, Snow et al., 
1994).  Estimates of the prevalence of epilepsy in African countries have varied greatly, 
from 2.2 to 58 per 1,000 (Diop et al., 2003, Preux and Druet-Cabanac, 2005), although 
differing research protocols and inclusion criteria make the comparison of figures difficult.  
The lowest rates reported from African countries come from South Africa (2.2/1,000) 
(Eastman, 2005, Diop et al., 2003).  South Africa is usually considered separately from 
other countries in SSA, however, due its particular combination of economic 
circumstances which effectively juxtapose conditions associated with both LMICs and HICs 
(Diop et al., 2003).  A review of door-to-door surveys from SSA excluding South Africa 
identified a median prevalence of 15/1,000, considerably higher than estimates from 
other regions of the world (Preux and Druet-Cabanac, 2005). 
The section that follows briefly discusses some work of historical interest before reviewing 
by country the community-based studies of epilepsy conducted in SSA over the past four 




1.5.3 A brief note on sub Saharan Africa 
Sub-Saharan Africa is the geographical area of the continent that lies south of the Sahara, 
and includes all countries which are fully or partially located in this region (United Nations, 
2009).  Sub-Saharan Africa contrasts with North Africa, which is considered a part of the 
Arab world.  The population of the region is growing by 2.3% per year, and is projected to 
reach 1.5 billion by the year 2050 (United Nations Department of Economic and Social 
Affairs, 2012).  The region as a whole is characterised by ecological diversity, climactic 
extremes, poor infrastructure and high poverty indices, including high rates of child and 
maternal mortality and low adult life-expectancy. 
1.6 Review of studies from sub-Saharan Africa 
1.6.1 Historical studies 
Studies conducted in the 1960s in black South African mine workers reported prevalence 
rates for epilepsy of 2.2 to 3.7/1,000 (Bird et al., 1962, Hurst et al., 1961).  The first of 
these studies reviewed clinical records relating to mineworkers being repatriated on 
medical grounds; all cases included were adult males aged fifteen years and above.  The 
second study reviewed local clinic records where registration cards indicated almost 
complete coverage of local patient population of approximately 60,000 people.  Fifty-one 
patients with seizures were identified (twenty-one male, twenty-nine female), of whom 
forty-one (80%) were described as having ‘grand mal’ seizures.  Aetiology was identified in 
fourteen (27.5%) cases, and included perinatal complications (seven), head injury (five), 
cysticercosis (one), and stroke (one). 
In 1964, to complement a hospital-based case series, houses in a reserve near Bulawayo, 
Zimbabwe, were visited by a local medical officer to seek out cases of epilepsy (Levy, 
1964).  A prevalence of 7.4/1,000 was estimated, with similar rates in males and females; 
56% of cases were under the age of twenty years.  Little detail on past history or risk 
factors is given, although a family history of epilepsy was elicited in 64% of cases.  The 




A brief report from Ghana in 1967 describes a study that questioned 3,912 inpatients and 
outpatients at a hospital in Accra about a history of grand-mal fits beyond infancy 
(Haddock, 1967).  Patients were also asked about a similar history in any full siblings.  
Combined results provided an estimate of prevalence of 33/1,000, with no significant 
difference in prevalence between men and women identified.  No further assessments are 
described in this paper, which also appears to use the term incidence in place of 
prevalence in the main text. 
From Ethiopia in 1970, a set of brief observations containing few clinical details describes 
two morbidity surveys conducted in the south western part of the country that gathered 
data on the prevalence of epilepsy (Giel, 1970).  In an urban sample of one hundred 
houses (384 people) the prevalence was estimated at 5/1,000; in a rural sample of 
another one hundred houses (370 people), the prevalence was 8/1,000.  No further details 
of case ascertainment, inclusion criteria or other clinical details are given, and most of the 
discussion focuses on the various privations suffered by PWE in Ethiopia at that time. 
Finally, from Tanzania in 1965, in a descriptive doctoral thesis based on observations 
made during her time as a mission doctor in the Ulanga district in the Mahenge 
mountains, Dr Louise Aall-Jilek noted an apparently high prevalence in one tribe in the 
Wapogoro tribe, with a strong familial tendency among cases being observed (Aall-Jilek, 
1965).  When local clinic records were interrogated more systematically a minimum 
estimate of prevalence based on known clinic attendees of 20/1,000 was made (Jilek and 
Jilek-Aall, 1970).  Precise details of case definitions and inclusion criteria are not given, 
although 85% of cases were reported to be suffering with ‘grand-mal’ fits, and of these 
nearly half reported prodromal features. 
All of the studies described above mention the stigmatising nature of epilepsy in the 
different communities and settings described.  Another common theme is the lack of 
clearly comparable criteria for the description and classification of seizures, an issue which 




1.6.2 Studies from sub-Saharan Africa since 1982 (excluding Tanzania) 
Over the past four decades there have been a number of community-based studies from 
countries in sub-Saharan Africa that have used a screening approach to identify PWE in 
order to estimate the prevalence of epilepsy.  These have generally been conducted in 
rural populations and collectively present widely varying estimates of prevalence.  Details 
of twenty studies conducted in eleven countries, excluding Tanzania, are summarised in 
Table 1.  From examining this table it can be seen that comparisons between studies are 
rendered difficult by a number of factors: wide variations in the size of denominator 
populations (from less than 200 to greater than 150,000), different inclusion criteria in 
terms of age groups or active versus lifetime epilepsy (if stated), a general lack of age-
standardised figures for prevalence (with different standard populations used when age-
standardisation is performed), and differing and non-standardised approaches to 
screening and case ascertainment.  Where details of seizures are given it is often difficult 
to compare findings as the distinction between seizures and epilepsies is not always 
clearly elucidated, and very few studies have recourse to further investigations to help 
further characterise seizures in terms of electro-clinical epilepsy syndromes.  Only two of 
the studies itemised in Table 1 benefitted from EEG investigations (Tekle-Haimanot et al., 
1990b, Prischich et al., 2008) and none of them benefit from imaging findings in the form 
of CT or MRI.  The descriptive review of these studies that follows is also intended to 
illustrate some of the wider issues associated with epilepsy in SSA to have been identified 




Country Year Setting Denom. 
(n) 




Benin (Debrock, 2000) 1997 Rural 3,134 Not stated Limoges protocol, KIs, 
medical records, data 
linkage 




Benin (Crepin, 2007) 2005 Rural 11,668 Not stated Limoges protocol LTE 12.7 N/A 1.1 Limited Case-control 
study of nutrition 
in epilepsy 
Cameroon 
(Nkwi and Ndonko, 1989) 




70.0 N/A Not stated No Sociological 
paper.  Few 
clinical details 
Cameroon 
(Kamgno et al., 2003a) 
1991 Rural Not stated Not stated KIs LTE 5.0 to 
87.0 
N/A Not stated Limited Retrospective 




(Prischich et al., 2008) 
2004 Rural 197 All 10-item instrument 
adapted from Limoges 
protocol 
AE 105.0 134.5 
(Cameroon 
2000) 
1.4 Yes Case-control 




1998 Rural 60,820 All Modified WHO protocol LTE 5.2 N/A 1.3 Yes Composite study 
of neurological 
disability 
Ethiopia (Almu, 2006) 2006 Rural 1,154 Not stated WHO protocol 
 
AE 29.5 N/A Not stated Yes  
Kenya (Edwards, 2008) 2008 Rural 151,408 ≥6 years Two questions from 
‘Ten Questions’ protocol 
AE 2.9 N/A  Limited Screening for 
ACE only 
Kenya (Snow, 1994) 1993 Rural 7,450 ≥6 years KIs AE 4.0 N/A 2.4 Limited Part of mortality 
study 
Kenya (Kaamugisha, 1998) 1986 Rural 2,961 All KIs and cluster sampling AE 18.2 vs. 
3.6 
N/A Not stated Limited  
Liberia 
(van der Waals et al., 1983) 
1982 Rural 4,436 All KIs AE 28.0 N/A 1:1 Yes  
*LTE – lifetime epilepsy/AE – active epilepsy 
 
†Age-standardised (standard population in parentheses) 
Table 1: Community-based prevalence studies of epilepsy from SSA (excluding Tanzania) 
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Nigeria (Osuntokun, 1982) 1982 Rural 903 All WHO protocol AE 37.0 N/A 0.6 No  
Nigeria (Osuntokun, 1987) 1982 Urban 18,954 All WHO protocol AE 5.3 5.0 
(US 1970) 
0.9 Yes  
Nigeria (Longe, 1988) 1986 Rural 2,925 All Modified WHO protocol AE 6.2 N/A 0.6 No  
Rwanda (Simms, 2008) 2005 Mixed 6,757 All Screening tool for 
musculoskeletal impairments 









Senegal (Ndoye, 2005) 2005 Urban 4,500 All ILAE protocol AE 14.2 N/A Not 
stated 
Yes  
Togo (Dumas, 1989) 1987 Mixed 5,264 >15 
years 













Uganda (Kaiser et al., 1996) 1994 Rural 4,743 All KIs AE 13.0 11.0 
(World) 




(Birbeck and Kalichi, 2004) 
2001 Rural 55,000 All Modified Ecuador protocol AE 14.5 N/A Not 
stated 
No  
*LTE – lifetime epilepsy/AE – active epilepsy 
 
†Age-standardised (standard population in parentheses) 




A survey in two villages (n=3,134) used the capture-recapture method to estimate the 
prevalence of epilepsy (Debrock C et al., 2000).  Diagnoses of epilepsy obtained through 
three sources were compared: a door-to-door screening survey, cases identified by key 
informants in their communities, and a review of medical records in local health centres.  
The overall crude lifetime prevalence of epilepsy was 21.1/1,000 (15.9/1,000 based on the 
door-to-door survey alone).  Tonic-clonic seizures accounted for 68.1% of cases, and it is 
implied that these were primary generalised seizures; complex partial seizures with 
secondary generalisation are described separately and account for 13.6% of cases.  The 
authors suggest that the use of overlapping sources and the application of capture-
capture methodology could better depict the frequency of epilepsy in Africa than more 
traditional cross-sectional methods. 
A study examining the relationship between malnutrition and epilepsy in a rural area 
screened 11,668 people in a door-to-door survey using the Limoges questionnaire (Crepin 
et al., 2007).  Screening was performed by local physicians who had received training in 
epilepsy as part of the study, with screened-positives being examined by a neurologist.  
The denominator population was derived from a recent census of the area.  The crude 
lifetime prevalence of epilepsy was 12.7/1,000.  Details on seizure type are limited, with 
“most” subjects having generalised tonic-clonic epilepsy.  Details are given on duration of 
epilepsy, with 82% stating seizure onset before twenty years of age, and on associated 
clinical findings, with 26% having neurological impairment.  The ETG in terms of AED use 
was 58%.  To examine the relationship with malnutrition, 262 controls were recruited and 
anthropometric measurements along with socio-demographic and nutritional data were 
collected.  The prevalence of malnutrition was found to be higher in PWE than in controls 
(22.1% vs. 9.2%, p=0.0006). 
  




An anthropological study in one village noted a very high prevalence of 70/1,000 (Nkwi 
and Ndonko, 1989).  No further details of case ascertainment, inclusion criteria or clinical 
details are given, and it is thus difficult to comment further on this study. 
A study to assess the demographic impact of epilepsy in terms of mortality used the 
results of a community based survey of fourteen village communities as a baseline 
(Kamgno et al., 2003b).  In the initial survey, conducted in 1991, village elders and other 
key informants were asked to identify and bring forward persons known or suspected to 
have epilepsy for assessment on given days.  Inclusion criteria were consistent with 
lifetime epilepsy, and the prevalence was reported as ranging from 5 to 87/1,000 among 
the fourteen communities studied, and exceeded 30/1,000 in four of them.  It is not made 
clear how the figure for the denominator population was arrived at.  Details on seizure 
types and clinical associations are limited, but are based on a follow-up of the original 
cohort conducted ten years later in 2001, during which only 122 of the original 271 PWE 
were assessed.  Of these, 80.8% had generalised convulsive seizures with no recognised 
partial onset, 17.6% had partial or secondary generalised seizures with no further 
distinctions being made, and 1.6% had absence seizures.  With regards to mortality, 
matched controls were retrospectively identified from the original 1991 survey to give 128 
pairs.  There was a significant excess mortality in PWE (28.9% vs. 4.7%, p<0.0001); the OR 
of dying for PWE compared with controls was estimated at 6.2 (95% CI 2.7 to 14.1).  The 
chief causes of death among PWE were status epilepticus, sudden unexpected death in 
epilepsy (SUDEP) and drowning during a seizure. 
A small door-to-door survey (n=197), conducted in one village in an area known to be 
hyper-endemic for onchocerciasis reported an age-adjusted prevalence of active epilepsy 
of 134.5/1,000 (Prischich F et al., 2008).  A high prevalence of epilepsy in this population 
had previously been noted anecdotally, and the authors hypothesised that this may be 
related to infection with the filarial worm Onchocerca volvulus which has been postulated 
as a possible cause of epilepsy in SSA (Druet-Cabanac et al., 2004).  The study had three 
phases: screening using a ten-item questionnaire derived from the Limoges protocol, 
clinical evaluation of identified possible cases to establish diagnoses, and a case-control 
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study to evaluate risk factors and socio-economic factors.  Individuals identified as having 
epilepsy also had an EEG.  The endemicity of onchocerciasis was assessed based on the 
prevalence of cutaneous nodules in adults.  The age-standardised prevalence of active 
epilepsy was very high, at 134.5/1,000.  Primary generalised seizures accounted for 52.6% 
of cases, partial seizures for 47.4%, and 31.5% were described as having partial seizures 
becoming secondarily generalised.  To identify risk factors for epilepsy two matched 
controls were identified for each case.  There was no significant difference in the 
prevalence of onchocercal nodules (seen in 61% of cases vs. 44.4% of controls), and the 
reported incidences of cerebral malaria, infectious and parasitic diseases and head injury 
were similar among cases and controls.  A history of febrile convulsions was considerably 
more frequent in PWE than controls (22.2% vs. 8.3%), although this was also non-
significant (OR 3.14; 95% confidence interval 0.4 to 23.8).  A family history of epilepsy in a 
1st degree relative was, however, more common in cases than in controls (100% vs. 69.4%, 
p=0.031). 
Ethiopia 
A community-based study screened a sample of 60,820 individuals in a rural area of 
Ethiopia for neurological disorders, including epilepsy, utilising the WHO protocol (Tekle-
Haimanot R et al., 1990).  The crude prevalence of active epilepsy was 5.2/1,000.  The 
study benefited from the availability of EEG, and while generalised tonic-clonic seizures 
were described clinically in 81% of cases, 68.7% overall were judged to have primary 
generalised seizures following EEG evaluation.  Only 1.6% of PWE had been treated with 
recognised AEDs prior to the study. 
A door-to-door screening study in the Zay society, a small, isolated, endogamous 
community with a total population of approximately 5,000, sampled 1154 individuals and 
screened for various conditions including epilepsy (Shitaye A et al., 2006, Almu et al., 
2006).  The WHO screening protocol was used and the prevalence of active epilepsy was 
estimated at 29.5/1,000.  Although no EEG was available, 82% of cases are described as 
having primary generalised epilepsy, and the authors postulate that this high proportion 
may point towards a genetic predisposition in this community.  All PWE gave a positive 
family history of epilepsy, although the criteria for a family history are not defined.  The 
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ETG was lower than in the earlier Ethiopian study (Tekle-Haimanot et al., 1990b), although 
44% of PWE were not receiving AED treatment. 
Kenya 
A study in a semi-urban Kenyan population compared the use of random cluster sampling 
and the key informant method in determining the prevalence of epilepsy (Kaamugisha and 
Feksi, 1988).  The sampling frames were different for the two techniques, with the 
denominator for the random cluster technique being based on school attendance 
registers and for key informants being derived from 1979 census data extrapolated to 
1985, the year of the study.  Households identified by random cluster sampling were 
visited by the study team to identify any PWE living within them, while key informants 
were interviewed to identify any cases of epilepsy known to them.  Random cluster 
sampling gave a prevalence of active epilepsy of 18.2/1,000 compared to 3.6/1,000 for key 
informants.  While no further details of seizure types are provided, the authors do 
comment that the lower prevalence obtained by the key informant method may be 
explained by a tendency to report only those cases that are clinically obvious; seizures at 
night, or partial seizures without secondary generalisation and brief absence seizures may 
have been frequently missed. 
In Kilifi, an established Kenyan DSS, a community-based mortality study noted a high rate 
of deaths being reported in association with epilepsy (Snow et al., 1994).  This prompted a 
prevalence survey which used key informants to screen 7,450 residents of a pre-defined 
study area.  The sampling frame was a 20% random sample of households drawn from an 
enumerated population of 51,183.  Each household was visited by a field worker and 
asked about occupants suffering from epilepsy using local terminology.  Children under 
the age of five years were not included in the study in order to exclude repeated febrile 
convulsions associated with malaria and other infectious diseases.  The crude prevalence 
of active epilepsy was 4/1,000.  Seizures were classified based on eye-witness accounts, 
with 53% being described as generalised tonic-clonic and all remaining cases being either 
complex partial or unclassified, albeit with loss of consciousness.  Ten per cent of cases 
had never received any form of treatment. 
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Over a decade later, a much larger community-based study using a three-phase screening 
protocol was conducted in the same population (Edwards et al., 2008).  Initial screening 
was performed across the whole population aged six years or older (n=151,408) using two 
questions derived from the Ten Questions composite screening instrument for 
neurological disability.  This instrument had previously been validated in the same 
population for the detection of convulsive epilepsy in children (Mung'ala-Odera et al., 
2006, Mung'ala-Odera et al., 2004).  Diagnoses in screened individuals were confirmed by 
a local physician and reviewed by an international panel of neurologists.  The crude 
prevalence of ACE was 2.9/1,000, rising to 4.5/1,000 after adjustment for non-response 
and sensitivity.  The ETG based on detection of AEDs in blood was 70.3%.  Risk factors for 
ACE were derived from frequency-matched controls identified during the screening phase, 
with the adjusted odds being significantly increased for all individuals with a family history 
of either febrile or non-febrile convulsions (ORs 3.3 and 14.6 respectively) and previous 
head injury (OR 4.1).  A multivariable analysis in children under the age of eighteen years 
also identified adverse perinatal events and the child’s mother being widowed as 
independent associations with epilepsy (ORs 5.7 and 5.1 respectively). 
Liberia 
A study using key informants screened a population of 4,436 people in a rural population 
that had previously been noted to have a high prevalence of seizures (van der Waals et al., 
1983).  The crude prevalence of active epilepsy was 28/1,000, with 37% of cases having 
generalised seizures, 13% simple partial seizures and 50% complex partial seizures.  
Historical information on risk factors was collected with an antecedent febrile illness being 
identified in 38% of cases.  Accidents and birth trauma were less frequent associations, 
being identified in 3.3% and 2.4% of cases respectively.  Data from this cohort were 
further analysed by Goudsmit et al, who postulated that the seizure disorder had been 
introduced into this population approximately thirty years prior to the study, and that an 






A pilot study to assess the utility of the WHO research protocol described above was 
conducted in a rural community of approximately 2,000 people (Osuntokun et al., 1982).  
The screening protocol, consisting of a questionnaire and simple examination, was 
designed to detect individuals with stroke, epilepsy, peripheral neuropathy, extra 
pyramidal disorders, migraine and persistent dysfunction of strength, coordination, 
sensation, vision or hearing.  The crude prevalence of active epilepsy among 903 screened 
individuals was 37/1,000.  No further descriptions of seizure types or any other clinical 
details are given. 
A larger door-to-door study in an urban population subsequently used the same protocol 
to screen 18,954 subjects (Osuntokun et al., 1987).  The prevalence of active epilepsy was 
5.0/1,000 after age-standardisation to the 1970 US population.  Details of seizures are 
given, with 25.7% of cases having generalised seizures, including 20.8% overall with tonic-
clonic seizures, and 55.4% having partial seizures, with 51.5% overall characterised as 
complex partial seizures; 18.8% of remained unclassified.  Putative causes of epilepsy 
were identified in 39.6% of cases, including 23.8% with a history of febrile seizures, 5.9% 
with a history of head injuries, 5.0% with a family history of epilepsy in first- or second-
degree relatives, 2.0% with a history of stroke prior to first seizure, and 1.0 % (one patient) 
identified as having a brain tumour.  No details on any overlap between these various 
groups are provided. 
A smaller study in a rural population of 2,925 also used the WHO protocol to screen for 
neurological disorders (Longe and Osuntokun, 1988).  The crude prevalence of active 





A national survey of musculoskeletal impairment used a seven-item screening tool that 
included a question relating to epilepsy (Simms et al., 2008, Atijosan et al., 2007).  
Random cluster sampling based on the 2002 Rwandan population census yielded a 
denominator of 8,400 individuals to be screened, with positive responders being further 
assessed by a physiotherapist working with the aid of a diagnostic questionnaire.  The 
prevalence of active epilepsy was 6.31/1,000 after age-standardisation to the 1998 
standard European population, and details on seizure frequency, age of onset and 
treatment access are all given.  Less than half of PWE identified (41%) were receiving AED 
treatment at the time of the study with the most commonly cited reason for this being the 
cost, identified as a barrier to treatment in 74% of untreated individuals.  No details of 
seizure types are provided. 
Senegal 
A door-to-door community-based study conducted in a sample of 4,500 from a suburban 
population of Dakar estimated the prevalence of active epilepsy to be 14.2/1,000 (Ndoye 
NF and et.al., 2005).  This study was conducted as part of one of the ILAE demonstration 
projects (Sander, 2002) and as such, clear definitions of seizures and epilepsies were 
stipulated.  The screening tool used was a local translation of an instrument used in the 
demonstration project in China (Wang et al., 2003a).  Generalised convulsive seizures 
were identified in 68.8% of cases, generalised non-convulsive seizures in 9.4%, and partial 
seizures in 21.9%, with 14.1% overall becoming secondarily generalised.  Additional 
impairments in the form of mental retardation plus or minus some form of paralysis were 
identified in 34.5% of PWE, and 23.4% of cases were not using AEDs at the time of the 
study.  Interviews to ascertain knowledge, attitudes and practice with regards to epilepsy 
were also conducted in 2,263 randomly selected individuals.  Of those that responded, 
66.1% had witnessed a person having a seizure while only 35.8% said that they had helped 
a person during a seizure.  Regarding treatment and aetiology, 17.7% felt that epilepsy 






A study in a rural area of Togo where pork consumption is common was conducted to 
establish the prevalence of epilepsy and to examine the relationship between epilepsy 
and cysticercosis in the study population (Dumas et al., 1989).  Random cluster sampling 
was used to identify 5,264 individuals aged fifteen years and above who were then 
screened by way of a questionnaire, for which no details are given, followed by 
examination of potential cases by a neurologist.  The crude prevalence of epilepsy was 
16.7/1,000, with epilepsy being over twice as common in men than in women (26.2 vs. 
10.7/1,000).  It is not clear whether the estimates are of lifetime or active prevalence, the 
terms ‘incidence’ and ‘prevalence’ appear to be used interchangeably, and no details on 
seizure type are provided.  All screened individuals were examined for the presence of 
subcutaneous cysts suggestive of cysticercosis, and individuals identified as having 
epilepsy were also examined for the presence of cysticercosis with skull and muscle X-rays 
and by serological analysis for the presence of antibodies to Taenia solium, the causative 
agent of cysticercosis.  While the data presented are somewhat difficult to interpret, it 
would appear that 12.5% of PWE had cysts typical of cysticercosis compared to 2.1% of 
individuals without epilepsy.  Of the PWE who had cranial X-rays, 7.4% had one or more 
calcifications typical of NCC, although none of these had positive serology and the one 
case that consented to biopsy proved to have onchocerciasis rather than NCC. 
A feasibility study for a programme of managing epilepsy in a rural setting in Togo 
included a community-based prevalence survey (Balogou et al., 2007).  The Limoges 
protocol was used to screen 6,249 people yielding a crude prevalence for active epilepsy 
of 15.7/1,000, with 78.6% of cases having active epilepsy at the time of the study.  Details 
on seizure type are provided, with generalised tonic-clonic seizures being observed in 
35.7% of cases.  EEG was available, and while 74.5% of cases overall appeared to have 
generalised seizures, generalised anomalies on EEG were only seen in only 39.8% of these.  
Suspected or confirmed aetiologies included head injury (10.2%), NCC (14.3%), CNS 
infections (44.9%) and perinatal morbidity (8.2%).  None of the patients identified had 





A community-based survey in rural western Uganda examined the relationship between 
epilepsy and of onchocerciasis (Kaiser et al., 1996).  A house-to-house survey of a 
complete parish (n=4,743) used local terminology to ask each household about any 
occupants with epilepsy living there.  Possible cases identified, along with a number who 
subsequently presented voluntarily, were examined by a physician to confirm diagnoses.  
The prevalence of active epilepsy was 13/1,000 after age-adjustment to a standard world 
population.  No further details of seizure type are provided and none of the cases 
identified were treated with AEDs at the time of the study.  The prevalence of epilepsy 
was heterogeneous within the geographical area studied, with areas of higher prevalence 
being significantly associated with areas where the prevalence of onchocerciasis was also 
high, based on a skin-snip survey for the presence of microfilariae. 
Zambia 
A large community-based study conducted in rural Zambia utilised a modified version of 
the Ecuador questionnaire (Birbeck and Kalichi, 2004).  Three additional questions were 
added to reduce the number of false positives generated by febrile and malaria-associated 
seizures in children, thus improving the PPV of the questionnaire.  A total of 55,000 people 
were screened with all those responding positively being assessed by a physician; 
denominator data were derived from a 1999 census conducted under a local insurance 
scheme.  The prevalence of active epilepsy was 12.5/1,000 after an adjustment based on 
validation of the screening instrument.  No details of seizure type are given, although the 
authors do comment on the predominance of generalised tonic-clonic seizures.  There are 




1.7 Review of studies from Tanzania 
This introductory chapter concludes with a review of studies of epilepsy that have been 
conducted within Tanzania.  This encompasses community-based studies of prevalence, 
hospital-based studies that have examined risk factors, and studies that have addressed 
wider issues relating to knowledge and practice with regards to epilepsy in Tanzania.  
Community-based studies of the prevalence of epilepsy that have been conducted in 
Tanzania are summarised in Table 2. 
1.7.1 A brief note on Tanzania 
Tanzania is a republic in sub-Saharan East Africa, covering an area 947,300 square 
kilometres and with an estimated population in July 2011 of 42,746,620 (CIA World 
Factbook).  Forty-five per cent of the population are aged fifteen years and under, and the 
total population is projected to reach 53.4 million by mid-2025 (World Population Data 
Sheet, 2010).  Tanzania is one of the poorest countries in the world with 36% of the 
population living below the international poverty income threshold of one USD per day 
(CIA World Factbook).  Life-expectancy is fifty-five years for men and fifty-six years for 
women, the infant mortality rate is fifty-eight per 1,000 live births, and the prevalence of 
HIV infection in the general population is 5.6% (World Population Data Sheet, 2010). 
1.7.2 Community-based studies 
As described in Section 1.6.1, a cohort of PWE in a rural district in the Mahenge mountains 
of southern Tanzania was initially identified during the latter half of the 1960s when a 
clinic was set up to treat PWE with phenobarbital (Aall-Jilek, 1965, Jilek and Jilek-Aall, 
1970).  The area was revisited thirty years later by the clinicians who had first established 
the clinic by which time only thirty-six (21.9%) of the 164 patients initially identified were 
known to still be alive (Jilek-Aall and Rwiza, 1992).  In those that had died, the cause of 
death was epilepsy-related in over 50%, including status epilepticus, drowning, burns, and 
dying during or immediately after a seizure.  Extrapolating from contemporary national 
statistics the mortality among PWE of all age groups was apparently higher than that of 
the general rural Tanzanian population.  While most deaths occurred during the first ten 
years of follow-up the proportional causes of death seemed to change once AEDs ceased 
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to become available from the clinic in 1971: prior to this date 42% of deaths were 
epilepsy-related compared to 72% of deaths thereafter. 
The same population has subsequently been further studied and in 1990 a community-
based study was conducted in Ulanga, a region which incorporates Mahenge (Rwiza et al., 
1992).  A population census was conducted during which 18,183 individuals were 
screened using a modified version of the WHO screening questionnaire (WHO, 1981).  The 
estimated prevalence of active epilepsy was 12.1/1,000 after age-standardisation to the 
1970 US population, with a wide variation of between 5.1 and 37.1/1,000 being observed 
between villages.  The prevalence was higher in females than males (11.1 vs. 9.2/1,000), 
although no statistical analysis of this difference is provided.  A peak of prevalence was 
observed in those between twenty and twenty-nine years old, with a second peak in those 
over aged over fifty years of age.  Fifty-eight per cent of all cases had generalised seizures, 
31.9% partial seizures, with 22.2% overall becoming secondarily generalised, and 10.1% 
remained unclassified.  EEG was not available in this study.  Possible aetiologies were 
identified in 25.3% of cases with the commonest being a history of febrile convulsions 
(13.4%) and unspecified encephalitis (4.7%).  Other aetiologies, identified in between 0.5% 
and 1.9% of cases, were birth trauma, cerebral malaria, meningitis, head trauma, 
cerebrovascular disease and suspected tumour.  Incidence, based on interviews with 
heads of households during which cases in which epilepsy had developed between 1979 
and 1988 were identified, was retrospectively estimated at 73.3/100,000 per year. 
PWE identified during this study were subsequently studied in more detail, providing an 
insight into the lot of PWE in this population (Rwiza et al., 1993b).  Although most patients 
had active epilepsy, with 81.3% having had seizures within the year prior to the initial 
study, none were on regular treatment.  Burns with contractures or disfiguring scars 
acquired during seizures were seen in 24.1% of cases.  Of 181 cases of school age 30.9% 
had never attended school and 62.9% of those who did attend left school prematurely, 
presumable as a result of epilepsy.  Of 116 individuals of marriageable age, 42.2% 
remained unmarried and 19.8% were divorced.  While more women with epilepsy tended 
to get married than men, the divorce rates in women were higher (29.9% vs. 4.5%).  
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Although PWE identified during this study were initially followed up for one year, at the 
time of publication continued funding for the supply and delivery of AEDs, either through 
government sources or private donations, was not guaranteed (Rwiza, 1994). 
The existence of an epileptogenic genetic disorder peculiar to this population had been 
postulated at the time of the initial study (Jilek and Jilek-Aall, 1970).  To investigate this 
further, data were collected from more than 1,600 relatives of twenty-six probands drawn 
from twenty families of PWE identified during the 1990 survey and pedigree analyses 
were performed to look for evidence of familial clustering (Neuman et al., 1995).  While 
the risks to first- and second-degree relatives were higher than would have been expected 
with no familial clustering, the mode of Mendelian inheritance, if any, could not be clearly 
characterised. 
A further study in the Mahenge population was subsequently conducted in 2001, using 
same modified WHO protocol as used previously to screen the population in thirteen 
villages (Matuja et al., 2001).  One hundred and seventy-four PWE were matched with 
controls in order to ascertain risk factors for epilepsy, and detailed histories and 
examinations were correlated with corroborative evidence from health records or reliable 
household or community witnesses where available.  Risk factors significantly associated 
with epilepsy in this population were a family history, defined as first-degree relatives only 
(OR 3.52), a history of febrile convulsions (OR 2.4), neonatal or intra-partum complications 
(OR 7.3) and a history of CNS infection (OR 2.4).  No details on the denominator 
population or estimates of prevalence are provided. 
In 1988 a survey of mental disorders, including epilepsy, was conducted among 10,776 
randomly selected people living on Zanzibar, a large island off the mainland of Tanzania 
with a predominantly Muslim population (Bondestam et al., 1990).  Sampling was based 
on the ten-cell administrative structure of communities that was introduced throughout 
Tanzania during Julius Nyerere’s initial post-independence presidency (Komba, 1995).  The 
average population of one ten cell unit was estimated at fifty people, and 200 units were 
randomly selected to give a denominator population of approximately 10,000 people.  
Nursing students described the symptoms of various mental disorders to the heads of the 
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selected ten cell units, any individuals identified on the basis of these descriptions were 
interviewed and examined, and all positive diagnoses were confirmed by a psychiatrist 
overseeing the study.  The crude prevalence of epilepsy was 4.9/1,000.  All ages were 
included, with prevalence in children under four years being highest at 7.7/1,000.  No 
further details of inclusion criteria, classification of seizures or distinction between lifetime 
and active epilepsy are given. 
In 1999 a door-to-door survey in a rural coastal district in the south east of Tanzania was 
performed (Dent et al., 2005).  Using random cluster sampling, 1,047 households 
containing 4,905 individuals were screened by a senior nursing officer and a final year 
medical student using the same modified WHO protocol as the Mahenge study described 
above (Rwiza et al., 1992).  All age-groups were included, and possible cases identified 
during screening were assessed by a neurologist.  The prevalence of active epilepsy was 
estimated at 7.1/1,000 after age-standardisation to the WHO world population.  ILAE 
criteria for seizure classification were applied, with 71.4% of cases having generalised 
seizures and 28.6% having partial seizures, with half of these (14.3% overall) becoming 
secondarily generalised.  Over one quarter of seizures (26.2%) were strongly suspected to 
be symptomatic, with putative aetiological factors including trauma, cerebral malaria, 
meningitis, or other undefined CNS infections.  One third of cases had a family history of 
epilepsy, although EEG was not available to help with further characterisation of possible 
idiopathic epilepsies.  Despite the close proximity of this study population to an 
established and well-utilised district health centre, only 4.2% of cases were receiving any 
form of modern anti-epileptic treatment at the time of the study.  Furthermore, more 
than half of PWE identified (56.5%) refused medical advice that was offered.  The authors 
suggest that this emphasizes the underlying socio-cultural stigma associated with epilepsy 
in Africa. 
The final community-based study from Tanzania of which we are aware is a more recent 
door-to-door study conducted in a remote rural part of northern Tanzania from 2003 to 
2004 (Winkler et al., 2009c).  Multi-stage random sampling was used to screen 7,399 
people for epilepsy.  The screening questionnaire used was derived from the Ecuador 
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questionnaire described earlier in this chapter (Placencia et al., 1992a).  Modifications to 
the original instrument were informed by experience with this instrument in Zambia 
(Birbeck and Kalichi, 2004) and by the experience of one of the authors in diagnosing and 
treating epilepsy in the study population over a period of three years.  The final screening 
instrument consisted of fifteen questions, with validation and pilot studies being 
conducted prior to the main study.  Inclusion criteria are clearly defined, and age-
standardised estimates are given for the lifetime prevalence (13.2/1,000) and active 
prevalence (9.1/1,000) of epilepsy.  Estimates were age-standardised to the standard 
WHO population (Ahmad et al., 2001).  Seizures were classified according to a set of 
criteria proposed by the author as an alternative to the standard ILAE classification, 
designed to be of greater clinical utility in resource limited settings (Winkler et al., 2008b).  
Generalised epilepsies in otherwise healthy individuals were identified in 44.6% of cases, 
with 9.6% of these being outside of the age range of between six and twenty-five years 
old.  According to the alternative classification, these individuals should be prioritised for 
further investigation.  Focal epilepsies were identified in cases with generalised seizures 
and obvious wide-spread brain damage (12.1%), in people with generalised seizures in the 
presence of focal neurology (9.6%), and in one individual (1.2%) with simple partial 
seizures.  Only one case (1.2%) had a clearly relevant past medical history (cerebral 
malaria), while 41% mentioned having relatives with epilepsy.  At the time of the study, 



































(Rwiza et al., 
1992) 
1989 Rural 18,183 All Modified WHO 
protocol 
AE 10.2 12.1 
(US 
1970) 
0.8 Yes  
Lindi 
(Dent et al., 
2005) 
1999 Rural 4,905 All Modified WHO 
protocol 
AE 8.6 7.4 
(WHO) 
1.2 Yes  
Haidom 
(Winkler et al., 
2009c) 






0.6 Yes  
*LTE – lifetime epilepsy/AE – active epilepsy 
 
†
AS – age-standardised (standard population in parentheses) 
Table 2: Community-based prevalence studies of epilepsy from Tanzania
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1.7.3 Hospital-based studies 
A review of 428 PWE over the age of eight years who were seen at the neurology clinic at 
Dar es Salaam University Teaching Hospital between 1983 and 1985 presents information 
on aetiological factors observed in different seizure types and age groups (Matuja, 1989).  
Aetiological factors were identified in 34% of cases overall, with 46% of these being under 
fifteen years of age and 24% being over thirty years.  The most commonly identified 
factors among children were febrile seizures and CNS infections (71%), while in adults 
head injury was the most commonly identified cause (74%).  In a related study of similar 
design, conducted in the same clinic, a high prevalence (60%) of psychiatric or 
psychological comorbidity requiring intervention was noted among PWE (Matuja, 1990).  
Psychological disturbance was significantly associated with the presence of a brain lesion, 
defined as clinically evident focal or diffuse neurology or focal epileptiform abnormalities 
on EEG (p<0.05). 
More recently, 8,676 patients admitted to a mission hospital in rural northern Tanzania 
over a nine month period between 2002 and 2003 were screened for neurological 
disorders, which were implicated in 747 (8.6%) of all admissions (Winkler et al., 2011).  
Two hundred and seventy-two of these (3.1%) were accounted for by patients presenting 
with seizures (Mosser et al., 2007) of which nearly one quarter (24%) were patients with 
epilepsy, as opposed to febrile seizures or acute provoked seizures.  Neurological 
problems are thus implicated in 8.5% of acute hospital admissions in this part of Tanzania, 
of which epilepsy accounts for a considerable proportion.  This may be reflective of 
community-held beliefs around epilepsy, such as the 5.2% of people interviewed in a rural 
Tanzanian population who stated that a person having a seizure should be rushed to 




1.7.4 Other work on epilepsy from Tanzania 
In a parallel with the 1992 prevalence study conducted by Rwiza et al (Rwiza et al., 1992), 
the need for health education with regards to epilepsy in a rural Tanzanian population was 
assessed and quantified (Rwiza et al., 1993a).  Interviews were held with 3,256 heads of 
household: 2,953 in the same district as the prevalence study, and a further 302 in a 
district on the eastern shore of Lake Victoria (it is not made clear how this second 
population was selected to be included in the study).  One third of respondents (33.3%) 
mentioned a variety of causes for epilepsy, including heredity, witchcraft and spinal 
infections, while 40.6% believed that epilepsy was infectious through physical contact.  
Similar perceptions to these were documented in a more recent study from northern 
Tanzania, with 46.7% of 167 people interviewed (a mix of PWE, their relatives and villagers 
without epilepsy) ascribing epilepsy to a supernatural cause and 65.3% stating that PWE 
should not attend school or go to work (Winkler et al., 2010a).  Both of these surveys 
identified the prominent role of traditional healers in the management of epilepsy in 
Tanzania.  The latter of these studies also found that non-biomedical treatment for 
epilepsy in Tanzania commonly includes the use of Christian prayer, and that a belief in 
the utility of traditional forms of treatment is more strongly held by PWE and their 
families than those not affected by epilepsy (Winkler et al., 2010a). 
Finally, the stigma associated with epilepsy in SSA that the various studies described 
above allude to has recently been characterised in a qualitative study conducted as part of 
the main study presented in this thesis (Mushi et al., 2010).  During semi-structured 
interviews with forty-one PWE, epilepsy was commonly ascribed to witchcraft and curses, 
with the majority of people interviewed describing discrimination and social exclusion as a 




1.8 Summary of introduction 
Epilepsy is a common neurological disorder worldwide.  The prevalence varies from region 
to region but is generally considered to be higher in LMICs, including those in SSA.  The 
reasons for this have yet to be accurately characterised in many populations, although are 
likely to be related to increased incidence of neurological infections along with indices 
associated with poverty, including higher rates of perinatal morbidity and of head injury.  
Stigma and aberrant perceptions relating to epilepsy are widespread, particularly in SSA.  
In SSA in general, including Tanzania, epilepsy remains largely or wholly untreated. 
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Chapter 2.  Aims and methods 
2.1 Aims 
The primary aim of this study is to determine the age-standardised prevalence of active 
epilepsy in the Hai demographic surveillance site (HDSS), a rural district in the Kilimanjaro 
region of northern Tanzania.  This study adds to a growing body of knowledge and 
expertise on the epidemiology of non-communicable diseases (NCDs) in this population as 
well as contributing novel data on a condition which, to the best of our knowledge, has 
not been formally studied in the HDSS population previously.  This study represents one of 
the largest and most comprehensive community-based studies of the epidemiology of 
epilepsy to be conducted in SSA to date, and thus makes a valuable contribution to the 
understanding of epilepsy in this region. 
The execution of a community-based prevalence study and establishing of a prevalent 
cohort of PWE also allowed a number of subsidiary aims to be pursued, as follows: 
 To assess the performance of a previously validated screening questionnaire in a 
Kiswahili-speaking African population. 
 To describe the pattern of epilepsy seen in the HDSS study population with regards 
to gender, age, age of onset of epilepsy, classification of seizures and of epilepsies, 
and associated morbidities and impairments. 
 To identify risk factors for developing epilepsy in this population through 
comparison with age- and sex-matched controls. 
 To specifically examine the contribution of neurocysticercosis (NCC) to the 
aetiology of epilepsy in this population, utilising neuro-imaging in cases and 
comparison of demographic and serological data from age- and sex-matched 
controls. 
 To examine the impact of living with epilepsy on individuals in this population 
through comparison with age- and sex-matched controls. 
 To quantify the ETG in this population. 
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The study consisted of three main phases.  In the first phase, a door-to-door screening 
survey of the entire adult population within the study area was conducted in order to 
establish the prevalence of active epilepsy in this population.  In the second phase, all 
PWE that had been identified during the prevalence survey were assessed in more detail 
in order to establish the pattern of disease, to characterise the socio-demographic profile 
of PWE, and to evaluate the level of access to treatment for epilepsy in this population.  
This phase included attendance at a local hospital for further investigation by way of CT 
head scans and EEG recordings.  In the third phase, individuals without epilepsy were 
recruited from the background population to act as controls, and data were collected in 
order to characterise the clinical and socio-demographic associations with epilepsy in this 
population.  The case-control component of the study also included analysis of blood 





Prior to the study, we hypothesised the following: 
 The prevalence of epilepsy in this population would be higher than that seen in 
HICs, but lower than the median of 15/1,000 previously reported from SSA (Preux 
and Druet-Cabanac, 2005).  The second assumption was made given that this was a 
large study with strict inclusion criteria for active epilepsy, both of which are 
factors previously associated with lower prevalence estimates. 
 There would be identifiable risk factors for epilepsy in this population and these 
were likely to reflect those described elsewhere in SSA: perinatal complications, 
febrile seizures in childhood, CNS infections and head injuries. 
 Cysticercosis would be endemic in the population, with NCC contributing to the 
burden of acquired epilepsy. 
 The ETG in this population would be in excess of 60%. 
 There would be evidence of stigmatisation and marginalisation of PWE in this 
population. 
The remainder of this chapter provides a broad overview of the methods employed during 
the three phases of the study.  More specific details are provided, where appropriate, in 




2.2 Study site 
2.2.3 Historical background and local context 
Hai is a rural district that lies on the slopes of Mount Kilimanjaro, in the Kilimanjaro region 
of northeast Tanzania (Figure 1).  The district was established as a DSS by the Tanzanian 
Adult Morbidity and Mortality Project (AMMP).  This was a large epidemiological 
programme funded by the United Kingdom Department for International Development 
and the Tanzanian Ministry for Health, and conducted by Newcastle University (Adult 
Morbidity and Mortality Project, 2010).  AMMP was set up to collect prospective data on 
various health and social indices in Tanzania, and was operational between 1992 and 
2003.  Three sentinel sites were established from which to gather data: an urban site in 
Dar es Salaam, a poor rural area in Morogoro, and a relatively more affluent rural area in 
Hai (Mswia et al., 2002).  The infrastructure of each DSS consisted of a network of village 
workers, at least one per village in rural sites, all of whom were trained and experienced in 
collecting census data and administering research questionnaires.  These workers, 
referred to as enumerators, worked closely with community leaders to inform 
communities of any current research activity and to facilitate access to their communities 
by visiting researchers. 
Since the AMMP finished in 2003, the DSS infrastructure in Hai has been maintained 
through a series of studies conducted in the district.  These have focused on the 
epidemiology of NCDs, and have included studies on the incidence, mortality and 
prevalence of morbidity from stroke (Walker et al., 2010, Walker et al., 2000b, Walker et 
al., 2000a), the prevalence of Parkinson’s disease and essential tremor (Dotchin et al., 
2008, Dotchin and Walker, 2008) and, more recently, studies of atrial fibrillation 
(Dewhurst et al., 2012d), disability in the elderly (Dewhurst et al., 2012a, Dewhurst et al., 
2012b, Dewhurst et al., 2012c), epilepsy (Burton et al., 2011, Burton et al., 2012a, Burton 
et al., 2012b, Hunter et al., 2012, Mushi et al., 2012, Mushi et al., 2010), and skeletal 
fluorosis (Jarvis et al., 2013).  As such, the HDSS represents one of only a limited number 




2.2.4 Geographical Area 
The district has an area of 1,300 km2 and spans three ecological zones, referred to as the 
lowland, midland and upland areas.  The lowland area lies between 750 and 1,000 metres 
above sea level, receives minimal rainfall (about 325 mm a year), experiences warm to hot 
temperatures and is sparsely populated (about 70 people per km2).  The midland area lies 
between 1,000 and 1,600 metres above sea level, receives higher rainfall (about 1,560mm 
a year), experiences moderate temperatures and has a higher population density (about 
150-160 per km2).  The upland area lies above 1,600m, is encompassed within the 
Kilimanjaro National Park, and is uninhabited.  This zone is characterised by heavy rainfall 
and cool temperatures, with an environment of mountain forests and grasslands.  Rainfall 
and glacial runoff from this zone constitute the principle water sources for the district, 
with multiple springs and rivers supplying water to lower-lying inhabited areas (Mswia et 
al., 2004, Mswia et al., 2002).  The three zones are illustrated pictorially in Figure 2. 
 






Figure 2: Ecological zones in Hai 
Clockwise from top left: densely forested uplands, fertile mid-zone, semi-arid lowlands 
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The low- and midland areas of the district are bisected by one paved road, part of one of 
the Tanzanian national highways, running roughly east to west.  There are another three 
paved roads in the district: one which forms part of the western boundary, one which 
serves Kilimanjaro International Airport south of the main road, and one which serves 
Machame, a central town in the district near the boundary with the National Park.  
Villages in the district are otherwise served by a network of unpaved roads and paths of 
varying quality. 
There are generally two distinct rainy seasons affecting the region: lighter rains during 
November and December and heavier rains in April and May.  During periods of heavy rain 
many roads in the district become impassable, making access to more remote 
communities for research purposes problematic. 
The nearest large town to Hai is Moshi, which is the administrative centre for Kilimanjaro 
region.  Kilimanjaro Christian Medical Centre (KCMC), a large referral hospital where EEG 
and CT facilities are available, is located in Moshi. 
2.2.5 Administrative divisions and demographic surveillance site 
The Hai district is divided administratively into four divisions, eleven wards and sixty-one 
villages.  Each village is further sub-divided into nominal groups of ten households known 
as cells, or shinas in Kiswahili.  Each shina has an administrative representative known as a 
ten-cell leader (balozi in Kiswahili). 
The Hai demographic surveillance site (HDSS) lies within the Hai district, between latitudes 
3.13o and 3.46o S, and longitudes 37.11o and 37.36o E.  Permanent delineated boundaries 
including rivers, roads and clearly demarcated administrative boundaries are recognisable 
on the ground (Figure 3).  The HDSS encompasses three of the four administrative 
divisions in the district: Lyamungo, Machame and Masama.  These in turn are comprised 
of eight wards and fifty-six villages.  For the purposes of this study, all references to Hai 
will be in relation to the HDSS.  For practical and enumeration purposes, the fifty-six 
villages in the HDSS are also divided into three geographical zones: Upland, Lowland and 
‘Umasaini’, comprising thirty-four, fourteen and eight villages respectively.  These 
divisions also roughly correspond to various demographic differences: the Upland 
54 
 
population belong mostly to the Chagga tribal group and is predominantly Christian, while 
the Lowland and Umasaini populations represent a more cosmopolitan tribal mix, 
including a greater proportion of people who are Muslims.  The Kiswahili term ‘Umasaini’ 
roughly translates to ‘of the Maasai people’, which reflects the historically predominant 
tribe living in these villages.  Seven of the villages in the HDSS are further designated as 
‘urban’ as opposed to ‘rural’.  The average village population within the HDSS after the 
2009 census, conducted for the purposes of this study, was 3,453 persons (median 4,835; 
range 386 to 7,003). 
At the time of the study, the human infrastructure of the HDSS consisted of sixty-one 
village enumerators coordinated by five supervisors.  All of the supervisors have clinical 
training as clinical officers or assistant medical officers, and are employed as practicing 
clinicians by the Community Health Management Team (CHMT) of the Hai District Medical 
Authority.  Four of these individuals also spent one year in the UK studying for a Diploma 
in Primary Health Care Management as part of the original AMMP project.  All five 
supervisors are native Kiswahili speakers and are also fluent in English.  In addition, some 




Figure 3: Approximate boundaries of the HDSS 
(Google Maps, 2012) 
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2.3 Prevalence Study 
A complete door-to-door census of the HDSS population was conducted between January 
and April 2009.  A census form was completed for each household updating demographic 
data on household occupants; at the same time a standardised Kiswahili translation of a 
previously validated screening questionnaire to detect possible cases of epilepsy was 
asked (Placencia et al., 1992a).  In the months prior to the census preparatory workshops 
were held in the district, the screening instrument was translated and revised, and a pilot 
study was conducted to establish the sensitivity and utility of the translated screening 
instrument in a Kiswahili-speaking Tanzanian population. 
2.3.1 Census preparations 
Prior to the main census an initial one-day training workshop for the HDSS enumerators 
was held in the district in July 2008.  Video demonstrations of different seizure types were 
used to illustrate the clinical spectrum of epilepsy that might be recognised in the 
community.  These demonstrations were accompanied by explanations relating to the 
nature of epilepsy as a brain disorder, and to the treatability of the disorder in most 
patients.  At this stage enumerators and other community representatives were asked to 
inform their communities of the forthcoming census, along with the rationale for seeking 
to identify patients with epilepsy.  This sensitisation work was consolidated later in the 
year by the distribution of a community newsletter reiterating the nature and rationale of 
forthcoming research projects to be conducted in the district, including the epilepsy study. 
Immediately prior to the census, in January 2009, a further week-long workshop was held 
for the census enumerators.  Materials delivered during the initial workshop the year 
before were reviewed and additional time was dedicated to group discussions in which 
questions relating to aetiology, treatment, stigma and safety issues were all answered 
(Figure 4).  The translated screening questionnaire was discussed in detail, with final 
amendments being agreed upon.  These processes are described in more detail in 




Figure 4: Pre-census workshops in Hai 
Video demonstrations of seizures and discussion of management of epilepsy in the community 
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2.3.2 Screening instrument and translation 
As discussed in Chapter One, a number of different screening protocols for epilepsy have 
been used in SSA, including in Tanzania.  The most recent study of epilepsy in Tanzania 
made use of a nine-item questionnaire designed for use in LMICs (Winkler et al., 2009c).  
This questionnaire was originally developed and evaluated in rural Ecuador, with 
subsequent validation in a rural African population being conducted in Zambia (Placencia 
et al., 1992a, Birbeck and Kalichi, 2004, Winkler et al., 2009c).  When used in Zambia, high 
rates of false positives were noted during a pilot study, primarily among children with 
seizures associated with malaria-related fevers (Birbeck and Kalichi, 2004).  In the 
paediatric element of the Hai study, in order to eliminate this problem, only the 
population aged six years and over was screened (Burton et al., 2012a).  This approach 
mirrors that taken by other studies from SSA for the same reasons (Edwards et al., 2008, 
Snow et al., 1994).  Concerns regarding the unwanted detection of febrile seizures are less 
relevant to studies in adult populations, such as the one described here, febrile seizures 
being very uncommon in these age groups. 
The screening questionnaire in its original nine-item format was forward- and back- 
translated between English and Kiswahili following published guidance on the translation 
of questionnaires for the purposes of epidemiological studies (RAND Corporation, 2013).  
More details of the translation process and of the final Kiswahili version of the 
questionnaire are given in the third and fourth chapters, which describe the pilot study 
and screening and case ascertainment during the main study. 
2.3.3 Pilot study 
A pilot study to assess the sensitivity and specificity of the screening questionnaire in a 
Tanzanian population was conducted in patients with and without epilepsy at two sites in 
Tanzania between July and November 2008.  Secondary aims were to detect any linguistic 
or cultural difficulties with the questionnaire and its translation that could be addressed 
during further workshop activity, to be held January 2009 prior to conducting the census 





The AMMP census system is based on door-to-door interviews, with ten-cell leaders 
(balozis) from each village being asked to identify all households within their ten-cell units 
(shinas).  Census measures include clear definitions of residence and household and 
account for migration into and out of the surveillance area.  All households and household 
members are assigned unique identifying numbers which they maintain from census to 
census.  Any new households or migrants into the HDSS have new unique numbers 
generated for them when detected at census.  Ages of individuals are recorded as 
precisely as possible; a standard list of historical events relevant to the Tanzanian 
population is used to estimate age when this is not known, a technique that has previously 
been validated elsewhere in SSA (Paraiso et al., 2010). 
A census of the HDSS was conducted annually between 1992 and 2003.  Formal AMMP 
funding ceased in 2003; the census for this final year and another one in 2005 were 
funded by the Tanzanian Stroke Incidence Project (TSIP) (Walker et al., 2010).  The current 
study employed the same HDSS enumerators and supervisors to conduct a further census 
in 2009. 
Baseline demographic data were updated and the screening questionnaire to detect 
possible cases of epilepsy living in the HDSS was administered.  A single census form was 
completed for each household, with details of all individuals within each household being 
captured on each household form.  During previous censuses, fields on this form were 
devoted to various demographic and health indices (e.g. smoking, drinking).  Given the 
number of questions used to screen for epilepsy (nine) during the 2009 census, the 
number of fields devoted to other information needed to be reduced.  The 2009 census 
form therefore included fields to collect the following demographic information: age, sex, 
village, occupation, educational level, marital status, religion, whether mother and father 
alive or dead, relationship to head of household and date of entry into the surveillance 
area.  In addition to the nine questions screening for epilepsy, an additional question was 
asked to establish the number of households in the district that kept pigs, and questions 
relevant to two other studies were also included, asking about any previous engagement 
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with health research and use of insecticide treated bed nets.  The 2009 census form is 
included here in Appendix I. 
Completed census forms were transported in batches by road to Dar es Salaam where 
they were entered onto a dedicated database by a team of data entry clerks hired by the 
study.  This work was overseen by a data manager who had previous training and 
experience as part of the original AMMP study.  Census data were made available to the 
field team in the form of a Microsoft Excel spreadsheet, with logistical support during case 
ascertainment provided by the data manager in Dar es Salaam. 
The census of the HDSS was conducted from late January through to May 2009, with all 
census work being completed by 1st June 2009.  This date was selected as the prevalence 
date for the purposes of the prevalence study. 
2.3.5 Other case-finding methods 
Other than the census-based screening, two other sources were used to detect possible 
cases of epilepsy in the HDSS population: key informants, and results from other screening 
studies that may also have detected cases of epilepsy. 
Key informants 
Village enumerators were asked to approach and bring forward any individuals who they 
either knew, or suspected, to be suffering from seizure disorders of any kind but who may 
not have responded to the census screening.  This is known as the key informant method, 
and has been used extensively in rural SSA (Kamgno et al., 2003a, van der Waals et al., 
1983, Kaiser et al., 1996), including as an adjunct to population screening (Debrock et al., 
2000, Kaamugisha and Feksi, 1988).  In studies of mental retardation in LMICs key 
informants with appropriate training have been shown to have a comparable efficacy to 
screening questionnaires in detecting cases (Stein et al., 1986).  Field work in the villages, 
including the census and subsequent case-ascertainment, was conducted during four 
distinct periods between January 2009 and September 2010.  The study team also 
maintained contact with identified PWE between these periods of field work as 
arrangements were made to bring patients to KCMC for investigations.  This meant that 
the study team was effectively able to maintain a continuous presence in the district for a 
61 
 
period of twenty months.  It was stressed to enumerators that any possible additional 
cases that came to light during this time would also be seen and assessed.  As the 
population became sensitised to the issue of epilepsy, and it became known that PWE 
were accessing treatment and gaining benefit, it was assumed that some of the more 
stigmatised and marginalised individuals who may have been hiding their condition or 
who had otherwise been unaware of the study previously may have been encouraged to 
come forward. 
Cases identified by other studies 
Two further studies concerned with neurological disability including epilepsy were 
conducted in the district during the same time frame: one which screened all ages in a 
single village only (Bower et al., 2012), and one which screened those aged seventy and 
over in several villages (Dewhurst et al., 2012a, Dewhurst et al., 2012b).  The epilepsy 
study had access to findings from both of these studies from which possible additional 
cases were identified (Jim Bower and Felicity Dewhurst, personal communications).  In 
addition to these contemporaneous studies, the records from two recent studies 
conducted in the district were also made available to the epilepsy study team and 
scrutinised for possible cases (Walker et al., 2010, Dotchin et al., 2008). 
2.3.6 Inclusion criteria 
Epilepsy was defined as having previously had two or more afebrile seizures which were 
unrelated to any acute metabolic disturbance, intoxication, withdrawal from alcohol or 
drugs or acute neurosurgical insults.  Active epilepsy was defined as having satisfied these 
criteria and having had any seizures in the five years prior to the study.  Previous studies 
have also included individuals who may not meet these criteria but who were taking AEDs 
at the time of the study.  As inclusion in our study was based exclusively on individual 
assessment by the research doctor we included individuals who were taking AEDs only 
where it was felt that the initial indication for administering AEDs was consistent with a 
prior history of epilepsy according to the history available. 
In order to be included in the study, patients had to be alive and living within the HDSS 
area on 1st June 2009, to be aged fifteen years or above on this date, and to have a clinical 
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diagnosis of active epilepsy confirmed by the research doctor.  In cases where the 
presence of epilepsy was considered possible or probable but in which the diagnosis 
remained unconfirmed, individuals were kept under observation and offered further 
assessment at a later stage but were not included in the active prevalence figure unless a 
clear diagnosis of epilepsy became apparent. 
Informed consent was sought from all participants prior to including them in the study.  
Information sheets and consent forms (English and Kiswahili versions) are provided in 
Appendix II. 
2.3.7 Case ascertainment 
All diagnoses were made by a single research doctor (Dr Ewan Hunter), accompanied by a 
Tanzanian nurse (Sister Jane Rogathe).  The research doctor held the MRCP (UK) 
qualification and had also spent six months prior to the study attending specialist epilepsy 
clinics in Newcastle-upon-Tyne, UK.  The research nurse had previous experience and 
training in diagnosing and managing epilepsy in Tanzania and had also spent one month in 
the UK prior to the study gaining further experience of epilepsy services.  The research 
doctor and research nurse were also accompanied during the initial field work, between 
March and May 2009, by a UK medical student who assisted with interviewing patients.  
These three individuals were assisted by the five clinical supervisors, at least one of whom 
was present on any given day in the field. 
The large geographical area to be covered and the large anticipated numbers of positive 
responders to be screened, coupled with concerns about access to certain villages 
following the onset of the impending rainy season, meant it was deemed necessary to 
begin clinical assessments prior to completion of the census.  Lists of positive responders 
were compiled locally as the census proceeded; these individuals were assessed for 
epilepsy and their identities were checked against the final census database when it 
became available.  Cases identified during the initial round of clinical assessments were 
followed up between June and September 2009, including individuals in whom a final 
diagnosis had been deferred during the initial assessment.  During this time, an attempt 
was also made to see any additional positive responders to the census that may have 
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been missed during the initial assessment round.  Data entry of the census was complete 
by early September 2009, and remaining positive responders were traced in two further 
rounds of field work, conducted in January 2010 and July and August 2010.  Once the final 
case list was complete, controls were generated and recruited in August and September 
2010. 
All diagnoses of epilepsy were reviewed by Dr Margaret Jackson, a consultant neurologist 
in the UK with a special interest in epilepsy, between November 2010 and January 2011.  
Investigations by way of CT head scan and EEG were done in parallel with on going field 
work, between July 2009 and November 2010. 
2.3.8 Interview process 
Individuals responding positively to any of the screening questions were approached by 
their local enumerator and asked to attend a local health facility or other convenient 
community centre for further assessment by the research team.  Individuals who 
consented to be seen but who were unable to attend their local facility for any reason, 
such as frailty or distance, were visited at home by the research team (Figure 5).  All 
interviews were conducted in Kiswahili or in Kichagga, with interpretation being provided 
by the Tanzanian research nurse or by one of the clinical supervisors.  All diagnoses, 
whether epilepsy or otherwise, were ultimately made by the research doctor only, with 
further clinical examination also being conducted by the research doctor. 
All individuals attending were also asked to bring with them a relative or other person that 
would be able to provide a first-hand collateral history: i.e. an eye-witness account of any 
events that may represent seizure activity.  Where no collateral history was immediately 
available, permission would be sought to contact witnesses by mobile telephone, to 
summon witnesses to attend on that day, or to ask witnesses to attend at any future 




2.3.9 Validation of diagnoses and classifications 
The research doctor had clinical support from Dr William Howlett, a UK-trained consultant 
neurologist working at KCMC with over 20 years’ experience as a physician working in 
Tanzania.  Dr Howlett is a recognised expert on clinical neurology in SSA (Howlett, 2012), 
and he advised on difficult diagnoses and on management of cases on an on going basis.  
Following completion of case-ascertainment, all case histories were reviewed in the UK by 
Dr Margaret Jackson, a consultant neurologist at the Royal Victoria Infirmary, Newcastle, 
who specialises in epilepsy. 
Following assessment, individuals were classified as ‘epilepsy’, ‘probable epilepsy’ or ‘not 
epilepsy.’  All individuals diagnosed with epilepsy were informed of their diagnosis, were 
given advice on treatment, and were invited to participate further in the study.  Access to 
further clinical care and follow-up by the research team was not dependent on patients 
consenting to undergo any investigations on behalf of the study.  Those agreeing to 
participate were invited to KCMC for further investigation by way of EEG, CT head scan 
and blood sampling. 
Individuals were classified as ‘probable epilepsy’ when they had a history suggestive of a 
seizure disorder but information available at initial assessment was not sufficient to 
confirm the diagnosis.  These individuals were not included in the final prevalent case 
series, but have been kept under follow-up by the study team until such time as their 
diagnoses, epilepsy or otherwise, can be confirmed. 
All cases of epilepsy or probably epilepsy were given a simple patient-held seizure diary to 
aid in follow-up and titration of treatment, or in confirmation of diagnosis where relevant.  
The seizure diary is included here in Appendix VI. 
Any individuals in whom an alternative diagnosis was made were given appropriate advice 
and referred for management locally where indicated.  The sequence of screening and 
case-ascertainment activities is illustrated schematically in Figure 6.  This figure is 




Figure 5: Field work in Hai. 





Figure 6: Schematic outline of screening and case ascertainment 
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2.4 Description of the cohort 
2.4.1 Clinical details 
Details were collected on onset of epilepsy, seizure frequency and semiology and on any 
seizure-related injuries, including burns.  Where injuries were present they were classed 
as disabling if any impairment of the activities of daily living were reported. 
A full medical history was taken from all cases.  This included specifically asking about 
possible risk factors for epilepsy, including perinatal complications, problems during early 
development, febrile seizures in childhood, head injury, cerebral infection of any kind, HIV 
status, brain tumours, strokes, and a family history of seizures in first- or second-degree 
relatives.  Head injuries were classed as significant if there was a history either of loss of 
consciousness or of hospitalisation as a result of the injury, or of any clearly related 
sequelae in terms of motor or cognitive deficits. 
Treatment history included details of current or previous use of AEDs, and of any 
traditional medicine or advice from traditional healers.  Where cases had previously 
sought medical attention, details on any services they had previously presented to along 
with the source of any current AED treatment were collected.  We also asked about any 
diagnoses for their epilepsy that patients had received previously, including from 
traditional healers.  For those taking AED treatment we identified the drug(s) where 
possible, and asked about dose, timing, compliance, affordability and source(s) of 
medication.  Patients were also asked about any perceived side-effects from their AED 
treatment, and asked to rate subjectively how efficacious they thought treatment was for 
them. 
Social history included details of tribe, religion, marital status, educational level and 
occupation.  Any patients with incomplete education were asked if this was due to 
epilepsy.  All patients subsequently attending for investigations or followed up in the 
community were also asked to complete a more detailed socio-economic questionnaire.  
This included questions on provision of sanitation within the household and meat 
consumption habits, including pork.  This questionnaire was derived from a previously 
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validated poverty index developed under the original AMMP programme (Adult Morbidity 
and Mortality Project, 2004).  The timing of this questionnaire (i.e. at follow-up rather 
than at initial assessment) was dictated by the logistics and human-resources available 
during the field study, with the questions being asked in Kiswahili by enumerators or 
clinical supervisors.  This questionnaire is given here in Appendix IV. 
Finally, a brief questionnaire relating to knowledge and attitudes surrounding epilepsy 
was asked during initial assessment once a diagnosis of epilepsy was established.  This was 
not included as a formal research tool, but rather was intended to further inform the 
research team of the social context of a diagnosis of epilepsy in this community.  The 
items used were based on a longer questionnaire developed for use at an epilepsy clinic in 
another region of northern Tanzania (Andrea Winkler, personal communication). 
Following the interview all cases received a physical examination, including a detailed 
neurological assessment.  Details of the examination findings are provided in Chapter Five. 
2.4.2 Interview pro-forma 
The interview pro-forma used in the field was designed to collect clinical and socio-
demographic data in a standardised format to facilitate subsequent data entry and 
analysis.  Socio-demographic items in the pro-forma were derived from experience in a 
previous community-based study in this district (Dotchin et al., 2008, Dotchin, 2007), with 
categories relating to education and employment being derived from the original AMMP 
enumeration system (Mswia et al., 2002).  Categories for further clinical details were 
derived from a standardised questionnaire designed to collect comparable 
epidemiological data on PWE in LMICs, independent of study design (Quet et al., 2011).  
This questionnaire is in the public domain, and is published on-line in several translations, 
including English (Institute of Neurological Epidemiology and Tropical Neurology, 2012).  
The most important part of each interview was an open clinical dialogue between the 
research doctor and the patient to establish the diagnosis.  Hand-written notes were 
taken in the field, and details for each case or possible case were transcribed into a 
structured format to facilitate subsequent review and validation of diagnoses by a 
consultant neurologist in the UK.  This portion of the pro-forma was derived from two 
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previously validated semi-structured questionnaires designed to aid trained interviewers 
in collecting information to facilitate the classification of seizures (Ottman et al., 1990, 
Reutens et al., 1992).  Both of these instruments performed well in validation studies 
comparing their performance to direct assessment by a neurologist, although to our 
knowledge neither has been used previously in either LMICs or in Africa.  The field pro-
forma is given here in Appendix III. 
2.4.3 Investigations 
All consenting patients were invited for further investigation by way of CT head scan and 
EEG, available locally at KCMC.  To facilitate these investigations all patients attending the 
study were registered at the hospital, if not previously registered, and a hospital file 
opened on their behalf.  All associated costs, including administration, investigations, 
transport and food, were met by the study.  When attending for CT and EEG patients were 
also asked for a blood sample, to be stored and later analysed for the presence of 






Controls were recruited into the study once case ascertainment was complete.  Using a 
random number sequence, six age- and sex-matched controls were identified for each 
case from the census database, providing a broadly matched pool of potential controls 
from which to recruit.  The list of names was compared with the census and field-work 
databases to ensure that no positive responders or identified PWE had been included, and 
lists of names of controls found in each village in the district were then distributed to the 
field team.  During August and September 2010 individuals appearing on these lists were 
approached and invited to participate in the study, and all individuals agreeing to act as 
controls were clinically assessed by the research doctor to ensure that there were no 
further cases of epilepsy within this group.  Participating controls then completed a 
questionnaire that mirrored the pro-forma used during case ascertainment and the socio-
economic questionnaire completed by cases during follow-up visits.  The control interview 
pro-forma, translated into Kiswahili, was completed by one of the field team (either an 
enumerator or clinical supervisor). 
The case-control portion of the study was designed to answer three principal questions: 
 What are the clinical associations with and risk factors for developing epilepsy in 
this population? 
 How important is cysticercosis as a risk factor for epilepsy in this population? 
 What are the socio-economic impacts of living with epilepsy in this population? 
More details on control recruitment are given in chapter Seven.  With regards to 
cysticercosis, sample size calculations derived from comparable populations in Burundi 
were made (Prado-Jean et al., 2007, Newell et al., 1997a) and full details are given in 




2.6 Additional activities 
During the course of field work some data were collected and work initiated that fall 
beyond the scope of this thesis.  These are briefly detailed below. 
2.6.1 Genetics of epilepsy 
Whole blood has been stored for future DNA analysis as part of a larger, multi-site study.  
These samples are currently held at the Wellcome/KEMRI research laboratory at Kilifi, 
Kenya.  Ethical approval for this aspect was sought prior to commencing the study, and 
prior to collecting any blood samples it was explained to study participants that some of 
the blood would be stored for analysis in the future and that this would be done 
anonymously.  A statement to this effect was also included in the study information leaflet 
that was given or read to all participants prior to enrolment in the study (Appendix II). 
2.6.2 Qualitative work 
An in-depth qualitative study was conducted in parallel with the main study in PWE 
attending for further investigation.  Using purposive sampling, semi-structured interviews 
and thematic analysis, this study sought to further characterise beliefs about epilepsy and 
the experience of living with epilepsy in this population.  The results of this related study 
have now been published (Mushi et al., 2010). 
2.6.3 Patient follow-up 
At the time of the initial interview all PWE were given written information relating to their 
diagnosis along with a prescription for AEDs to be shown to local dispensing authorities to 
facilitate continued access to appropriate treatment.  Along with this written information 
patients and their relatives were also instructed in keeping a simple seizure-diary in order 
to keep a record of seizure frequency from the time of diagnosis.  Patients were asked to 
bring this record with them to any subsequent follow-up with the research team.  This 
patient-held record is included in Appendix VI. 
Following the initial phase of clinical assessments of positive responders patients were 
followed up, either at KCMC or in the community, to assess for sustained access to 
treatment, treatment response, and any complications or side-effects.  Any patients in 
whom a firm diagnosis had not been initially possible were also followed up in a bid to 
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confirm or reject a diagnosis of epilepsy, based on reporting of any further events or any 
additional collateral history that may have become available in the interim.  The majority 
of patients identified received clinical follow-up in this way on at least one occasion during 
the course of the prevalence and case-control studies.  We continue to collect follow-up 
data on a prospective basis, as well as offering on-going advice and support to the local 
healthcare team around the clinical care of cases identified.  The results of this follow-up, 
including clinical outcomes and extent of access and response to treatment, are being fed 
back to the local CHMT on an on-going basis. 
2.6.4 Training of local healthcare workers 
During the course of the study, the research team was approached by members of the Hai 
district CHMT and asked to provide input in terms of training for local health workers in 
the community-based management of epilepsy.  In response to this request a one day 
workshop was delivered on 15th September 2009, during which simple guidelines and an 
algorithm for the pharmacological management of epilepsy were presented.  These were 
based on guidelines developed by the ILAE (Shorvon et al., 1991) and by the Mental 
Health Association of Tanzania (MEHATA), a Tanzanian non-governmental organisation 
concerned with raising awareness and promoting the treatment of mental illness including 
epilepsy (Mental Health Association of Tanzania, 2012). 
2.6.5 Mortality 
Data on the mortality associated with epilepsy in SSA are scarce.  Having established a 
prevalent cohort of PWE in a functioning DSS, we are presented with the opportunity of 
generating robust mortality data in terms of case fatality rates and, by extrapolation from 
the original AMMP data and from national mortality statistics, standardised mortality 
ratios for deaths of any cause and proportional mortality ratios for specific causes of 
death.  A verbal autopsy system was established under the AMMP and the current clinical 
supervisors working in the HDSS are trained in this methodology (Aspray, 2005, United 





2.8.1 Data Entry 
All data were entered into a Microsoft Excel 2007 spreadsheet as field work progressed.  
On completion of field work all data were re-entered directly from field notes into a 
database written specifically for the study (Microsoft Access 2007), with all categorical 
data coded numerically.  All data were therefore double-entered, with data entry carried 
out exclusively by the research doctor.  Corresponding columns from the two databases 
were compared and any discrepancies were corrected with reference to the original hand-
written field notes, thus providing a quality control step prior to final analysis of the data. 
2.8.2 Statistical procedures 
Statistical analyses were performed using the SPSS 17.0 software package (SPSS, Chicago, 
IL, USA).  The Kolmogorov-Smirnov test for normality was used for all continuous variables.  
For continuous variables that were normally distributed, means were compared using 
Student’s independent t-test.  For non-normally distributed continuous variables, non-
parametric comparisons were made using the Mann-Whitney U test.  Variations within 
groups of continuous variables were assessed using one-way analysis of variance (ANOVA) 
when distributions were normal, and using the Kruskal-Wallis test when one or more 
variables were not normally distributed. 
Associations between categorical data were assessed using either the chi-square test or 
Fisher’s exact test for small groups where cross-tabulation cells contained counts of less 
than five.  Kappa statistics were used to quantify agreement between data sources. 
When comparing cases and controls, categorical predictor variables from both groups 
were dichotomised according to the presence or absence of the characteristic in question.  
For ordinal variables where dichotomisation was not appropriate a baseline comparator 
level was selected.  The outcome of interest for each predictor variable was ‘epilepsy’ or 
‘not epilepsy’, with uni-variable odds ratios (ORs) with 95% confidence intervals being 
calculated for all predictor variables.  Multi-variable logistic regression was used to 
examine the joint effects of multiple predictors.  Regression models were constructed 
using a backwards stepwise elimination strategy based on the likelihood ratio test (LRT), 
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with non-significant uni-variable predictor variables with a p-value of 0.1 or greater being 
excluded at each step.  A p-value of 0.05 or less was considered significant for all other 
statistical tests performed. 
Further details of specific statistical procedures are given in the individual chapters, where 
appropriate. 
2.9 Ethics 
Ethics committee approval was sought and obtained prior to the start of the study.  Given 
that the study was conducted entirely outside the UK, but that NHS staff were to be 
involved, a voluntary favourable opinion was offered by the Leeds (West) Research Ethics 
Committee (Ref: 08/H1307/128).  Formal approval in Tanzania was obtained from the 
National Institute of Medical Research (NIMR), based in Dar es Salaam (Ref. 
NIMR/HQ/R.8a/Vol IX/786).  Documents relating to ethical approval in the UK and 
Tanzania are provided here in Appendix VII.  The research doctor obtained a temporary 
medical licence from the Tanganyika Medical Council that was valid for the duration of the 
study, included here in Appendix VIII. 
The process of obtaining informed consent may be subject to imbalances when externally 
sponsored research is conducted in LMICs.  In such circumstances, it is recognised that 
truly informed consent may be compromised by a failure on the part of the research team 
to take into account the cultural setting of the project, the local beliefs and customs of the 
study population, and any communication issues that may affect comprehension of 
information (Tekola et al., 2009).  Recognised examples are the inclusion of unfamiliar 
technical concepts without sufficient culturally appropriate explanation (Molyneux et al., 
2004), or the fact that provision of healthcare as part of a research project may represent 
an undue inducement for participating in research (Tekola et al., 2009).  In some settings 
the norms of decision-making may not lie solely at an autonomous individual level, and it 
may be culturally inappropriate to seek individual permission in advance of approaching 
community leaders or elders (Molyneux et al., 2004, Boahen et al., 2013).  With due 
regard to such issues, numerous guidelines have been developed that variously stress the 
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importance of community-level consultation at an early stage (Dawson and Kass, 2005, 
Molyneux et al., 2004, Molyneux et al., 2005), using verbal consent in parallel with written 
consent in communities where literacy rates are low (Dawson and Kass, 2005, Sanchez et 
al., 2001), and providing information about the study at the correct level of 
comprehension (Council for International Organisations of Medical Sciences, 2002).  We 
hope that the measures employed during the Hai epilepsy study described here were 
devised with due regard to these considerations. 
All patients identified as having epilepsy were asked to give consent prior to participating 
further in the study.  Written information describing what the study involved, translated 
into Kiswahili, was given to patients or their carers to read; where patients or carers were 
illiterate the information was read to them by a member of the local field team.  Any 
patients giving consent but who could not write were asked for a thumb print by way of a 
signature.  Patient information and consent forms are included here in Appendix II.  The 
content of these was developed in consultation with the local field team and their 
opinions were sought as to the appropriateness and comprehensibility of the content.  It 
was explained to all participants that they were free to withdraw from the study at any 
stage should they wish to do so.  It was also explained that any advice or treatment 
offered by the study team would not be contingent on their agreeing to either to 
participate in the study, or to their remaining in the study should they decide to withdraw 
at a future date.  In the months leading up to the main study community consultation 
exercises were conducted with village elders, local religious leaders and other community 
leaders, informing them of the study plans and seeking their permission to proceed.  
Leaflets were distributed in the community, and community leaders were also invited to 
preparatory workshops held in the district in July 2008 and January 2009.  This approach 
has been employed for a number of years by study teams working in the HDSS, and 
visiting researchers are well recognised and accepted within the community (Dotchin et 
al., 2008, Walker et al., 2000b). 
Photographic material was collected during the study, including photographs illustrating 
clinical features of interest.  While this activity was not specifically included in the ethics 
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application, permission was sought on an individual basis for all photographs that were 
taken.  An explanation was given in all cases that images may be used for teaching or 
research purposes and may appear in medical publications.  There were no instances of 
individuals refusing to have their photographs taken. 
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Chapter 3.  Screening tool and pilot study 
Abstract 
Background 
Community-based door-to-door prevalence studies require sensitive screening 
instruments to detect possible cases of the disease or condition under investigation.  A 
tool with a very high sensitivity is often compromised by a lower specificity, leading to 
logistical difficulties in studies of any size.  Screening tools should be culturally and 
linguistically appropriate to the setting in which they are used.  We assessed the utility for 
use in Tanzania of a previously validated screening tool for epilepsy. 
Methods 
A previously validated screening tool for epilepsy designed for use in community-based 
studies in resource-poor settings was forward- and back-translated between English and 
Kiswahili.  The sensitivity, specificity and positive predictive value of the translated 
questionnaire were assessed in volunteers with and without epilepsy recruited at two 
hospital sites in Tanzania. 
Results 
The translated instrument performed with a sensitivity of 100% and specificity of 54.5%.  
Given that the study population of the main study was anticipated to be in excess of 
161,000, based on the most recent census of the HDSS in 2005, further statistical 
modelling was performed to identify optimal combinations of screening items to be used 
in the advent of a very high response rate.  A combination of three of the original nine 
questions was predicted to perform with an improved specificity of 86.4% while 
maintaining a sensitivity of 100%. 
Conclusions 
The translated screening tool had a good sensitivity for the detection of epilepsy in a 
Kiswahili-speaking Tanzanian population.  The low specificity could potentially be 




Cases of a given condition may be identified in the community utilising a two-stage 
approach: a simple screening test, such as a questionnaire, followed by more 
sophisticated diagnostic methods to distinguish true from false positives (Schoenberg, 
1982, Senanayake and Roman, 1993).  In the case of epilepsy, which is a clinical diagnosis, 
it is appropriate that the second step consists of a clinical history and examination 
(Placencia et al., 1992a, Sander and Shorvon, 1987).  The sensitivity of a screening test is a 
measure of the test’s ability to detect those individuals who truly have the condition, and 
is defined as the number of true positives correctly identified divided by the sum of the 
true positives and false negatives.  Conversely, the specificity is a measure of the ability to 
correctly identify those individuals who do not have the condition, and is defined as the 
number of true negatives correctly identified divided by the sum of the false positives and 
true negatives.  Both measures are usually expressed as percentages.  More sensitive 
screening tests are generally less specific, with large numbers of false positives which have 
to be examined and subsequently rejected (Shorvon and Farmer, 1988).  The positive 
predictive value (PPV) of a test is the proportion of individuals who test positive who truly 
have the condition in question. 
Validation of screening tests may be undertaken in clinic-based settings, utilising cases 
and controls in whom the diagnostic status is known, or in community-based settings 
where the screening test is applied to a sample of the population followed by formal 
diagnostic examination of all subjects, regardless of outcome of the screening test.  Data 
extrapolated from the latter method are more powerful, having been obtained in a less 
biased setting, but are more difficult to obtain due to the expense and logistics of scale 
(Placencia et al., 1992a).  Screening tools previously used in SSA have included both 
composite instruments, aiming to detect a variety of neurological conditions, and 
instruments developed specifically for the detection of epilepsy. 
The generally accepted method of linguistic translation of screening instruments is the 
‘forward and backward’ approach, whereby anomalies in meaning are detected when the 
instrument is translated back into its original language from the local language in which it 
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will be used (RAND Corporation, 2013).  Beyond the issues of linguistic translation there 
may also be ethnographic barriers to case ascertainment, whereby traditional concepts of 
illness, symptoms and aetiology may be very different from the biomedical model of 
disease from which screening questions are derived (Sander and Shorvon, 1987).  While 
these issues have been widely discussed, relatively few details of the linguistic or socio-
cultural translation of screening instruments have appeared in the published literature 
(Baskind and Birbeck, 2005b, Senanayake and Roman, 1993, Quet et al., 2011, 
Andermann, 2008). 
For the purposes of this study, we elected to develop a Kiswahili translation of a nine-item 
screening instrument originally developed in an Ecuadorian population.  This instrument 
was chosen as there are detailed descriptions of its validation and initial application 
available (Placencia et al., 1992a, Placencia et al., 1992d, Placencia et al., 1992b).  It has 
also recently been used successfully, in modified forms, in published studies from Zambia 
and Tanzania (Birbeck and Kalichi, 2004, Winkler et al., 2009c).  Notable features of this 
questionnaire are the inclusion of questions intended to detect cases of more subtle 
seizure types beyond generalised convulsive seizures, and the inclusion of a disease-
specific question in order to increase the chances of detecting known or previously 
diagnosed cases.  These elements were initially included to improve on the sensitivity of a 
questionnaire developed by the WHO for use in studies of neurological disability in LMICs 




The nine questions included in the original version of the questionnaire were: 
1. Have you ever had attacks of shaking of the arms or legs which you could not 
control? 
2. Have you ever had attacks in which you fall and become pale? 
3. Have you ever lost consciousness? 
4. Have you ever had attacks in which you fall with loss of consciousness? 
5. Have you ever had attacks in which you fall and bite your tongue? 
6. Have you ever had attacks in which you fall and lose control of your bladder? 
7. Have you ever had brief attacks of shaking or trembling in one arm or leg or in the 
face? 
8. Have you ever had attacks in which you lose contact with your surroundings and 
experience abnormal smells? 
9. Have you ever been told that you have or have had epilepsy or epileptic fits? 
In its original format a positive response was taken either as both questions one and two 
being answered in the affirmative together, or as an affirmative answer to any of the 
remaining seven questions.  This format was originally arrived at for reasons of balancing 





3.2.1 Translation process 
The approach used to the translation of the screening questionnaire was based on 
published guidelines for the translation of health survey tools (RAND Corporation, 2013).  
Translators were briefed on the socio-demographic characteristics of the target 
population, the setting for the study and the proposed mode of administration of the 
survey instrument.  Following identification of any terms or concepts likely to present 
difficulties to translation, an initial forward-translation was made by a professional 
Tanzanian translator belonging to a pool of translators used by NIMR, Tanzania.  These 
translators are experienced in the translation of materials used in qualitative studies 
(Plummer et al., 2004).  Translations back into English were then performed 
independently by four individuals.  Two were native Kiswahili speakers who are also fluent 
in English: a Tanzanian doctor trained and working in the UK, and a Tanzanian social-
scientist studying for a PhD in the UK.  Both of these individuals originally come from the 
Kilimanjaro Region in Tanzania (of which Hai is a part), and are familiar with the local 
population.  In addition the Tanzanian social scientist had previous experience of 
community-based studies in the HDSS (Mshana et al., 2008).  The third individual was an 
English statistician who is fluent in Kiswahili who also has extensive prior experience of 
community-based studies conducted in the HDSS as part of the original AMMP team 
(Mswia et al., 2004, Mswia et al., 2002).  The final person was a German-born 
paediatrician, fluent in both English and Kiswahili, who has over ten years’ experience as a 
doctor practicing in Kilimanjaro Region with a special interest in neurodevelopmental 
problems including epilepsy (Oneko et al., 2002, Klingenberg et al., 2003). 
Following identification and discussion of anomalies and discrepancies between the three 
back-translations, a final forward translation into Kiswahili was made.  This version was 
then used in a pilot study to assess for the utility of the questionnaire in translation in 




3.2.2 Pilot study 
Subjects were recruited into the pilot study from two sites: KCMC in Moshi, and Muhimbili 
National Hospital (MNH) in Dar es Salaam.  Cases from MNH consisted of individuals with 
confirmed diagnoses of epilepsy who were attending for EEG over the course of one week 
in July 2008.  Controls were recruited during the same period from out-patients attending 
the MNH neurology clinic and who did not have epilepsy.  The screening questions were 
asked by a Tanzanian nurse who had been to the UK for training in epilepsy as part of the 
study.  Cases recruited at KCMC also consisted of individuals with epilepsy attending for 
EEG, with controls being recruited from medical in-patients after medical notes had been 
examined to exclude anybody with epilepsy or seizures.  At KCMC all screening 
questionnaires were administered by the study research nurse who had also spent time in 
the UK gaining further experience of epilepsy services as part of the project. 
Sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) 
were calculated using the clinical diagnosis of epilepsy in known cases as the gold 
standard.  Kappa statistics (κ) were calculated to examine the level of agreement between 
different combinations of screening questions and a clinical diagnosis of epilepsy.  The 
interpretation of kappa statistics is summarised in Table 3 (Altman, 1991). 
Prior to the pilot study a desirable sample size was calculated using the standard error of a 
proportion.  To demonstrate a sensitivity and specificity both of 80%, with a standard 
error of five per cent, sixty-four cases and sixty-four controls would need to be included in 
the study.  Reducing this number to forty-five cases and forty-five controls would give a 
standard error of six per cent. 
Value of κ Strength of agreement 
<0.20 Poor 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Good 
0.81 – 1.00 Very good 





3.3.1 Translation process 
During the initial translation process two screening questions in particular presented 
difficulties, prompting discussion among the translators. 
Question two – “Have you ever had attacks in which you fall and become pale?” 
The idea of turning pale was anticipated to cause confusion and to be difficult to translate 
for use in a dark-skinned African population.  The initial translation used the term 
“kupoteza rangi”, literally translating back to English as “losing colour”.  On discussion it 
was felt that this would be confusing and sound bizarre, being taken to refer to a radical 
change in appearance to resemble a person of Caucasian origin.  At the same time it was 
felt by the native Tanzanian translators that the concept of both pallor, as seen in anaemia 
or hypovolaemia, and of duskiness of the palms, lips and face, as seen in transient losses 
of consciousness associated with cyanosis, would be recognised and understood.  
Consequently it was decided to specifically itemise the colour changes in terms of 
anatomical location as follows:  
“…kubadilika rangi na kuwa mweupe kwenye viganja, midomo na usoni” 
(i.e. “changing colour in the palms, lips or face”). 
Question eight – “Have you ever had attacks in which you lose contact with the 
surroundings and experience abnormal smells?” 
The initial translation of this question used the term “kunusa harufu isiyosawa”, which 
was felt to translate more closely to the active verbal sense of sniffing (kunusa – to sniff or 
to smell), rather than the passive sense of experiencing smells.  In the final translation this 
was changed to “kusikia”, which translates more closely to the concept of “sensing” or 
“being aware of”.  Furthermore, it was felt that the question could be misinterpreted in 
both English and Kiswahili as a patient may experience a number of different abnormal 
sensations in association with an impairment of consciousness, including visual and 
auditory experiences, or may not experience any abnormal sensations at all.  For this 
reason the "and" was changed to "or" ("na" to "au" in Kiswahili). 
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There was also some discussion around which version of the past tense would be most 
appropriate: the past simple tense or the past perfect tense.  It was felt that this 
distinction was important given that in colloquial Kiswahili the past simple tense may 
more readily be taken to refer to all past events, including those in the more distant past, 
while the past perfect tense carries a sense of events being more immediately recent: 
“have you ever….?”, i.e. past simple, versus “have you…?”, i.e. past perfect.  For this 
reason the past simple tense was chosen for the final translation. 
3.3.2 Pilot study: recruitment and demographics 
Fifty-two subjects were recruited into the pilot study across the two sites: twenty-eight 
(53.8%) men and twenty-four (46.2%) women.  On reviewing clinical details it became 
apparent that no formal diagnoses were available for three of the subjects recruited 
initially, and these individuals were excluded from further analysis.  Forty-nine individuals 
were therefore included in the final analysis: twenty-seven cases of epilepsy and twenty-
two controls.  The characteristics of these individuals are summarised in Table 44 and 
Figure 7.  No data were available on the background populations from which cases and 
controls were drawn, other than being native Kiswahili speakers with or without epilepsy; 
further analysis of the characteristics of cases and controls was therefore not pursued. 
The ages of both cases and controls were not normally distributed (Figure 7), with cases 
being relatively younger than controls (Mann-Whitney U 99.50, z=-3.95, p<0.001).  There 
was no significant difference in the proportions of the sexes between cases and controls 
(χ2(1)=0.15, p=0.70).  Cases were more likely to come from MNH and controls from KCMC 
(KCMC) (19 vs. 8; χ2(1)=9.01, p=0.003). 
All of the epilepsy cases recruited into the pilot study had a diagnosis of epilepsy recorded 
in their medical notes, although few further details with regards to seizure semiology or 




Cases (n=27) Controls (n=22) 
n (%) n (%) 
Female, n (% of total) 12 (44.4%) 11 (50.0%) 
Male, n (% of total) 15 (55.6%) 11 (50.0%) 
Median age in years (inter-quartile range) 13 (8.0) 30.5 (26.5) 
Site of recruitment, n (% of total) MNH 19 (70.4%) 6 (27.3%) 
KCMC 8 (29.6%) 16 (72.7%) 








3.3.3 Pilot study: response to screening questionnaire 
According to the original design of the screening questionnaire, a positive response was 
defined as either an affirmative answer to questions one and two together, or an 
affirmative answer to any of questions three to nine.  According to these criteria, thirty-
seven (75.5%) subjects were identified as possible cases of epilepsy, including all twenty-
seven true cases, while twelve (24.5%) were deemed unlikely to have epilepsy.  The 
screening questionnaire thus successfully detected all true cases of epilepsy, with ten 
people being identified as possibly having epilepsy who did not (Table 5).  The sensitivity 
and specificity of the screening questionnaire were therefore 100% and 54.5% 
respectively.  The PPV of the questionnaire was 73.0% and the NPV was 100.0%.  Overall 
there was a moderate level of agreement between the screening questionnaire and a 
clinical diagnosis of epilepsy (κ = 0.57). 
Screening response 
Epilepsy present 
Yes No Total 
Positive 27 10 37 
Negative 0 12 12 
Total 27 22 49 





3.3.4 Pilot study: analysis of individual components 
Only three (6.1%) subjects responded positively to both question one and question two, 
with these three respondents being included in the twenty-seven confirmed cases of 
epilepsy.  With twenty-four (88.9%) cases of epilepsy being missed, the combination of 
questions One and Two was a poor predictor of epilepsy (κ = 0.10).  Taking these 
questions individually, twenty (40.8%) subjects answered positively to question one, of 
whom eighteen had epilepsy and two did not.  Six (12.2%) subjects answered positively to 
question two, of whom five had epilepsy and one did not.  Question one was therefore a 
moderate predictor of epilepsy (κ = 0.56) and question two was a poor predictor of 
epilepsy (κ = 0.13). 
Thirty-seven (75.5%) subjects answered positively to at least one of questions three to 
nine, twenty-seven of whom had epilepsy and ten of whom did not.  All twenty-seven 
cases of epilepsy were therefore identified by these questions, and questions three to 
nine collectively were a moderate predictor of epilepsy (κ = 0.57).  All three cases who 
responded positively to questions one and two were also independently identified as 
having epilepsy by an affirmative answer to any of questions three to nine.  As such, the 
combination of questions one and two could be considered as being redundant in this 
study group. 
The sensitivity, specificity, PPV and NPV for each of the nine screening questions are 
illustrated Table 6 and Figure 8, and a summary of the individual analyses for each of 






















1 Have you ever had attacks of shaking of the 
arms or legs which you could not control? 18 2 9 20 66.7% 90.9% 90.0% 69.0% 
2 Have you ever had attacks in which you fall 
and change colour in the palms, lips or face? 
5 1 22 21 18.5% 95.5% 83.3% 48.3% 
3 Have you ever lost consciousness? 26 8 1 14 96.3% 63.6% 76.5% 93.3% 
4 Have you ever had attacks in which you fall, 
with loss of consciousness? 
18 4 9 8 66.7% 36.4% 81.8% 47.1% 
5 Have you ever had attacks in which you fall 
and bite your tongue? 
11 1 16 21 40.7% 95.5% 91.7% 56.8% 
6 Have you ever had attacks in which you fall 
and lose control of your bladder? 
16 0 11 22 59.3% 100.0% 100.0% 66.7% 
7 Have you ever had brief attacks of shaking 
or trembling in one arm or leg or in the 
face? 
11 3 16 19 40.7% 86.4% 78.6% 54.3% 
8 Have you ever had attacks in which you lose 
contact with the surroundings or experience 
abnormal smells? 
6 3 21 19 22.2% 86.4% 66.7% 47.5% 
9 Have you ever been told that you have or 
have had epilepsy or epileptic fits? 
19 0 8 22 70.4% 100.0% 100.0% 73.3% 
(N.B. for all rows: a+c = 27 cases, b+d = 22 controls) 




Figure 8: Performance of individual screening questions in pilot study 
 
1 2 3 4 5 6 7 8 9 
Sensitivity (%) 66.7% 18.5% 96.3% 66.7% 40.7% 59.3% 40.7% 22.2% 70.4% 
Specificity (%) 90.9% 95.5% 63.6% 36.4% 95.5% 100.0% 86.4% 86.4% 100.0% 
PPV (%) 90.0% 83.3% 76.5% 81.8% 91.7% 100.0% 78.6% 66.7% 100.0% 






















Epilepsy present (n=27) 
Κappa 
(κ) Predictive ability 
Screening response 
Positive Negative 
3 34 26 1 0.62 Good 
4 22 18 9 0.48 Moderate 
5 12 11 16 0.34 Moderate 
6 16 15 11 0.53 Good 
7 14 11 16 0.26 Poor 
8 9 6 21 0.08 Very poor 
9 19 19 8 0.68 Very good 
Table 7: Summary of pilot study responses to screening questions 3 to 9 
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3.3.5 Pilot study: best overall models 
Thirty participants (61.2%) responded positively to at least one of questions six, seven or 
nine, of whom only three did not have epilepsy (Table 8).  These three questions picked up 
all twenty-seven cases of epilepsy, and in combination were therefore a very good 
predictor of epilepsy (κ = 0.88).  The combined sensitivity of questions six, seven and nine 
was 100%, the specificity was 86.4%, the PPV was 90% and the NPV was 100%. 
The subjects of the pilot study were recruited from hospital neurology departments and 
the true cases of epilepsy were therefore highly likely to be aware of their diagnoses.  This 
introduces bias to the responses to question nine, and a model that excluded this 
question was therefore devised.  Thirty-six (73.5%) people answered ‘yes’ to either 
question one, three or six, including all twenty-seven cases of epilepsy and Nine false 
positives (Table 9).  A positive answer to question One, Three or Six was a good predictor 
of epilepsy, with κ = 0.61.  The combined sensitivity of questions One, Three and Six was 





Yes No Total 
Positive response to questions 6, 7 or 9 
Yes 27 3 30 
No 0 19 19 
Total 27 22 49 
Table 8: Relationship between final diagnoses and questions 6, 7, and 9 
 
 
 Epilepsy present 
Yes No Total 
Positive response to questions 1, 3 or 6 Yes 27 9 36 
No 0 13 13 
Total 27 22 49 





Various screening questionnaires have been used in a number of epidemiological studies 
of epilepsy in SSA over the past four decades, most of which have utilised the two-stage 
door-to-door approach.  Of the twenty-four studies summarised in Table 1 and Table 2 in 
Chapter One, eighteen describe prevalence surveys based on this approach.  Only five of 
these studies provide details of any validation of the screening tool used derived from 
within the populations being studied, including one study from Tanzania (Winkler et al., 
2009c).  Outside of Tanzania, validation data are reported in studies from Kenya, Rwanda, 
Senegal and Zambia (Edwards et al., 2008), (Simms et al., 2008), (Ndoye et al., 2005), 
(Birbeck and Kalichi, 2004). 
In a recent community-based study from Kenya, the second of two screening questions 
used was found to have a sensitivity for convulsive seizures of 100%, albeit when asked to 
parents in a study of children only (Mung'ala-Odera et al., 2004).  A cross-sectional survey 
of the prevalence of musculoskeletal impairments performed in Rwanda made use of a 
composite questionnaire which included a question designed to detect individuals who 
had fallen as a result of convulsions (Simms et al., 2008).  While a pilot feasibility study 
was performed in Rwanda in a sample of 608 individuals, the questionnaire was originally 
validated in a sample of 179 individuals in Malawi (Atijosan et al., 2007).  In this validation 
study the diagnoses made by an orthopaedic surgeon and a senior physiotherapist in 
ninety-three individuals were compared with the results from the screening questionnaire 
which was administered by technicians in a rehabilitation centre.  The overall sensitivity, 
specificity and PPV are reported as 97.8%, 98.8% and 99% respectively, although no 
details are offered as to how many of the cases in the validation study had epilepsy, or 
even as to why epilepsy and seizures should be included in a survey of musculoskeletal 
impairment.  A study from urban Senegal states that a clinic-based validation of the ILAE 
protocol yielded a sensitivity of 100% and specificity of 78.5%, although no further details 
are provided (Ndoye et al., 2005).  The final study from outside Tanzania to provide 
validation data is a large study from rural Zambia (Birbeck and Kalichi, 2004).  The authors 
provide details of a clinic-based validation of a modified version of the Ecuador protocol in 
100 PWE and fifty controls, quoting a specificity of 86% and PPV of 92%, although no 
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estimate is given for sensitivity.  The authors do comment that while no difficulties with 
understanding the screening instrument in translation were encountered, large numbers 
of false positives were initially observed and accounted for by young children who had 
presented with febrile seizures.  This led to a modification of the original screening tool 
with three questions designed to eliminate seizures in children associated with malaria or 
fever being added. 
Of the four door-to-door studies conducted within Tanzania to date only one has 
presented validation data of the screening instrument (Winkler et al., 2009c).  This study 
also used a modified version of the Ecuador protocol, and clear details are provided of a 
clinic-based validation in 106 PWE and 104 others followed by a community-based pilot 
study in a sample of 400 to assess the feasibility of the screening tool.  Sensitivity and 
specificity of 92.5% and 95% respectively are quoted. 
The original validation study of the screening questionnaire piloted here, and previously 
used in Tanzania and Zambia, was conducted some twenty years ago and involved clinic-
based validation followed by extensive validation in the field (Placencia et al., 1992a).  An 
original bank of twenty questions was piloted in eighty-seven PWE with seizures of 
different types and in sixty-three controls, with a sensitivity of 100% and specificity of 
50.8%.  A cluster analysis of response rates yielded nine questions with a collective 
sensitivity of 98% and specificity of 92%.  Following a seven-stage field validation in a rural 
population of 72,121 people, which included examination of screening-negative cases and 
re-examination of screening-positive cases which had been diagnosed as negative, a 
sensitivity of 79.3%, specificity of 92.9% and PPV of 18.8% were estimated. 
From this brief review it can be seen that the sensitivity of the Ecuador questionnaire and 
others is generally high regardless of the clinical setting, although specificity is more 
variable.  The results of our pilot study conform to this picture and, to an extent, reflect 
the experience of the original validation study, albeit in a more limited setting.  The 
translation presented no apparent difficulties in terms of how it was understood, and 
appeared to be highly sensitive for the detection of epilepsy in a Kiswahili-speaking 
Tanzanian population.  While the low specificity was of concern given the large target 
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population, it seemed that this could be improved upon if the need arose by selecting a 
reduced combination of questions without sacrificing sensitivity; i.e. in the advent of a 
very large response rate during the population census, which would have presented 
logistic challenges that would be insurmountable with the resources available to the 
study. 
There are important limitations to the pilot study presented here which must be 
considered.  Firstly, the numbers recruited to the study were very small, and fell short of 
the total sample sizes that would have been needed to confidently report sensitivity and 
specificity with a standard error of five to six per cent (n=90 to 120).  The sample that was 
included was limited by the number of PWE attending clinics at two hospitals during the 
time that was available.  This number was not easily predictable, and to increase the 
sample of cases for inclusion in the pilot study would have meant extending the period of 
the pilot study.  This was not possible as the population census, a major logistical exercise, 
was due to commence in January 2009, and the screening questionnaire needed to be 
finalised in advance of this in order for census forms to be printed. 
Secondly, we had very limited information about the PWE that were included as cases in 
the pilot study in terms of their seizure history and classification.  Medical records often 
stated simply ‘epilepsy’, or ‘seizures’.  On interviewing the nurses who had administered 
the screening questionnaire during the pilot study it was stated that all of the patients 
included had described having convulsions.  This raised concerns as to the veracity of the 
‘gold standard’ diagnosis on which the validation was based, and also as to how sensitive 
the translated screening questionnaire would prove to be for the detection of more subtle 
seizure types. 
Without such pressure on time and resources we ideally would have pursued a more 
rigorous evaluation of the screening instrument, and a larger and better characterised 
pilot sample would have allowed for exploration of the internal consistency and construct 
validity of the tool in this setting.  Psychometric methods such as the use of Kronbach’s 
alpha statistic are suitable for such work (Cicchetti, 1994, Mbuba et al., 2012a). 
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While the authors of the original questionnaire acknowledged that there were no 
questions included that would be likely to detect absence or myoclonic seizures, it was 
otherwise shown to be effective in detecting focal-onset seizures that did not become 
secondarily generalised to tonic-clonic seizures (Placencia et al., 1992a), (Placencia et al., 
1992c).  It is interesting to note that in the two African studies that have used the Ecuador 
questionnaire, one does not provide details of the types of seizures that were detected 
(Birbeck and Kalichi, 2004), and the other does not apply the recognised ILAE criteria for 
classification (Winkler et al., 2009c).  In this second study clear details of sixty-one out of 
eighty-three PWE are given, of whom sixty appear to have generalised seizures of some 
type, whether primary or secondary, although no details of tonic-clonic activity or 
otherwise are provided.  One case is described as having simple partial seizures and the 
remainder are described as having two types of seizure, with no further details given. 
3.5 Summary and conclusions 
The screening questionnaire as a whole had a sensitivity of 100% and a specificity of 
54.5%.  Using only a positive response to three of the nine questions gave a more accurate 
screening tool for epilepsy than the full questionnaire, with seven fewer false positives 
(sensitivity 100%, specificity 86.4%).  The pilot study was limited by small numbers and the 
limited clinical details available, and it was not clear that non-convulsive forms of epilepsy 
would be detected.  Due to limited time and resources no larger field-based validation was 
possible prior to the population census and screening. 
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Chapter 4.  Census screening, case ascertainment and prevalence 
Abstract 
Background 
Estimates of the prevalence of epilepsy from around the world have varied greatly.  Most 
large studies from low- and middle-income countries including those in SSA have been 
based on door-to-door screening of rural populations. 
Methods 
A door-to-door census of the HDSS population was conducted between January and May 
2009.  During the census a screening questionnaire demonstrated to have 100% sensitivity 
for known cases of epilepsy in a pilot study was used to detect possible cases of epilepsy 
in the community.  In addition census enumerators were asked to identify possible cases 
that may not have given a positive response at census screening, and the results of other 
contemporaneous studies conducted in the HDSS area were scrutinised for additional 
cases. 
Results 
The total population of the HDSS was 161,119, including 103,026 people aged fifteen 
years and above.  A total of 291 people with epilepsy were identified from multiple 
overlapping sources, all of whom were suffering from active epilepsy with convulsive 
seizures.  The age-standardised prevalence of active epilepsy was 2.91/1,000 adults (95% 
CI 2.58 to 3.24); the crude prevalence adjusted for non-response and deaths was 
3.82/1,000 (95% CI 3.45 to 4.20). 
Conclusions 
The age-standardised prevalence of epilepsy in adults living in the HDSS is lower than the 
median of 15/1,000 previously reported in SSA, although is in line with a recent large 
study of comparable design from Kenya.  Only cases of epilepsy with convulsive seizures 





Most prevalence studies of epilepsy from SSA, including Tanzania, have been conducted in 
rural populations and have utilised a number of different screening tools.  Although most 
of these tools have been previously validated most studies from SSA have provided only 
limited details on validation or pilot data from their local study populations.  Reviews of 
prevalence studies have established some important differences in the prevalence of 
epilepsy when comparing studies from LMICs, including SSA, and studies from HICs.  While 
estimates of prevalence from LMICs tend to be higher there are considerable variations, 
not all of which can be explained by differences in study design and inclusion criteria 
(Ngugi et al., 2010, Ngugi et al., 2013b).  The median prevalence in SSA has been reported 
as 15/1,000 (Preux and Druet-Cabanac, 2005), compared to a range of 4.2 to 9.0/1,000 in 
the UK (Ferro, 2011), and 4.5 to 7.0/1,000 in Europe (Forsgren et al., 2005a).  In HICs the 
prevalence of epilepsy follows a bi-modal pattern, with peaks observed in childhood and 
then in later life (Cockerell et al., 1995, Hauser et al., 1993).  In SSA it is more frequently 
observed that there is a single peak of prevalence in older children and young adults 
(Edwards et al., 2008, Winkler et al., 2009c, Rwiza et al., 1992, Simms et al., 2008, 
Osuntokun et al., 1987, Tekle-Haimanot et al., 1990b, Kaiser et al., 1996, Ndoye et al., 
2005).  This is not universally the case, however, and some studies have observed a peak 
prevalence in younger children (Longe and Osuntokun, 1988, Bondestam et al., 1990, 
Birbeck and Kalichi, 2004), while others have replicated the bi-modal peak seen in HICs 
(Osuntokun et al., 1982, Dent et al., 2005).  Another frequent observation in studies from 
SSA has been heterogeneity of prevalence and clustering of cases within study populations 
(Edwards et al., 2008, Rwiza et al., 1992, Kaiser et al., 1996), with variations in prevalence 
as wide as 5.1 to 37.1/1,000 being observed within one study population (Rwiza et al., 
1992). 
This chapter describes screening, case ascertainment and estimation of prevalence of 






A complete door-to-door census of the HDSS population was conducted between mid-
January and late May 2009.  Prior to the census, a week of preparatory workshops was 
held in the district.  All census enumerators and supervisors were provided with further 
training on the recognition of seizures and different seizure types.  Focus group 
discussions were held during which the individual components of the translated screening 
questionnaire were scrutinised and further refinements made to optimise its utility in the 
field.  The census commenced in the week following the workshops on 20th January, and 
all census work was complete by 1st June 2009.  This date was selected as the prevalence 
date.  The procedures used during the census are described in more detail in Chapter Two, 
section 2.3.4.  Given that the specificity of the screening questionnaire was estimated at 
54.5% during the pilot study, it was stipulated that a positive response to any of the 
screening questions should be made known to the study team to allow for further 
selection.  In the event that an unmanageable number of possible cases were yielded, as 
seemed likely with a specificity of 54.5% and a study population that was anticipated to be 
in excess of 160,000, only those that had responded to questions six, seven or nine, a 
combination that had performed with 100% sensitivity and 86.4% specificity in the pilot 
study (see section 3.3.5).  Allowing for public holidays, weekends and the logistics of 
travelling around the district, it was calculated that up to 2,000 individuals could be 
assessed clinically between March and September 2009, the time available for initial field 
work.  To optimise the time available for clinical assessments, an initial round was 
commenced from early March, prior to completion of the census, working from lists of 
positive responders held locally. 
Further possible cases were identified from the results of four other screening studies that 
have been performed in the district.  Two of these were conducted during the same 
period and made use of baseline demographic data from the same census data set as the 
epilepsy study.  The first of these studies was a field-based validation of a screening 
instrument designed to measure the prevalence of neurological disability, including 
epilepsy, in resource-poor settings (Bower et al., 2009, Bower et al., 2012).  In this field-
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based validation study, the entire population of a single village within the HDSS was 
screened.  The final results of this study were yet to be published at the time of the 
epilepsy study, although details of cases of epilepsy that had been identified were made 
available (Jim Bower, personal communication).  The second of these studies, a 
companion study to the epilepsy study with the same clinical supervisor and principle 
investigators, also screened for neurological disability, this time in all those aged seventy 
years and above in a selection of twelve villages (Dewhurst et al., 2012a, Dewhurst et al., 
2012b).  Again, details of cases of epilepsy from within this study cohort were made 
available to the epilepsy study team prior to publication (Felicity Dewhurst, personal 
communication).  Finally, case records from two recent community-based studies in the 
district were retrospectively scrutinised for cases of epilepsy: a study of the incidence of 
stroke in the HDSS population conducted between 2003 and 2006 (Walker et al., 2010), 
and a door-to-door study of the prevalence of Parkinson’s disease (Dotchin et al., 2008).  
Cohorts from both of these studies remain under follow up (Howitt et al., 2011, Dotchin et 
al., 2011). 
Following completion of case ascertainment, all diagnoses were reviewed and confirmed 
by Dr Margaret Jackson, a consultant neurologist with a special interest in epilepsy 
working at the Royal Victoria Infirmary in Newcastle, UK. 
4.2.2 Statistics and analysis 
Data entry and approaches to continuous and categorical variables are described in 
Chapter Two, section 2.8.  Overlapping sources of cases were used as the basis of a 
sensitivity analysis of the performance of the screening questionnaire in the field, with 
sensitivity and PPV being calculated for the screening questionnaire as a whole.  
Combinations of questions that appeared to perform well in the field were also identified.  
As no formal field validation with complete examination of a sample of the population was 
feasible given the time and resources available, it was not possible to calculate specificity 
or NPV. 
Age- and sex-specific prevalence rates for the HDSS adult population were calculated in 
five-year age-bands.  Age-standardisation to the WHO world standard population was 
102 
 
carried out using the direct method, with 95% confidence intervals (CIs) calculated based 
on a Poisson assumption (Ahmad et al., 2001, Hennekens and Buring, 1987).  The WHO 
standard population was chosen as the reference in order to be in line with the 
standardisation strategy employed by other studies conducted in the same population 
(Dewhurst et al., 2012b, Dewhurst et al., 2012d).  This study is only concerned with 
individuals aged fifteen years and above, and both the HDSS and WHO standard 
populations were therefore weighted accordingly.  A crude prevalence estimate adjusted 
for non-response was calculated using the PPV derived from the field-based sensitivity 
analysis. 
To look for evidence of clustering of cases, prevalence estimates within geographic and 
administrative divisions within the district were compared parametrically or non-
parametrically according to their distribution.  To examine for uniformity of case finding 
the crude prevalence rate per 1,000 was applied to the adult population of each village to 
generate an expected number of cases.  This was then compared to the observed number 
of cases (observed/expected = rho (ρ)).  The distributions of rho statistics within 
geographic and administrative divisions were then compared parametrically or non-
parametrically, as with crude prevalence.  For both crude prevalence and rho, the 
Kolmogorov-Smirnov test was use to identify normal and non-normal distributions.  For 
normally distributed data, one-way ANOVA was used to compare means, and for non-
normally distributed data the Kruskal-Wallis test was used.  Where only two groups were 
compared Student’s independent t-test was used for normally distributed data, and the 






4.3.1 Screening questionnaire: final refinements 
The translation of the questionnaire that had been used in the pilot study was presented 
to the HDSS enumerators and supervisors for further discussion and clarification, and the 
following points emerged. 
It was felt that the concept of an “attack”, which features in questions one, two, and four 
to eight, was difficult to translate accurately, and that this would be particularly 
problematic when applied to episodes of falling down.  It was decided that the final 
version for use in the census should have the words “…ghafla bila sababu yeyote” 
(“…suddenly and without any apparent reason”) to further qualify this concept.  In 
addition, census enumerators recommended that it should specifically be explained that 
these questions did not refer to episodes such as intoxication with alcohol, mechanical 
trips or falls or being knocked down by bicycles, livestock or other traffic.  The revised 
wording for “attack” was applied to all the questions in which it appears. 
Question nine – “Have you ever been told that you have, or have had, epilepsy or epileptic 
fits?” 
The usual Kiswahili translation of the word “epilepsy” is “kifafa”; this was felt to be a very 
stigmatising word and was also not felt to capture the various concepts of convulsive 
activity that the local population may be familiar with.  For these reasons two additional 
terms were added to the final version of the questionnaire used in the census: “degedege” 
(Kiswahili) and “kiumangungu” (Kichagga).  Both of these terms are used to refer to febrile 
seizures in children, but are also widely used to refer to convulsions in general in all age 
groups. 
The final version of the screening questionnaire used during the census, and its Kiswahili 





1.  Have you ever had attacks of shaking of the arms or legs which you could not control? 
 
Je, ulishawahi kupatwa na hali ya kutetemeka mikono au miguu, ghafla bila sababu yeyote, ambayo 
hukuweza kuizuia? 
 
2. Have you ever had attacks in which you fall suddenly, without any reason, changing colour in the 
palms, lips or face? 
 
Je, ulishawahi kupatwa na hali ambayo ilikufanya uanguke, ghafla bila sababu yeyote, kubadilika rangi 
na kuwa mweupe kwenye viganja, midomo na usoni? 
 
3.  Have you ever lost consciousness? 
 
Je, ulishawahi kupoteza fahamu? 
 
4.  Have you ever had attacks in which you fall with loss of consciousness? 
 
Je, ulishawahi kupatwa na hali ambayo ilisababisha uanguke na kupoteza fahamu, ghafla bila sababu 
yeyote? 
 
5.  Have you ever had attacks in which you fall and bite your tongue? 
 
Je, ulishawahi kupatwa na hali iliyokusababisha uanguke ghafla bila sababu yeyote, na 
kuuma/kung’ata ulimi wako? 
 
6.  Have you ever had attacks in which you fall and lose control of your bladder? 
 
Je, ulishawahi kupatwa na hali ambayo ilikufanya uanguke ghafla bila sababu yeyote na kutoa mkojo? 
 
7.  Have you ever had brief attacks of shaking or trembling in one arm or leg or in the face? 
 
Je, ulishawahi kupatwa na hali ya muda mfupi ya kutetemeka au kutikisika mkono au mguu mmoja au 
kwenye uso? 
 
8. Have you ever had attacks in which you lose contact with the surroundings and experience abnormal 
smells? 
 
Je, ulishawahi kupatwa na hali ambayo ilikufanya upoteze ufahamu wa mahali ulipo na kusikia harufu 
zisizo za kawaida? 
 
9.  Have you ever been told that you have or have had epilepsy or epileptic fits? 
 
Je, ulishawahi kuelezwa kuwa una au ulishawahi kuwa na kifafa au kuanguka kifafa, au degedege, au 
kiumangungu? 
Box 4: Final screening questionnaire, English and Kiswahili, 2009 HDSS census 
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4.3.2 Census: population demographics 
There were a total of 43,794 households in the HDSS area, with no households refusing to 
participate in the census.  The total population was 161,119 (83,180 female, 77,939 male), 
of whom 103,026 (63.9%) were aged fifteen years or above (54,386 female, 48,640 male) 
(Figure 9, Table 10). 
4.3.3 Census: door-to-door screening 
Of the 103,026 adults in the HDSS population, 568 (0.55%) individuals (286 female, 282 
male) responded positively to at least one of the nine screening questions that were asked 
during the census (Table 11).  The response rate was therefore lower than anticipated, 
and it was deemed feasible to attempt an assessment of all of the positive responders 
with no further sub-selection based on the modelling of pilot study data described in 




Figure 9: Hai adult population structure (2009 census)
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Age-band Females (% of females) Males (% of males) Total (% of total) 
0-14* 28,794 (34.6) 29,299 (37.6) 58,093 (36.1) 
15-19 8,114 (9.8) 8,648 (11.1) 16,762 (10.4) 
20-24 5,225 (6.3) 4,719 (6.1) 99,44 (6.2) 
25-29 5,487 (6.6) 4,467 (5.7) 99,54 (6.1) 
30-34 5,381 (6.5) 4,961 (6.4) 10,342 (6.4) 
35-39 5,216 (6.3) 4,852 (6.2) 10,068 (6.3) 
40-44 4,800 (5.8) 4,234 (5.4) 9,034 (5.6) 
45-49 4,156 (5.0) 3,630 (4.7) 7,786 (4.8) 
50-54 3,727 (4.5) 2,986 (3.8) 6,713 (4.2) 
55-59 2,911 (3.5) 2,437 (3.1) 5,348 (3.3) 
60-64 2,390 (2.9) 1,949 (2.5) 4,339 (2.7) 
65-69 2,135 (2.6) 1,732 (2.2) 3,867 (2.4) 
70-74 1,684 (2.0) 1,475 (1.9) 3,159 (2.0) 
75-79 1,351 (1.6) 1,180 (1.5) 2,531 (1.6) 
80-84 8,24 (1.0) 623 (0.8) 1,447 (0.9) 
85+ 9,85 (1.1) 747 (1.0) 1,732 (1.1) 
Total 83,180 (100.1)** 77,939 (100.0) 161,119 (100.1)** 
Total adults† 54,386 (65.4) 48,640 (61.6) 103,026 (64.0) 
*Ages 14 and under not considered further in this study **Totals exceed 100% due to rounding 
†
Defined as aged 15 years and above 









% of all positive 
responders 
1 Have you ever had attacks of shaking of the arms or legs which you could not control? 259 45.6% 
2 Have you ever had attacks in which you fall, suddenly and for no reason, and change 
colour in the palms, lips or face? 
363 63.9% 
3 Have you ever lost consciousness? 362 63.7% 
4 Have you ever had attacks in which you fall with loss of consciousness? 316 55.6% 
5 Have you ever had attacks in which you fall and bite your tongue? 213 37.5% 
6 Have you ever had attack in which you fall and lose control of your bladder? 177 31.2% 
7 Have you ever had brief attacks of shaking or trembling in one arm or leg or in the 
face? 
200 35.2% 
8 Have you ever had attacks in which you lose contact with the surroundings or 
experience abnormal smells? 
152 26.8% 
9 Have you ever been told that you have or have had convulsions, epilepsy or epileptic 
fits? 
173 30.5% 
Table 11: Positive response rates to individual screening questions 
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4.3.4 Case ascertainment: positive responders to door-to-door screening 
Clinical assessments were conducted during three separate periods of field work: early 
March to late June 2009, January 2010, and July to August 2010.  Possible cases assessed 
included positive responders to the census screening, individuals identified by key 
informants, and cases identified by other studies in the same population. 
Of the 568 adult positive responders, 395 (69.5%) were available for assessment.  A 
diagnosis of active epilepsy was made in 209 (52.9%) of those assessed, of whom 101 
(48.3%) were female and 108 (51.7%) were male (Table 12).  A detailed account of all 
individuals diagnosed with epilepsy is given in Chapter Five. 
Of the 568 positive responders, 173 (30.5%) were not available for clinical assessment.  
Stringent efforts were made to trace all of the 173 individuals who were not initially 
available; eighty-nine (51.4%) of these did not attend for assessment on at least two 
occasions despite, to the best of our knowledge, being aware of the study.  All those who 
refused or who did not attend were visited at home by their local village enumerator to 
ensure that they were aware of the study and its aims.  It also became apparent that four 
names had been wrongly included in the list of adult positive responders: two duplicate 
names for individuals already assessed, and two children who had being given the wrong 
date of birth in the census database.  Twelve (2.1%) positive responders had died prior to 
assessment, with information on the cause or circumstances of death being available for 
eight of these: one had been admitted to hospital with confusion (male, seventy-four 
years, died July 2009), one was described as having Parkinson’s disease (male, eighty-two 
years, died on uncertain date in 2009), one died of ‘old age’ (female, seventy-five years, 
died July 2010), two died of pneumonia (one female, seventy-six years, died January 2010; 
one male, forty-six years, died in 2009), one was described as having heart failure and 
hypertension (male, eighty-seven years, no further details available), one was described as 
having died unexpectedly during their sleep (male, twenty-five years, died July 2010), and 
one was described as being a known case of epilepsy who had drowned during a seizure 
(female, twenty-eight years, died April 2009).  The details of the 173 positive responders 
who were not assessed clinically are summarized in Figure 10. 
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4.3.5 Case ascertainment: key informants 
In addition to those responding positively to the screening questionnaire, a further 130 
individuals identified by the village enumerators as possibly suffering from epilepsy were 
assessed by the research team, and active epilepsy was diagnosed in 80 (61.5%) of these 
individuals.  Final diagnoses made in individuals brought forward by the enumerators are 
summarised in Table 13. 
4.3.6 Case ascertainment: cases identified by other studies 
Under the study which aimed to validate a composite screening tool for neurological 
disability, 4,974 people in one village were screened with five cases of epilepsy being 
detected (Jim Bower, personal communication).  The epilepsy study detected sixteen 
cases in the same group of screened individuals (eleven from census, five identified by 
village enumerators), including three of the cases detected by the other study.  The two 
additional cases were not available for clinical assessment by the epilepsy study and have 
not been included in the final case series. 
The second study screened a total of 2,221 individuals aged seventy years and above in 
twelve villages for neurological disability (Felicity Dewhurst, personal communication).  Six 
cases of epilepsy were detected, including one incident case with first onset of seizures 
subsequent to 1st June 2009.  Of the five prevalent cases, one was detected independently 
by the epilepsy study and two of the additional four were available for further clinical 
assessment, with a diagnosis of active epilepsy being confirmed in both of these cases.  
The two cases that were not available for assessment were discussed with the research 
doctors involved and although it was apparent that they would qualify for inclusion as 
cases of active epilepsy, to preserve the uniformity of the method they have not been 
included in the final case series here. 
Examination of the follow-up records of the TSIP study yielded a further three possible 
cases of epilepsy (Howitt et al., 2011).  None of these cases were detected at census by 
the epilepsy study, and on further assessment a diagnosis of epilepsy was not confirmed 
in any of these three individuals.  Finally, case records of the prevalence survey of 
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Parkinson’s disease did not yield any further possible cases of epilepsy (Catherine Dotchin, 
personal communication). 
In summary, six out of a possible ten additional cases identified by other studies were 
available for assessment by the epilepsy study, with a diagnosis of epilepsy being 
confirmed in three of these: one incident case and two prevalent cases.  No clear 
diagnoses were made in the remaining three.  The identification of cases from other 
studies is illustrated schematically in Figure 11. 
4.3.7 Case ascertainment: deferred diagnoses 
A deferred diagnosis of ‘probable epilepsy’ was made in fourteen cases (eight identified by 
census screening, six identified by village enumerators).  In these individuals, although the 
history was in some way suspicious of a seizure disorder, there was insufficient clinical 
information or corroborative collateral history available to make a firm diagnosis.  These 
individuals have not been included in the final case series, but will be kept under follow-up 
by the study and have been advised on observing and recording any further episodes and 
on where to seek help locally. 
4.3.8 Case ascertainment: false positives 
Diagnoses other than seizures or epilepsy were categorised according to the main 
problem with which the individual had presented to the study.  There were no instances 
of individuals falling into more than one diagnostic category.  The most common diagnosis 
other than seizures or epilepsy was syncope, accounting for 35.9% of false positives from 
screening, 47.1% of individuals identified by key informants, and 37.8% of false positives 
overall.  Other neurological problems that were seen included cerebral palsy, cognitive 
impairment, tremor or Parkinsonism, other movement disorders, muscular dystrophy and 
stroke.  Cardiovascular problems included one case of severe aortic stenosis complicated 
by syncope.  Respiratory problems included asthma and one case of likely lung cancer.  
Musculoskeletal problems generally consisted of generalised joint pains associated with 
osteoarthritis in the elderly.  Ophthalmological problems included cataract or other causes 
of reduced visual acuity.  Genitourinary presentations included recurrent urinary tract 
infections, pyelonephritis, urinary retention and chronic loin pain radiating to the scrotum.  
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Diagnoses related to alcohol included episodes of intoxication where there was no history 
suggestive of provoked or withdrawal seizures, and instances where individuals were 
intoxicated with alcohol on the day of assessment rendering objective assessment 
impossible.  In individuals where no diagnosis was possible there was either a history 
which could not be related to any active problem or clear diagnosis, or the individual 
concerned denied having any active problems.  Diagnoses other than epilepsy are 
summarised in Table 14 and Figure 12. 
4.3.9 Summary of case ascertainment 
A total of 527 individuals were assessed clinically, with 291 (55.2%) cases of active 
epilepsy being identified.  Of these, 209 (71.8%) were detected by the screening 
questionnaire, eighty (27.5%) were identified independently by the village enumerators, 
and two (0.7%) were identified from other studies.  A witness was available to help clarify 
the diagnosis and to characterise the features of epilepsy in 202 (69.4%) of the confirmed 




Diagnosis Female (n) (% of females) Male (n) (% of males) Total (n) (% of total) 
Active epilepsy 101 (49.5%) 108 (56.35) 209 (52.9%) 
Probable epilepsy 3 (1.5%) 5 (2.65) 8 (2.0%) 
Inactive epilepsy 1 (0.5%) 3 (1.6%) 4 (1.0%) 
Provoked seizures 5 (2.5%) 2 (1.0%) 7 (1.8%) 
Not seizures 93 (45.6%) 74 (38.5%) 167 (42.3%) 
Total 204 (100.0%) 192 (100.0%) 395 (100.0%) 
Table 12: Diagnoses in positive census responders 
 
Diagnosis Female (% of females) Male (% of males) Total (% of total) 
Active epilepsy 35 (58.3%) 45 (64.3%) 80 (61.5%) 
Probable epilepsy 4 (6.7%) 2 (2.9%) 6 (4.6%) 
Inactive epilepsy 0 (0.0%) 2 (2.9%) 2 (1.5%) 
Incident case 0 (0.0%) 1 (1.4%) 1 (0.8%) 
Isolated seizure 0 (0.0%) 1 (1.4%) 1 (0.8%) 
Provoked seizures 2 (3.3%) 3 (4.3%) 5 (3.8%) 
Resident outside HDSS 1 (1.7%) 0 (0.0%) 1 (0.8%) 
Not seizures 18 (30.0%) 16 (22.9%) 34 (26.2%) 
Total 60 (100.0%) 70 (100.0%) 130 (100.0%) 















Total Census screening Key informants 
n (%) n (%) n (%) 
Syncope 60 (35.9%) 16 (47.1%) 76 (37.8%) 
Neurological 25 (15.0%) 5 (14.7%) 30 (14.9%) 
No diagnosis possible 22 (13.2%) 2 (5.9%) 24 (11.9%) 
Other miscellaneous 16 (9.6%) 5 (14.7%) 21 (10.4%) 
Musculoskeletal problem 17 (10.2%) 2 (5.9%) 19 (9.5%) 
Ophthalmological 7 (4.2%) 2 (5.9%) 9 (4.5%) 
Respiratory 7 (4.2%) 0 (0.0%) 7 (3.5%) 
Alcohol 3 (1.8%) 1 (2.9%) 4 (2.0%) 
Cardiovascular 3 (1.8%) 0 (0.0%) 3 (1.5%) 
Genitourinary 3 (1.8%) 1 (2.9%) 4 (2.0%) 
LOC - non-epileptic 4 (2.4%) 0 (0.0%) 4 (2.0%) 
Total 167 (100.0%) 34 (100.0%) 201 (100.0%) 









Figure 13: Schematic overview of final case ascertainment 
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4.3.10 Brief demographic details of cases identified 
A total of 291 cases were identified that were alive and resident in the study area on the 
prevalence date of 1st June 2009: 155 (53.3%) males, 136 (46.7%) females.  The age 
distribution of cases was positively skewed for both sexes ( 
Figure 14), with a median age for females of twenty-nine years and for males of thirty-one 
years (Table 15).  Age did not differ significantly between the sexes (Mann-Whitney 
U=9900, z=-0.89, p=0.37). 
 
Figure 14: Age distribution of cases 
 
  Age in years 
Sex n Median 
Range 
IQR Min Max 
Female 136 29.0 15 72 23.0 
Male 155 31.0 15 85 21.0 
Combined 291 30.0 15 85 21.0 
Table 15: Age distributions of cases by sex 
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4.3.11 Performance of the screening questionnaire in the field 
While the diagnosis of active epilepsy in this study was based on strict inclusion criteria 
(Chapter Two, section 2.3.6), the performance of the screening questionnaire has been 
analysed on the basis of its ability to detect cases of particular clinical interest; i.e. cases of 
active epilepsy, seizure diagnoses other than active epilepsy and cases suggestive of 
epilepsy or seizures in whom a final diagnosis has yet to be reached. 
The overall response rate to the screening questionnaire during the census was low, with 
568 positive responses from a screened population of 103,026 (0.55%).  Of these, 395 
(69.5%) were clinically assessed: 209 (52.9%) had active epilepsy, eleven (2.8%) had a 
history of seizures but not epilepsy, and in eight (2.0%) a final diagnosis was deferred 
(total 228).  For the purpose of assessing the performance of the screening questionnaire 
this group of 228 positive responders were collectively classed as true positives (57.7% of 
those assessed).  In the remaining 167 (42.3%) of the 395 positive respondents who were 
clinically assessed there was no history suggestive of seizures and these were classed as 
being false positives.  The total number of negative responses was 102,458, of whom 134 
(0.1%) were identified by key informants or by other studies and subsequently assessed.  
Eighty-two of these (61.2%) were found to have active epilepsy, eight (6.0%) gave a 
history otherwise consistent with seizures but not active epilepsy and a final diagnosis was 
deferred in a further six (4.5%).  Again, for the purpose of analysing the screening 
questionnaire, this group of ninety-six were classed as false negatives.  The two incident 
cases identified during the study (one by key informants, one from another study) have 
been left as true negatives for the purposes of this analysis, as these negative responses 
would have held true at the time of screening.  The combined total of negative responders 
plus positive responders who were clinically assessed was therefore 102,853 (Table 16).  
Based on these totals, the sensitivity of the screening questionnaire for a diagnosis 
consistent with seizures in general, including all those confirmed as having epilepsy, was 
70.4% and the PPV was 57.7%.  Complete assessment of a population sample was not 




The combination of questions one, five, six and nine had a sensitivity of 92.1% and 
specificity of 53.9%; questions one, five, six, seven and sine collectively had a sensitivity of 
94.7% and a specificity of 44.9%.  The frequency of positive responses, sensitivity and PPV 
for each of the individual screening questions are summarised in Table 17 and Figure 15. 
Using data for all 395 individuals (203 female, 192 male) who screened positively for 
epilepsy during the census, a further analysis similar to that used during the pilot study 
was performed.  The analysis is limited by the inclusion only of false negative responders 
known to the study.  Kappa statistics were calculated for each individual question and 
combinations of questions as a measure of agreement between the actual diagnosis and 
the response to the screening questionnaire (Table 18).  Using this approach a model 
based on questions one, five and nine appears to be the most useful, with a sensitivity of 
89.0% and a specificity of 59.3%.  A model based on questions one and five only has a 




Total Seizures Not seizures 
Positive 228 167 395 
Negative 96 102,362 102, 458 
Total 324 102,529 102,853 


















Have you ever had attacks of shaking of the arms or legs 
which you could not control? 
142 52 86 62.3% 73.2% 
2 
Have you ever had attacks in which you fall, changing colour 
in the palms, lips or face? 
173 89 55 75.9% 66.0% 
3 Have you ever lost consciousness? 182 91 46 79.8% 66.7% 
4 
Have you ever had attacks in which you fall with loss of 
consciousness? 
169 72 59 74.1% 70.1% 
5 
Have you ever had attacks in which you fall and bite your 
tongue? 
142 28 86 62.3% 83.5% 
6 
Have you ever had attack in which you fall and lose control 
of your bladder? 
120 22 108 52.6% 84.5% 
7 
Have you ever had brief attacks of shaking or trembling in 
one arm or leg or in the face? 
111 45 117 48.7% 71.2% 
8 
Have you ever had attacks in which you lose contact with 
the surroundings and experience abnormal smells? 
85 37 143 37.3% 69.7% 
9 
Have you ever been told that you have or have had 
convulsions, epilepsy or epileptic fits? 
120 16 108 52.6% 88.2% 




Figure 15: Sensitivity and PPV of individual screening questions during census
1 2 3 4 5 6 7 8 9 
Sensitivity (%) 62.3% 75.9% 79.8% 74.1% 62.3% 52.6% 48.7% 37.3% 52.6% 
















(% of total) 
Epilepsy present Kappa statistic 
(κ) Predictive ability True positives False negatives 
1 194 (49.1%) 142 86 0.30 Moderate 
2 262 (66.3%) 173 55 0.23 Poor 
3 273 (69.1%) 182 46 0.26 Poor 
4 241 (61.0%) 169 59 0.31 Moderate 
5 170 (43.0%) 142 86 0.44 Moderate 
6 142 (35.9%) 120 108 0.37 Moderate 
7 156 (39.5%) 111 117 0.21 Poor 
8 122 (30.9%) 85 143 0.14 Very poor 
9 136 (34.4%) 120 108 0.40 Moderate 
1,5,6,9 287 (72.7%) 210 18 0.48 Moderate 
5,3 298(75.4%) 203 25 0.34 Moderate 
3,5,6 307 (77.7%) 209 19 0.35 Moderate 
1,5 256 (64.8%) 193 35 0.48 Moderate 
1,5,9 271 (68.6%) 203 25 0.50 Good 
1,5,6,7,9 308 (78.0%) 216 12 0.42 Moderate 
Table 18: Agreement between diagnoses and screening questions 
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When considering diagnoses of active epilepsy only, i.e. 209 diagnoses from 395 positive 
responders assessed and eighty-two known false negatives, the screening questionnaire 
performed with a sensitivity and PPV of 71.8% and 52.9% respectively. 
The low specificity demonstrated in the pilot study raised concerns about the logistics of 
using this tool in a large population.  In the event, a low response rate made an attempt at 
screening all positive responders feasible.  Local key informants involved in the study also 
made a valuable contribution by identifying additional cases within their communities that 
had been missed by the census-based screening.  A positive response to the screening 
questionnaire was generally a weaker predictor of a clinical diagnosis of epilepsy during 
the census than during the pilot study, with a sensitivity for epilepsy of 71.8% compared 
to 100%, and a PPV of 52.9% compared to 73.0% in the pilot study.  On analysis of 
individual components of the screening questionnaire’s performance in the field, no clear 
model emerged that might guide future studies using this instrument in African 
populations. 
4.3.12 Crude and age-standardised prevalence of active epilepsy 
All 291 active cases identified were suffering from convulsive epilepsy.  The overall crude 
prevalence of ACE in the HDSS adult population on 1st June 2009 was therefore 2.82 per 
1,000 adults (95% CI 2.50 to 3.15).  As this study is concerned with adults only (i.e. aged 
fifteen years and above), the HDSS and WHO populations were weighted accordingly prior 
to age-standardisation (Table 19).  To accommodate small numbers of cases in the older 
population, ages of seventy years and above were combined into a single age band.  Age- 
and sex- specific prevalence rates are shown in Table 20 and summarised in Figure 16.  
While males had a significantly higher prevalence of epilepsy than females (3.19 vs. 2.50; 
difference in proportions of 0.69/1,000, 95% CI 0.03 to 1.34), this was marginal, and would 
not have been the case with two fewer male cases or two more female cases.  The age-
standardised prevalence of epilepsy in the adult HDSS population was 2.91 per 1,000 





HDSS adult-weighted (%) WHO (%) WHO adult-weighted (%) n (%) 
0-14 58,093 (36.1%) - 26.2% - 
15-19 16,762 (10.4%) 16.3% 8.5% 11.5% 
20-24 9,944 (6.2%) 9.7% 8.2% 11.1% 
25-29 9,954 (6.2%) 9.7% 7.9% 10.7% 
30-34 10,342 (6.4%) 10.0% 7.6% 10.3% 
35-39 10,068 (6.3%) 9.8% 7.2% 9.7% 
40-44 9,034 (5.6%) 8.8% 6.6% 8.9% 
45-49 7,786 (4.8%) 7.6% 6.0% 8.2% 
50-54 6,713 (4.2%) 6.5% 5.4% 7.3% 
55-59 5,348 (3.3%) 5.2% 4.6% 6.2% 
60-64 4,339 (2.7%) 4.2% 3.7% 5.0% 
65-69 3,867 (2.4%) 3.8% 3.0% 4.0% 
70+ 8,869 (5.5%) 8.6% 5.3% 7.2% 
All-ages 161,119 (100.1%)* - 100.2%* - 
Adult population 103,026 - 100.2%* - 100.1%* 
*Totalss may not add up to 100% due to rounding 

























15-19 23 8,114 2.83 
(1.68 to 3.99) 
19 8,648 2.20 
(1.21 to 3.18) 
42 16,762 2.51 
(1.75 to 3.26) 
20-24 25 5,225 4.78 
(2.91 to 6.66) 
36 4,719 7.63 
(5.15 to 10.11) 
61 9,944 6.13 
(4.60 to 7.67) 
25-29 23 5,487 4.19 
(2.48 to 5.90) 
14 4,467 3.13 
(1.49 to 4.77) 
37 9,954 3.72 
(2.52 to 4.91) 
30-34 12 5,381 2.23 
(0.97 to 3.49) 
18 4,961 3.63 
(1.96 to 5.30) 
30 10,342 2.90 
(1.86 to 3.94) 
35-39 9 5,216 1.73 
(0.60 to 2.85) 
13 4,852 2.68 
(1.22 to 4.13) 
22 10,068 2.19 
(1.27 to 3.10) 
40-44 10 4,800 2.08 
(0.79 to 3.37) 
17 4,234 4.02 
(2.11 to 5.92) 
27 9,034 2.99 
(1.86 to 4.11) 
45-49 13 4,156 3.13 
(1.43 to 4.83) 
11 3,630 3.03 
(1.24 to 4.82) 
24 7,786 3.02 
(1.85 to 4.31) 
50-54 7 3,727 1.88 
(0.49 to 3.27) 
7 2,986 2.34 
(0.61 to 4.08) 
14 6,713 2.09 
(0.99 to 3.18) 
55-59 6 2,911 2.06 
(0.41 to 3.71) 
8 2,437 3.28 
(1.01 to 5.55) 
14 5,348 2.62 
(1.25 to 3.99) 
60+ 8 9,369 0.85 
(0.26 to 1.45) 
12 7,706 1.56 
(0.68 to 2.44) 
20 17,075 1.17 
(0.66 to 1.68) 
Total 136 54,386 2.50 
(2.08 to 2.92) 
155 48,640 3.19 
(2.69 to 3.69) 
291 103,026 2.82 
(2.50 to 3.99) 
*Denom.pop. – denominator population 




Figure 16: Graphical summary of crude prevalence rates of epilepsy in HDSS 





























4.4.13 Crude prevalence adjusted for non-response and deferred diagnoses 
There were 173 individuals who responded positively to the screening questionnaire who 
we were not able to assess clinically for the presence of epilepsy.  Four of these were 
accounted for by data entry errors, one died prior to the prevalence date, and no precise 
dates of death were available for a further three who had died some time in 2009.  The 
remaining 165 individuals may have been eligible for inclusion in the study had they been 
assessed, and by applying the PPV of 52.9% calculated for detection of active epilepsy by 
the screening questionnaire an estimated eighty-seven additional cases may have been 
missed.  This would bring the total number of active cases to 378, giving a crude 
prevalence of 3.67 per 1,000 (95% CI 3.3 to 4.0). 
Diagnoses were deferred in fourteen individuals (eight census positive responders, six 
identified by key informants), and four cases identified by other studies were not available 
for assessment by the epilepsy study team.  If a diagnosis were also to be confirmed in 
these eighteen individuals the total case series would be 396, giving a crude prevalence of 
3.84 per 1,000 (95% CI 3.47 to 4.22). 
4.3.13 Lifetime prevalence 
A diagnosis consistent with epilepsy in remission, i.e. no seizures for five years or more 
without AED treatment, was made in six cases: four census responders and two identified 
by village enumerators.  Adding these to the observed series of 291 active cases would 
give an estimated crude lifetime prevalence of 2.88 per 1000 (95% CI 2.56 to 3.21).  If the 
adjustments made above are included, the crude lifetime prevalence, based on 402 




4.3.14 Distribution of cases 
Prevalence by village had a non-normal distribution for the HDSS as a whole, within the 
Lowland geographic zone, within the Masama and Lyamungo divisions, within all eight 
wards, and within the forty-nine rural villages.  Normal distributions were observed in the 
Upland and Umasaini zones, the Machame division and in all seven urban villages.  As 
each grouping variable (division, ward, geographic zone or urban/rural) contained a mix of 
normal and non-normal distributions of prevalence, variance was therefore assessed non-
parametrically.  Descriptive and test statistics for prevalence within geographic zones, 
administrative divisions and urban and rural villages are given in Table 21.  There was no 
significant variance in prevalence within any of these groups, suggesting that clustering of 
epilepsy is unlikely in the Hai population. 
The crude estimated prevalence for epilepsy in the HDSS based on case-ascertainment 
only (i.e. no adjustment for non-response) was 2.82/1,000.  This was applied to the adult 
population in each village to generate an expected number of cases.  This was then used 
as the denominator to be compared with the observed number of cases for each village to 
generate rho statistics (ρ).  The distribution of ρ was normal within geographic zones, 
administrative divisions and within urban and rural villages, but not within administrative 
wards.  Means for normally distributed values of ρ were therefore compared 
parametrically using ANOVA for geographic zones and administrative divisions and 
Student’s independent t-test for urban and rural villages; interpretation of the t-test was 
based on Levene’s test for equality of variance within the two groups (Field, 2009b).  
Within administrative wards ρ was compared non-parametrically using the Kruskal-Wallis 
test.  Descriptive and test statistics are given in Table 22 and Table 23.  As with prevalence, 
there were no significant differences observed between any divisions within the HDSS, 
suggesting that case ascertainment had been uniform and proportional to the local study 
populations.  The raw data by for these calculations, by village, are given in Appendix X.
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 Villages Prevalence/1,000 
Test statistic (n) Median Min Max IQR 
Geographical 
zone 
Upland 34 2.53 0.00 6.24 1.91 Kruskal Wallis 
H(2)=0.482; p=0.786 Lowland 14 2.82 0.00 2.85 0.02 
Umasaini 8 2.80 2.77 2.83 0.04 
Administrative 
division 
Lyamungo 18 2.82 0.00 6.24 0.85 Kruskal-Wallis 
H(2)=0.725; p=0.711 Machame 9 2.91 0.51 5.65 2.02 
Masama 29 2.81 0.00 60.2 0.39 
Administrative 
ward 
Lyamungo Machame Kusini 9 2.83 0.00 2.85 0.02 Kruskal-Wallis 
H(7)=4.033; p=0.800 Machame Kaskazini 4 2.75 2.02 3.75 1.38 
Machame Magharibi 2 3.08 0.51 5.65  N/A* 
Machame Mashariki 9 2.26 0.00 6.24 1.85 
Machame Uroki 3 3.23 2.22 4.53 N/A* 
Masama Kusini 12 2.82 2.77 2.83 0.03 
Masama Magharibi 10 2.81 0.57 6.02 3.49 
Masama Mashariki 7 2.51 0.00 4.11 1.28 
Urban/Rural Urban 7 2.83 2.81 2.85 0.02 Mann-Whitney U 
U=1.22, z=-1.226; p=0.233 Rural 49 2.80 0.00 6.24 0.85 
*n<4 therefore quartiles not calculated 
Table 21: Epilepsy distribution by geographical and administrative division of HDSS 
132 
 
 Villages ρ (observed cases/expected cases) 
Test statistic (n) Mean Standard deviation 
Geographical 
zone 
Upland 34 0.97 0.57 ANOVA 
F(2,53)=0.766; p=0.470 Lowland 14 1.04 0.74 
Umasaini 8 0.72 0.38 
Administrative 
division 
Lyamungo 18 0.93 0.66 ANOVA 
F(2,53)=0.243; p=0.785 Machame 9 1.08 0.53 
Masama 29 0.93 0.58 
Urban/Rural Urban 7 1.23 0.82 Levene’s test. 
F(1,54)=3.043; p=0.087 
 
Independent t-test (equal variance 
assumed). 
t(54)=1.48; p=0.146 
Rural 49 0.91 0.55 




 Villages ρ (observed cases/expected cases) 
Test statistic (n) Median Min Max IQR 
Administrative 
ward 
Lyamungo Machame Kusini 9 0.92 0.00 1.88 1.46 Kruskal-Wallis 
F(7)=1.440, p=0.987 
Machame Kaskazini 4 0.98 0.71 1.33 0.49 
Machame Magharibi 2 1.09 0.18 2.00 N/A* 
Machame Mashariki 9 0.81 0.00 2.19 0.66 
Machame Uroki 3 1.15 0.79 1.59 N/A* 
Masama Kusini 12 0.82 0.00 2.55 0.64 
Masama Magharibi 10 0.92 0.20 2.12 1.27 
Masama Mashariki 7 0.89 0.00 1.46 0.45 
* n<4 therefore quartiles not calculated 




This study is one of the largest community-based surveys of the prevalence of epilepsy in 
an adult population to have been conducted in SSA to date.  The age-standardised 
prevalence for active ACE in adults of 2.91/1,000 (95% CI 2.58 to 3.24) and crude 
prevalence adjusted for non-response of 3.84/1,000 (95% CI 3.47 to 4.22) are considerably 
lower than both the median prevalence for all epilepsies of 15/1,000 previously reported 
from SSA (Preux and Druet-Cabanac, 2005), and the range for active prevalence of 8.0 to 
10.0/1,000 previously reported from Tanzania (Winkler et al., 2009c, Rwiza et al., 1992, 
Dent et al., 2005).  They are however in line with a recent study of comparable size and 
design in a rural Kenyan population which found a crude prevalence of 2.9/1,000 (95% CI 
2.6 to 3.2), rising to 4.5/1,000 (95% CI 4.1 to 4.9) after adjustment for non-response and 
sensitivity (Edwards et al., 2008).  This latter study sought to identify ACE only, and the 
lower prevalence figures of both studies may reflect this. 
Studies from Europe and the USA have identified peaks in the incidence of epilepsy in 
young children and in the elderly (Cockerell et al., 1995, Banerjeea et al., 2009, Hauser et 
al., 1993).  We did not find a peak in prevalence in those aged sixty or above, although this 
age group represents only 10.6% of the total HDSS population and it is difficult to draw 
comparisons with populations from HICs which have very different population structures.  
We did find a peak in prevalence of 6.13/1,000 in those aged between twenty and twenty-
four years, with a concentration of male cases in this age group (crude prevalence in 
males 7.63/1,000).  This is in keeping with a higher prevalence in adolescents and young 
adults identified by other studies in rural SSA (Preux and Druet-Cabanac, 2005, Edwards et 
al., 2008, Dent et al., 2005, Winkler et al., 2009c, Rwiza et al., 1992).  Whether the lower 
prevalence in later adult life points to early mortality or spontaneous remission remains 
unclear (Edwards et al., 2008).  A similar distribution in both the active and lifetime 
prevalence of epilepsy has been observed elsewhere in Tanzania, suggesting that those in 
remission may not report their previous seizures (Rwiza, 1994, Rwiza et al., 1992).  
Conversely there is mounting evidence of early mortality in epilepsy in LMICs in excess of 
that seen in HICs (Ding et al., 2006).  Observational studies suggest that this is likely to be 
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the case in SSA (Snow et al., 1994, Jilek-Aall and Rwiza, 1992, Diop et al., 2005), although 
there are presently very few formalised data with comparable standardised mortality 
ratios to confirm this (Diop et al., 2005). 
In community-based studies from SSA heterogeneity of prevalence within study 
populations has frequently been observed (Preux and Druet-Cabanac, 2005, Edwards et 
al., 2008, Rwiza et al., 1992).  Whether this reflects clustered exposure to environmental 
or genetic risk factors or a tendency for PWE to live closer to locally available treatment 
services remains unclear.  In our study case ascertainment was grossly uniform across 
administrative divisions, and there was no observation of clustering based on analyses of 
variance within geographic and administrative divisions of the HDSS. 
We found a higher prevalence in males than in females, although the difference was 
marginal.  A review of nineteen studies of the prevalence in SSA in which data on gender 
were available found a mean ratio of males to females of 1.4:1, although this difference 
was significant in only a quarter of studies (Preux and Druet-Cabanac, 2005).  While it has 
been suggested that a higher prevalence of epilepsy in males in Tanzania may reflect a 
higher risk of cranial trauma through a tendency to engage in more dangerous 
occupations (Dent et al., 2005), other studies from Tanzania have found higher 
proportions of females with epilepsy (Rwiza et al., 1992, Winkler et al., 2009c).  It has 
been postulated that this may be accounted for by a higher mortality rate among males, 
again because of dangerous occupations (Rwiza et al., 1992), although Tanzania is a 
country with a high maternal mortality rate and the strength of this argument could be 
questioned (Janson, 2007).  It has also been observed that the women in one study 
population appeared to be more health-conscious then men (Winkler et al., 2009c).  The 
authors suggest that being accustomed to attending maternity and child-care clinics and 
speaking openly about health issues may contribute to higher ascertainment rates in 
women.  Overall there remains no clear consensus on whether observed differences 
between the sexes in the prevalence of epilepsy in SSA are due to gender-specific 
aetiological factors, bias arising through artefact in case-ascertainment or competing 
mortality risks (Birbeck and Kalichi, 2004). 
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While our pilot study established the sensitivity of the screening tool in a Kiswahili-
speaking Tanzanian population, a field-based validation study with complete 
ascertainment in a larger sample would have facilitated a sensitivity analysis of the 
screening questionnaire and would also have allowed us to comment on the likely 
prevalence of non-convulsive epilepsies, given that these were not detected by our 
screening protocol.  Epilepsy with non-convulsive seizures can account for up to 50% of all 
epileptic disorders in community-based studies (Cockerell et al., 1995, Banerjeea et al., 
2009); only cases of convulsive epilepsy were detected in our study, despite the aim of 
detecting all seizure types, and the true prevalence of all epilepsies in the Hai population 
may therefore approach 6/1,000. 
Community-based studies from Zambia and Tanzania have used modified versions of the 
screening instrument used in the Hai study.  In Zambia, three additional questions were 
used to reduce the false-positive rate due to detection of febrile and malaria-associated 
seizures in children under the age of seven years (Birbeck and Kalichi, 2004).  The 
paediatric study in the HDSS excluded children under the age of six years for this reason 
(Burton et al., 2012a), and these additional questions were therefore not used in our 
study.  Elsewhere in Tanzania, a fifteen-item instrument based on the Ecuador 
questionnaire has been used (Winkler et al., 2009c), although results of this study were 
not available at the time of planning and initiating our population census.  In this study 
only one case of non-convulsive seizures was identified out of a total of eighty-three cases 
of epilepsy.  We anticipated difficulties with at least one of the specific screening 
questions (Question Eight) which may have picked up non-convulsive seizures, and sought 
to address these prior to the census through focus group work with the census 
enumerators (section 4.4.1 of this chapter and 3.4.1 of Chapter 3).  The fact that no non-
convulsive epilepsy was detected despite these efforts supports the suggestion that 
screening on this scale in rural SSA should focus on convulsive epilepsies only (Edwards et 
al., 2008, Ngugi et al., 2013b).  The difficulties of identifying focal-onset epilepsies without 
secondary generalisation in community-based studies in SSA have previously been 
acknowledged and reflected in study design (Edwards et al., 2008), and our experience in 
Hai supports this approach. 
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Nearly one third of individuals (30.5%) who responded positively to the screening 
questionnaire were not available for clinical assessment.  While this decreases the internal 
validity of our study and must be acknowledged as a limitation, Hai is an established DSS 
and this high rate of non-attendance may also reflect the degree of stigma associated with 
epilepsy in this population (Mushi et al., 2010).  Such factors may also have contributed to 
non-response at census by the eighty individuals with epilepsy who were identified by key 
informants.  While an investigation of such factors was not included in the design of this 
study, further assessment of this group of individuals may yield further insights as to the 
performance of the screening questionnaire and of the screening methodology as a 
whole.  The use of capture-recapture techniques has previously been used to maximise 
case-ascertainment of non-communicable diseases in a clinic-based setting in South Africa 
(Gill et al., 2001), although has been less successful in community-based settings in 
Tanzania, including Hai (Black et al., 1994), and was not pursued in our study. 
We report here on the prevalence of epilepsy in adults only, and the estimate has been 
age-standardised to facilitate comparison with other studies.  The crude prevalence in 
children over the age of six years in the same population was 2.91 per 1,000 (Burton et al., 
2012a). 
4.5 Summary and conclusions 
Active epilepsy with convulsive seizures has a lower prevalence in this part of Tanzania 
than elsewhere in SSA.  The previously reported high prevalence rates for epilepsy in SSA 




Chapter 5.  Convulsive epilepsy in the HDSS 
Abstract 
Background 
Comparison of findings from different study populations of PWE has been difficult due to 
incompletely described clinical details, and few studies of epilepsy from SSA benefit from 
investigation with neuro-imaging or electrophysiology.  Epilepsy is a highly stigmatised 
condition in SSA and PWE are known to suffer exclusion across major life domains. 
Methods 
Clinical, demographic and socio-economic details were collected from 291 adults with 
active epilepsy in the HDSS.  Clinical details were correlated with CT imaging and EEG.  
Seizures and epilepsies were classified according to internationally recognised criteria. 
Results 
All PWE identified had convulsive epilepsy: 208 (71.5%) had focal epilepsy and eight (2.7%) 
had generalised epilepsy; seizures and epilepsies remained unclassified in seventy-five 
(25.8%) cases.  Co-morbidities included cognitive impairment in eighty-nine (30.6%) cases, 
motor impairment in forty-eight (16.5%) cases, and seizure-related burns in seventy-six 
(26.1%) cases; disability due to seizure-related injuries was observed in twenty-one (7.2%) 
cases.  One fifth of all cases (20.7%) had no formal education, with this being significantly 
associated with epilepsy that began before school age.  The majority of cases aged 
nineteen years and above remained unmarried (58.5%), and being single was significantly 
associated with epilepsy that had started before nineteen years of age.  Nearly one 
quarter of cases (24.1%) were economically inactive due to perceived illness or disability. 
Conclusions 
CT and EEG aided in the classification of epilepsies in this population.  Rates of co-
morbidity with neurological impairments and seizure-related injury are high.  PWE living in 
the HDSS are marginalised, and exclusion from education and marriage is correlated with 




The comparison of epidemiological studies of epilepsy, whether conducted in HICs or 
LMICs, can be complicated by the application of different definitions of epilepsy or by a 
lack of clinical details to qualify diagnoses (Thurman et al., 2011), (Sander, 2003, Sander 
and Shorvon, 1996).  This is especially true of studies that have been conducted in SSA 
(Preux and Druet-Cabanac, 2005).  Generalised seizures have been the most commonly 
reported seizure type worldwide, although it has been suggested that careful application 
of seizure classifications and the use of EEG may reveal many of these to be focal onset 
seizures, with or without secondary generalisation (Sander and Shorvon, 1996).  While 
proportions of generalised seizures as high as 88% have been reported (Li et al., 1985), 
other studies in which routine investigations have been available, such as the United 
Kingdom National General Practice Study of Epilepsy, have reported partial seizures in 
52% of patients and generalised seizures in 39%, with the remainder being unclassifiable 
(Sander et al., 1990).  A recent review of the records of over 2,000 PWE identified in 
thirteen studies from twelve African countries (Quet et al., 2011).  Generalised epilepsy 
was reported in 65.9% of cases, focal epilepsy in 33.8%, with the remainder being 
unclassified.  The proportion of generalised epilepsy accounted for by focal-onset seizures 
becoming secondarily generalised is not clearly expressed.  Although rates of focal-onset 
seizures have been higher in African countries, accounting for between 59.4% and 74.3% 
of all cases, with up to 44.7% of these becoming secondarily generalised (Senanayake and 
Roman, 1993), community-based studies from SSA have found a predominance of 
generalised tonic-clonic seizures, accounting for around 60% of all cases (Preux and Druet-
Cabanac, 2005).  This figure may be biased by the use of screening methodologies based 
on interviewing undiagnosed cases or their families in the community, which will tend to 
detect more easily recognised seizure types (Sander and Shorvon, 1987, Ottman et al., 
2010, Placencia et al., 1992a). 
Three community-based studies from Tanzania over the past twenty years have provided 
details on seizure classification and aetiology (Dent et al., 2005, Rwiza et al., 1992, Winkler 
et al., 2009c).  In the first of these, conducted in 1989, contemporary ILAE criteria were 
applied to 207 PWE (Commission on Classification and Terminology of the International 
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League Against Epilepsy, 1981, Rwiza et al., 1992).  Partial seizures accounted for 31.9% of 
all cases, with seizures becoming secondarily generalised accounting for 22.2% of cases 
overall.  Generalised onset seizures accounted for 58.0% of all seizures, with tonic-clonic 
seizures accounting for 54.1% of seizures overall.  Possible aetiological factors were 
identified in 25.3% of cases, with febrile convulsions and unspecified encephalitis being 
the most commonly reported.  A study conducted in 1999 applied updated ILAE criteria to 
forty-two PWE (Dent et al., 2005, Commission on Classification and Terminology of the 
International League Against Epilepsy, 1989).  In this cohort 71.4% of cases had 
generalised seizures, although further details are limited, and 28.6% had partial seizures.  
Half of these (14.3% overall) had partial seizures becoming secondarily generalised.  In this 
study a probable aetiology for the epilepsy was identified in 26.2% of cases, including 
trauma, cerebral malaria, meningitis and other cerebral infections.  No EEGs or neuro-
imaging were available to aid in diagnosis or classification in either of these studies.  
Finally, a study from northern Tanzania conducted between 2003 and 2004 identified 
eighty-three PWE in a remote rural population, of whom sixty-four had active epilepsy 
(Winkler et al., 2009c).  The authors apply their own classification system (Winkler et al., 
2008b).  This makes comparison with other studies difficult, although it appears that 
44.6% of cases had generalised epilepsy and 21.7% cases had generalised seizures with 
clinical findings suggestive of a focal onset.  While no EEGs were performed, some cases 
from this study were investigated with CT head scans as part of a study of cysticercosis in 
epilepsy (Winkler et al., 2009b).  The findings of this study are discussed in more detail in 
Chapter Eight.  None of these three studies discusses the prevalence of HIV or its possible 
contribution to the prevalence of seizure disorders within their study populations. 
Numerous causes and risk factors for epilepsy peculiar to populations in SSA have been 
described, with a focus largely on infectious aetiologies (Senanayake and Roman, 1993, 
Preux and Druet-Cabanac, 2005).  Associations between epilepsy and viral encephalitis, 
meningitis, parasitic infections, cerebral malaria and HIV have all been well described 
(Misra et al., 2008, Furyk et al., 2011, Garcia and Del Brutto, 2005, Singhi, 2011, Singh and 
Prabhakar, 2008, Ngoungou and Preux, 2008, Bhigjee, 2005), although given the 
descriptive nature of most studies from SSA, the relative contribution of any given 
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aetiological factor is difficult to determine (Preux and Druet-Cabanac, 2005).  In such 
studies risk factors have been identified in around 50% of cases (Preux and Druet-
Cabanac, 2005, Quet et al., 2011).  In HICs cerebrovascular disease has been identified as 
the leading cause of epilepsy in older people (Kramer, 2001, Myint et al., 2006), with up to 
11.5% of patients with strokes developing seizures within five years (Myint et al., 2006).  
This issue has yet to be comprehensively studied in SSA, but with ageing populations and a 
demographic transition towards more urbanised lifestyles this may become more 
important as an aetiology of epilepsy in this region (Walker et al., 2010, Walker et al., 
2000a). 
Familial clustering of epilepsy or high rates of PWE giving a family history of epilepsy have 
been noted in a number studies from Africa (Neuman et al., 1995, Winkler et al., 2009c, 
Edwards et al., 2008).  Genetic epilepsies are thought to have a complex mode of 
inheritance, and genes identified so far account for only a minority of families and 
sporadic cases (Gutierrez-Delicado and Serratosa, 2004).  A number of 
neurodevelopmental disorders which do have familial patterns of inheritance, including 
neuro-cutaneous disorders such as neurofibromatosis and tuberous sclerosis, may feature 
symptomatic epilepsy as part of their presentation (Kullmann, 2002).  While there have 
been retrospective, hospital-based series of such disorders from Africa (Aiyesimoju et al., 
1984, Amir et al., 1993), to the best of our knowledge there are no systematic community-
based data on the prevalence of these disorders in SSA.  Similarly, we know of no large-
scale genetic studies utilising human DNA to examine the inheritance of epilepsy in 
communities from SSA. 
Injuries, including burns and scalds, have long been recognised as a risk for PWE (Hampton 
et al., 1988), with 16% of 302 PWE in a UK series having reported receiving burns over the 
course of one year (Buck et al., 1997).  In Africa this has been noted as a particular 
problem, with burns having been described as “an unrecognised epidemic” (Nuss et al., 
1974).  A hospital-based series from South Africa found that 50% of patients presenting 




Epilepsy in SSA is often associated with considerable stigma, particularly in poorer or rural 
areas (Baskind and Birbeck, 2005b).  In spite of a high degree of awareness of epilepsy 
among people in LMICs, misconceptions abound, meaning that PWE in such communities 
are less likely to be sent to school, find employment or to marry (Radhakrishnan, 2009), 
(Birbeck et al., 2007, Birbeck and Kalichi, 2003).  While some social limitations experienced 
by PWE in LMICs may relate to underlying brain disorders which may manifest as cognitive 
impairments or behavioural disorders as well as seizures, studies of stigma in epilepsy in 
SSA have nevertheless identified a high level of enacted as opposed to felt stigma (i.e. 





Cases of active epilepsy identified during the prevalence survey were interviewed and 
examined in detail, as described in Chapter Four.  Data were collected on age of onset and 
duration of epilepsy, manifestations of seizures including prodromal features, timing of 
seizures, any reported antecedent history that may constitute a risk factor for acquired 
epilepsy, and family history of seizures. 
Following the interview all cases received a full physical examination including a detailed 
neurological examination.  Formal cognitive testing was not performed, but where any 
degree of cognitive impairment or learning difficulty was apparent this was classified as 
mild, moderate or severe as follows: 
 Mild - some impairment, causing either no or only mild restrictions in daily life; 
most of the time they are independent. 
 Moderate – clear restriction in daily life, but only partly depends on 
relatives/others. 
 Severe – fully dependent on relatives/others at all times. 
This classification was recommended through personal communication with another 
research team with extensive experience of diagnosing and managing epilepsy in 
Tanzania, and was developed as part of a proposed alternative classification system for 
epilepsy designed to be of greater clinical utility in resource-limited settings (Winkler et 
al., 2008b). 
CT head scans were performed with and without contrast on a Philips Tomoscan 4000 
machine.  All scans were reported locally to exclude any acute pathology that might 
require urgent further investigation or management.  CT films were then transported as 
hard copy to the UK to be digitised and reported in the UK by Dr Daniel Birchhall, a 
consultant neuro-radiologist at the Royal Victoria Infirmary in Newcastle.  All identified 
pathologies were reported.  Specific details on the radiologic criteria used in the diagnosis 
of neurocysticercosis are described in Chapter Eight. 
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EEGs were performed using a Neohen Kohden Neurofax 11000K, a PC-based thirty-six 
channel system.  The project nurse is trained and experienced in the use of this machine.  
Patients had waking EEGs that included recording during hyperventilation and photo-
stimulation.  EEGs were recorded over thirty minutes using a standard twenty lead 
montage.  Recordings were stored electronically locally and transferred to compact disc 
for transport to the UK where they were reported by Dr Roger Whittaker, a consultant 
neurophysiologist also working at the Royal Victoria Infirmary, Newcastle.  EEGs were 
reported using a standard format (Marson et al., 2007b, Marson et al., 2007a).  There 
were no facilities for reporting EEGs locally. 
Following completion of case-ascertainment all case histories were reviewed in the UK by 
Dr Margaret Jackson, a consultant neurologist who specialises in epilepsy.  Cases were 
initially reviewed on the basis of the recorded clinical history alone and without the 
benefit of any further investigations that may have been performed.  All cases in which a 
clinical diagnosis of epilepsy was confirmed were classified according to current ILAE 
recommendations for the clinical classification of seizures.  Following clinical classification 
all cases were reviewed with EEG and CT findings to hand and further classified, as far as 
possible, according to electro-clinical syndrome and aetiology, again according to current 
recommendations from the ILAE (Berg et al., 2010, Thurman et al., 2011). 
Categorical data on tribal group, religion, and educational, marital and occupational status 
were collected, as described in Chapter Two, section 2.4.2.  Education has been free and 
compulsory from the age of eight years in Tanzania since 1976.  This age was therefore 
used as a cut-off for being of pre-school age when considering access to education.  On 
discussion with local staff and people in the villages it seemed that young people could 
traditionally expect to get married from the age of nineteen years onwards, and this was 
therefore chosen as a cut-off when examining the effect of age of onset of epilepsy and 
marital status. 
Data presented in this chapter are largely descriptive.  The chi-square test was used to 
compare categorical variables, and non-parametric comparisons between non-normally 
distributed continuous variables were made using the Mann-Whitney U test. 
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5.3 Results: clinical 
5.3.1 Age of onset and duration of epilepsy 
Data on age of onset and duration of seizures were available for 284 (97.6%) of 291 cases 
(Table 24, Figure 17, Figure 18); neither of these variables was normally distributed.  There 
was no significant difference between the sexes for in age of onset (Mann-Whitney 
U=8986.0, z=-1.516, p=0.129), or duration of epilepsy (Mann-Whitney U=9673.0, z=-0.520, 
p=0.603). 
5.3.2 Manifestations of seizures: prodrome, automatisms and timing 
All 291 cases identified gave a history consistent with convulsive epilepsy.  Of these, 117 
(40.2%) gave a history suggestive of an aura or prodrome of which the patient was 
subjectively aware (Table 25).  The category ‘non-specific awareness’ refers to cases who 
clearly recognised stereotypical prodromal events but found these difficult to describe in 
such a way as could be easily categorised.  These include various bodily sensations (e.g. 
warmth, cold, numbness, headache or nausea), psychological disturbance (e.g. feelings of 
intense fear, anxiety or elation) or cases where the patient was aware of impending 
seizures but was unable to further characterise any defining sensations.  Cases where the 
patient was unable to give a history due to cognitive impairment, but where eye witnesses 
described changes in behaviour prior to a seizure that could be taken to indicate 
awareness, such as holding on to furniture or other people, were also included in this 
category.  The relative proportions of reported prodromal features are summarised 
graphically in Figure 19. 
Behavioural features possibly suggestive of automatisms were reported in sixty-eight 
(23.4%) of 291 cases (Table 26).  Behavioural features such as smacking lips, chewing, and 
picking at clothing or unseen objects were classed as mild automatisms, while shouting 
loudly, undressing or wandering off were classed as being seriously disruptive. 
There was a clear diurnal pattern of seizures in 164 (56.4%) of 291 cases, with forty-eight 






Inter-quartile range Min Max 
Age of onset (years) Female 132 11.0 <1 66 16.0 
Male 152 14.0 <1 81 22.0 
Total 284 13.0 <1 81 19.5 
Duration epilepsy (years) Female 132 16.0 1 54 11.0 
Male 152 16.0 <1 51 16.0 
Total 284 16.0 <1 54 13.8 




Figure 17: Age of onset of epilepsy 
 
 




  Female (n=136)  Male (n=155)  Total (n=291) 
 n (% of females)  n (% of males  n (% of total) 
None reported  87 (64.0%)  87 (56.1%)  174 (59.8%) 
Non-specific  26 (19.1%)  33 (21.3%)  59 (20.3%) 
 Gastric  10 (7.4%)  9 (5.8%)  19 (6.5%) 
Visual  3 (2.2%)  9 (5.8%)  12 (4.1%) 
Motor onset  3 (2.2%)  7 (4.5%)  10 (3.4%) 
Auditory  6 (4.4%)  3 (1.9%)  9 (3.1%) 
Olfactory  1 (0.7%)  7 (4.5%)  8 (2.7%) 
Total  136 (100.0%)  155 (100.0%)  291 (100.0%) 










Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males) n (% of total) 
None reported 104 (76.5%) 119 (76.8%) 223 (76.6%) 
Mild 25 (18.4%) 23 (14.8%) 48 (16.5%) 
Seriously disruptive 7 (5.1%) 13 (8.4%) 20 (6.9%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 




Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males n (% of total 
Day 40 (29.4%) 76 (49.0%) 116 (39.9%) 
Night 24 (17.6%) 24 (15.5%) 48 (16.5%) 
Both day and night 72 (52.9%) 55 (35.5%) 127 (43.6%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 




5.3.3 Associated clinical features: cognitive and motor impairments 
A degree of cognitive impairment was observed in eighty-nine (30.6%) of 291 cases, and 
was classed as mild in forty-three (48.3%) individuals, moderate in eighteen (20.2%) and 
severe in twenty-eight (31.5%).  The onset of cognitive impairment could be defined in 
fifty-nine (66.3%) cases, with forty (67.8%) of these describing cognitive impairment 
arising either at or subsequent to the onset of seizures.  In thirty-five (39.3%) cases with 
cognitive impairment there was also associated motor impairment.  Findings other than 
motor impairment that were seen in association with cognitive impairment included 
features consistent with Down’s syndrome (two cases), tuberous sclerosis (one case) and 
neurofibromatosis (one case). 
Motor impairment was observed in a total of forty-eight (16.5%) of 291 cases, thirty-five 
(72.9%) of which presented with an upper motor neurone (UMN) pattern of weakness 
associated with cognitive impairment.  In a further thirteen (27.1%) cases, motor 
impairment was not associated with cognitive impairment.  Seven (53.8%) of these had an 
UMN hemiparesis only, of which four were apparent from birth or early childhood with no 
clear cause, one was associated with congenital hydrocephalus, one was presumed 
secondary to an undefined febrile illness with coma in childhood and one was secondary 
to a previous traumatic head injury.  Three cases had an UMN hemiparesis associated with 
ipsilateral sensory loss of which two were related to previous traumatic head injury, the 
other being apparent from early childhood with no clear cause.  Of the remaining three 
cases, one had an UMN hemiparesis and dysphasia secondary to a cerebrovascular 
accident (CVA) in adulthood, although epilepsy had been present prior to the CVA, one 
had gross generalised UMN signs presumed secondary to a previous febrile illness 
associated with coma, and one had a unilateral lower limb lower motor neurone (LMN) 
weakness secondary to previous trauma sustained in a road traffic accident.  This last case 
had also suffered a traumatic head injury at the same time, but did not manifest any UMN 




5.3.4 Other associated clinical findings 
Relevant examination findings other than cognitive or motor deficits were as follows: 
evidence of previous traumatic head injury (five cases, Figure 21), bi-temporal hemianopia 
(one case), dysmorphic features and fused digits consistent with a cranial synostosis such 
as Apert’s syndrome (one case, diagnosis unconfirmed), facial port-wine stain in keeping 
with Sturge-Weber syndrome (one case, Figure 21), optic atrophy with visual loss 
secondary to intracerebral neoplasm (one case), Parkinsonian tremor presumed 
secondary to monthly depot injections with antipsychotic medication used to treat 
seizures (one case), benign essential tremor (one case), and intraocular calcification (one 
case).  Two female patients were pregnant at the time of assessment. 
Two (0.7%) of 291 cases revealed that they were HIV positive.  The first of these (female, 
aged 29 years), had suffered seizures since early childhood and had been diagnosed with 
HIV at the age of twenty-eight on routine testing.  At the time of initial assessment by the 
epilepsy study she had yet to start anti-retroviral therapy, and manifested no outward 
clinical features suggestive of advanced immune suppression; she had a recent CD4 count 
of 261 cells/mm3 and was maintained on co-trimoxazole prophylaxis.  This patient died 
before she could be followed up at an interval of four months from initial assessment; it 
was reported locally that she had suffered a diarrhoeal illness, presumed to be HIV-
related.  The second HIV-positive patient (male, aged thirty-seven years) had also suffered 
seizures since childhood and had been diagnosed with HIV at the age of thirty-four after 
presenting for voluntary counselling and testing.  At the time of initial assessment by the 
epilepsy study he was well, with no signs of immune suppression, was on no treatment 
related to HIV, and had a recent CD4 count of 1,333 cells/mm3.  Given the very high CD4 





Figure 20: Clinical features in patients with epilepsy and cognitive impairment. 
Clockwise from left: dermal fibromas and cafe-au-lait patches suggestive of neurofibromatosis, adenoma sebaceum suggestive of tuberous 




Figure 21: Associated clinical findings in epilepsy patients. 
Left: Sturge-Weber syndrome. 




Figure 22: Congenital abnormalities seen in one epilepsy patient 
Note fused digits, left 3rd cranial nerve palsy, dysmorphic facies and cystic swelling lateral left thigh.  The patient had no apparent 
cognitive, motor or sensory deficits. 
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5.3.5 Seizure-related injuries 
Seizure-related injuries were seen or reported in 256 (88.0%) of 291 cases: 123 (90.4%) of 
136 females and 133 (85.8%) of 155 males.  The slightly higher rate of injuries seen in 
females was not significant (χ2(1)=1.47, p=0.225); types of injury are summarised in Table 
28.  While the high rates of injury reported are largely accounted for by the number of 
cases reporting tongue-biting during convulsive seizures (84% overall), there was also a 
considerable number of cases (26.1% overall) who had sustained burns during seizures 
(32.4% of females, 20.6% of males; (χ2(1)=5.15, p=0.023).  Of the 256 injured patients, 
twenty-one (9.6%) could be considered in some way disabled from their injuries (fourteen 
female, seven male; χ2(1)=3.61, p=0.057).  The majority of these were accounted for by 
seizure-related burns, with disability arising through soft-tissue contractures or the loss of 
one or more digits from the hands.  One case, a twenty-one year old female, had a below-
knee amputation after a seizure-related burn to the right lower leg had become infected 
and then gangrenous.  Lack of post-operative physiotherapy had led to a fixed-flexion 
contracture in the knee, meaning she could not be fitted with a prosthetic leg, and was 
therefore dependent on crutches for mobility.  Seizure type (generalised, focal or 
unclassified) was not correlated with the overall risk of injury (χ2(2)=1.973, p=0.373), or 
with the risk of having sustained burns (χ2(2)=0.919, p=0.631).  Details of seizure 
classifications are given later in this chapter.
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 Female (n=136) Male (n=155) Total (n=291) 
n (% of females n (% of males) n (% of total) 
Tongue bite 102 (75.0%) 113 (72.9%) 215 (73.9%) 
Burns 44 (32.4%) 32 (20.6%) 76 (26.1%) 
Deep cuts/lacerations 8 (5.9%) 12 (7.7%) 20 (6.9%) 
Bruises/superficial cuts 7 (5.1%) 6 (3.9%) 13 (4.5%) 
Fractures 4 (2.9%) 10 (6.5%) 14 (4.8%) 
Dental injuries 7 (5.1%) 7 (4.5%) 14 (4.8%) 




Figure 23: Examples of disabling seizure-related injuries seen in Hai 
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5.3.6 Risk factors for seizures and epilepsy among PWE in the HDSS 
Medical histories that represented possible risk factors for developing epilepsy were 
established in 127 (43.6%) of 291 cases: fifty-eight (42.6%) of 136 females and seventy-
one (45.8%) of 155 males (Table 29,  
Figure 24).  Eight cases (2.7%) reported two separate risk factors.  The most commonly 
reported acquired risk factors were febrile seizures in childhood (10.7% of all cases), 
perinatal complications (7.9%), head injury (6.9%), or prior febrile illness associated with 
loss of consciousness or convulsions (6.9%).  A family history of epilepsy was reported by 
fifty-one (17.5%) of 291 cases: 6.2% in first degree relatives, and 11.3% in second degree 
relatives (Table 30). 
Data on alcohol use were available for all cases, with 238 (81.8%) of 291 cases stating that 
they did not drink alcohol.  Of the fifty-three (18.2%) cases that did drink alcohol, twenty 
(37.7%) said they drank heavily, defined as four or more days per week or regularly 
drinking to intoxication (Table 31).
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 Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males) n (% of total) 
Febrile seizures in childhood 16 (11.8%) 15 (9.7%) 31 (10.7%) 
Perinatal complication 11 (8.1%) 12 (7.7%) 23 (7.9%) 
Febrile illness with LOC/convulsions 12 (8.8%) 8 (5.2%) 20 (6.9%) 
Head injury 6 (4.4%) 14 (9.0%) 20 (6.9%) 
Meningitis 4 (2.9%) 2 (1.3%) 6 (2.1%) 
Malaria with LOC/convulsions 0 (0.0%) 5 (3.2%) 5 (1.7%) 
Stroke 1 (0.7%) 2 (1.3%) 3 (1.0%) 
Brain abscess 1 (0.7%) 0 (0.0%) 1 (0.3%) 






























 Female (n=136) Male (n=155) Total (n=291) 
n (%of females) n (% of males) n (% of total) 
1st degree relative 4 (2.9%) 14 (9.0%) 18 (6.2%) 
2nd degree relative 12 (8.8%) 21 (13.5%) 33 (11.3%) 
None reported 120 (88.2%) 120 (77.4%) 240 (82.5%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 
Table 30: Cases reporting a family history of epilepsy 
 
 
 Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males) n (% of total) 
None 124 (91.2%) 114 (73.5%) 238 (81.8%) 
Light 5 (3.7%) 17 (11.0%) 22 (7.6%) 
Moderate 4 (2.9%) 7 (4.5%) 11 (3.8%) 
Heavy 3 (2.2%) 17 (11.0%) 20 (6.9%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 




5.4 Results: investigations 
A total of 229 (78.7%) of 291 cases were able to attend KCMC for further investigation 
with CT head scan, EEG or both.  The age- and sex- distributions of cases that did and did 
not attend for investigation are summarised in Table 32 and Table 33.  Attendance and 
non-attendance for investigation was proportionately distributed between the sexes 
(χ2(1)=0.321, p=0.667), although cases that did attend were older than cases that did not 
(Mann-Whitney U=5808, z=-2.197; p=0.028).  When organising patients to attend KCMC 
for investigations there was some discussion among field staff around which patients 
might not be appropriate to bring to the hospital, focusing on patients with cognitive 
impairment or learning disabilities who were perceived to be ‘mentally unstable’.  This 
was discouraged, with reassurances and explanations given, and attendance for 
investigations does not ultimately appear to have been biased by the presence of either 
cognitive impairment (χ2(1)=3.796, p=0.061) or motor impairment (χ2(1)=3.390, p=0.066). 
Of the 229 cases that attended for investigation, EEG results were available for 216 
(94.3%), and CT results for 200 (87.3%); both CT and EEG findings were available for 187 
(81.7%) cases (Table 34).  Days on which the CT scanner at KCMC was being serviced or on 
which the hospital had run out of intravenous contrast medium account for the twenty-
nine patients for whom only EEG results are available.  Due to technical problems data 
could not be retrieved from the hard drive of the EEG machine for a further thirteen 




CT and/or EEG available 
Sex 
Female Male Total 
n (% of females) n (% of males) n (% of total) 
No 27 (19.9%) 35 (22.6%) 62 (21.3%) 
Yes 109 (80.1%) 120 (77.4%) 229 (78.7%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 
Table 32: Availability of CT/EEG by sex 
 




IQR Min Max 
No 62 25.5 15.0 81.0 20.0 
Yes 229 31.0 15.0 85.0 22.0 
Table 33: Availability of CT/EEG by age 
 
 
 CT Scan 
 No (%) Yes (%) Total (%) 
EEG No (%) 62 (21.3) 13 (4.5) 75 (25.8) 
Yes (%) 29 (10.0) 187 (64.3) 216 (74.2) 
Total (%) 91 (31.3) 200 (68.7) 291 (100.0) 
Table 34: Overall availability of CT/EEG 
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5.4.1 Computed tomography 
A total of 200 (68.7%) of 291 cases had a CT scan: ninety-four (69.1%) of 136 females and 
106 (68.4%) of 155 males.  CT findings were abnormal in fifty-one (25.5%) of all scans: 
twenty-three (24.5%) of ninety-four females and twenty-eight (26.4%) of 106 males.  CT 
findings are summarised in Table 35; the category ‘other’ includes opacification of frontal 
or maxillary sinuses (two cases), bilateral ocular calcification (one case), and 
maldevelopment of the frontal and sphenoid sinuses and thickened calvaria, in keeping 
with fibrous dysplasia with (one case).  The findings from eight (4.0%) out of 200 scans 
were in keeping with neurocysticercosis (NCC): six (6.4%) of ninety-four females and two 
(1.9%) of 106 males. 
5.4.2 Electroencephalography 
EEG recordings were available from 216 (74.2%) of 291 cases: 100 (73.5%) of 136 females 
and 116 (74.8%) of 155 males.  EEG abnormalities were reported in a total of eight-four 
(38.9%) of 216 cases: forty-five (45.0%) of 100 females and thirty-nine (33.6%) of 116 
males (χ2(1)=2.987, p=0.225).  Seventy-three (33.8%) cases had epileptiform changes: 
twenty (23.8%) with generalised abnormalities, fifty-three (63.1%) with focal 
abnormalities (Table 36).  Focal abnormalities, when present, were most commonly seen 
in the temporal lobes, being reported in thirty-four (64.2%) of fifty-three cases (Table 37).  
The technical quality of the recording due to artefact was very poor in sixteen EEGs: these 
were classified as normal for the purposes of this analysis.  The quality of the recordings 
obtained was otherwise considered to be excellent by the reporting neurophysiologist.
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 Female (n=94) Male (n=106) Total (n=200) 
n (% of females) n (% of males) n (% of total) 
Normal 71 (75.5%) 78 (73.6%) 149 (74.5%) 
Vascular 6 (6.4%) 7 (6.6%) 13 (6.5%) 
Discrete calcification 5 (5.3%) 2 (1.9%) 7 (3.5%) 
Encephalomalacia 1 (1.1%) 4 (3.8%) 5 (2.5%) 
Trauma 1 (1.1%) 4 (3.8%) 5 (2.5%) 
Ventricular dilatation 3 (3.2%) 2 (1.9%) 5 (2.5%) 
Hemispheric atrophy 2 (2.1%) 2 (1.9%) 4 (2.0%) 
Other (non-cerebral) 1 (1.1%) 3 (2.8%) 4 (2.0%) 
Hydrocephalus 1 (1.1%) 2 (1.9%) 3 (1.5%) 
Lobar atrophy 1 (1.1%) 2 (1.9%) 3 (1.5%) 
Cystic changes 1 (1.1%) 1 (0.9%) 2 (1.0 %) 
Dural calcification 2 (2.1%) 0 (0.0%) 2 (1.0%) 
Tumour 1 (1.1%) 1 (0.9%) 2 (1.0%) 
Generalised atrophy 1 (1.1%) 0 (0.0%) 1 (0.5%) 
Lobar calcification 0 (0.0%) 1 (0.9%) 1 (0.5%) 
Porencephalic cyst 1 (1.1%) 0 (0.0%) 1 (0.5%) 
Consistent with NCC 6 (6.4%) 2 (1.9%) 8 (4.0%) 
N.B. Categories not exclusive, therefore no column totals given. 




 Female (n=45) Male (n=39) Total (n=84) 
n (% of females) n (% of males) n (% of total) 
Non-specific 6 (13.3%) 5 (12.8%) 11 (13.1%) 
Generalised – slow + spike 7 (15.6%) 1 (2.6%) 8 (9.5%) 
Generalised – slow, no spike 4 (8.9%) 8 (20.5%) 12 (14.3%) 
Focal – slow + spike 28 (62.2%) 25 (64.1%) 53 (63.1%) 
Focal - slow, no spike 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Table 36: EEG abnormalities seen (SANAD classification) 
 
Site of focal abnormality n % of total 
Temporal (unilateral) 27 50.9% 
Frontal 9 17.0% 
Bi-temporal 7 13.2% 
Fronto-temporal 4 7.5% 
Multi-focal 3 5.7% 
Centro-parietal 2 3.8% 
Para-sagittal 1 1.9% 
Total 53 100.0% 
Table 37: Sites of focal EEG abnormalities 
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5.4.3 Classification of seizures 
All 291 cases identified suffered from generalised convulsive seizures, with no instances of 
purely focal seizures that did not develop to secondary generalisation being recorded.  By 
considering the clinical case history, including collateral history, in combination with EEG 
and CT findings where available, the onset of seizures was classified as being either focal, 
generalised or undefined (Table 38).  Focal onset seizures were identified in 208 (71.5%) of 
291 cases, and with the benefit of CT and EEG findings, eight cases (2.7%) were diagnosed 
with primary generalised seizures.  The onset of seizures and remained undefined in 
seventy-five (25.8%) of 291 cases. 
The relative contributions of clinical history and examination, CT and EEG to identifying 
focal onset seizures are illustrated schematically in Figure 25.  Of note, in twenty-five 
(12.0%) of 208 cases with focal -onset seizures the diagnosis was contingent on 
investigation findings being available: these patients would otherwise have been 
described as having generalised convulsive seizures with undefined seizure onset, and 
their epilepsy would ultimately have remained unclassified.  In a further 127 (61.1%) cases 
with focal onset seizures the diagnosis was based on clinical evidence alone: i.e. seizure 
semiology, the presence of focal neurological deficits or both.  Of these, no investigation 
findings were available for thirty-five cases (27.6%), and EEG and/or CT findings were 
normal in the remaining ninety-one cases (71.7%).  Investigation findings were also 
available in forty-nine (65.3%) of seventy-five cases in which a distinction between focal or 
generalised onset could not be made clinically, but did not contribute any additional 
evidence to aid in making this distinction. 
5.4.4 Classification of epilepsies 
Six (75%) out of eight cases with a clinical diagnosis of generalised onset seizures were 
confirmed as having a genetic generalised epilepsy (GGE) based on EEG findings:  two 
cases were specifically identified as juvenile myoclonic epilepsy (JME), with a further four 
being considered as idiopathic generalised epilepsy (IGE) of some form.  The prevalence of 
GGE within the total cohort of 291 PWE was therefore 2.1% (2.8% of the 216 cases who 
had EEGs).  Based on a combination of CT findings and clinical evidence, sixty-seven 
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(32.2%) of 208 cases with focal onset seizures were classified as being symptomatic of 
acquired brain pathology, thus conforming to the currently recommended classification of 
‘structural/metabolic’.  Radiological evidence of specific aetiologies was present in twenty-
nine (43.3%) of these, as follows: vascular (thirteen cases), neurocysticercosis (eight), 
trauma (five), neoplasia (two) and porencephaly (one).  In the remaining thirty-eight cases 
in this group radiological abnormalities were considered likely to be directly related to the 
presence of seizures although without pathognomic features of any given aetiology (see 
section 5.4.8, Table 35).  No further classification was possible in 141 (67.8%) of 208 focal-
onset seizures, in two (25.0%) of eight generalised onset seizures, and in all seventy-five 





Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males) n (% of total 
Focal 90 (66.2%) 118 (76.1%) 208 (71.5%) 
Generalised 6 (4.4%) 2 (1.3%) 8 (2.7%) 
Undefined 40 (29.4%) 35 (22.6%) 75 (25.8%) 
Total 136 (100.0% 155 100.0% 291 100.0% 









Female (n=136) Male (n=155) Total (n=291) 
n (% of females) n (% of males) n % of total 
Focal – structural/metabolic 31 (22.8%) 36 (23.2%) 67 (23.0%) 
Focal - unclassified 59 (43.4%) 82 (52.9%) 141 (48.5%) 
Generalised - IGE 4 (2.9%) 0 (0.0%) 4 (1.4%) 
Generalised - JME 2 (1.5%) 0 (0.0%) 2 (0.7%) 
Generalised - unclassified 1 (0.7%) 1 (0.6%) 2 (0.7%) 
Unclassified 39 (28.7%) 36 (23.2%) 75 (25.8%) 
Total 136 (100.0%) 155 (100.0%) 291 (100.0%) 
Table 39: Combined classification of seizures and of epilepsies 
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5.6 Results: socio-demographic 
5.6.1 Tribal and religious background 
Data on tribal background were available for 275 (94.5%) of 291 cases.  The main tribal 
group within the Hai population are the Chagga, and this is reflected in the tribal 
background of the cases, with 220 (80.0%) belonging to this group.  Other predominant 
tribal groups were Pare (twenty cases, 7.3%) and Maasai (six cases, 2.2%).  The remaining 
10.5% of cases belonged to a mix of other tribal groups.  Data on religious background 
were available for 282 (96.9%) of 291 cases, with 223 cases (79.1%) describing themselves 
as Christian, with the remaining fifty-nine (20.9%) being Muslim. 
5.6.2 Education and literacy 
Data on the highest educational level attained were available in 275 (94.5%) of 291 cases, 
including seventeen who were in full-time education at the time of assessment (fourteen 
at secondary school and three in further education).  Of these, fifty-seven (20.7%) had no 
schooling at all and seventy-five (27.3%) had not completed primary school.  Ninety-five 
(36.8%) of 258 cases who were not in education at the time of the study said that their 
education had been interrupted directly as a result of epilepsy: fifty (42.4%) of 118 
females and forty-five (32.1%) of 140 males (χ2(1)=2.881, p=0.090).  As the presence of 
cognitive impairment could also account for an incomplete education, this analysis was 
repeated after excluding individuals with any degree of cognitive impairment.  Data were 
available for 191 (94.6%) of 202 individuals with no cognitive impairment, and while the 
overall proportion of cases with no education fell to 9.9%, the proportions of cases in 
other categories remained broadly similar. 
To further examine the influence of epilepsy on education, analyses relating attendance at 
school to age of onset of epilepsy were also performed.  Data on both age of onset and 
educational level were available for 269 (92.4%) of 291 cases.  Thirty-five (40.2%) of 
eighty-seven cases in whom epilepsy started pre-school age never went to school, 
compared to twenty-one (11.5%) of 182 cases in whom epilepsy started over the age of 
eight years (χ2(1)=29.395, p<0.001).  When this analysis was restricted to cases in whom 
epilepsy had started only under the age of sixteen years, i.e. the years during which 
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children may be expected to start attending school, the association between age of onset 
under eight years and non-attendance at school remained significant.  Epilepsy started 
under the age of sixteen years in 175 (61.6%) of 284 cases in which age of onset was 
available, with data on educational level being available for 169 (96.6%) of these.  In this 
group, thirty-five (40.2%) of eighty-seven cases with an age of onset of under eight years 
had no education, compared to nine (11.0%) of eighty-two cases in who epilepsy started 
between the ages of eight and sixteen years (χ2(1)=18.760, p<0.001). 
Information on literacy was available from 276 (94.5%) of 291 cases, of whom 135 (48.9%) 
said they could not read or write: sixty-one (46.9%) of 130 females and seventy-four 
(50.7%) of 146 males (χ2(1)=0.390, p=0.533).  Data on literacy were available in 192 
(95.0%) of 202 cases who had no cognitive impairment, with sixty (31.3%) saying that they 
could not read or write: twenty-seven (29.3%) of ninety-two females and thirty-three 




Female (n=129) Male (n=146) Total (n=275) 
n (% of females) n (% of males) n (% of total) 
No education 25 (19.4%) 32 21.9% 57 20.7% 
Incomplete primary education 35 (27.1%) 40 27.4% 75 27.3% 
Completed primary education 50 (38.8%) 61 41.8% 111 40.4% 
Any secondary/further education 19 (14.7%) 13 8.9% 32 11.6% 
Total 129 (100.0%) 146 100.0% 275 100.0% 
Table 40: Highest education level of all cases 
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5.6.3 Marital status 
Two hundred and fifty-eight (88.7%) of 291 cases were aged nineteen or above: 116 
(85.3%) of 136 females and 142 (91.6%) of 155 males.  Data on marital status were 
available for 248 (96.1%) of these individuals (Table 41).  The majority of cases remained 
unmarried (58.5% overall), although when seventy-six (30.6%) individuals with cognitive 
impairment were excluded from this analysis, as these individuals could be considered less 
likely to get married for this reason, the proportion of unmarried cases fell to 44.8%.  
When marital status was dichotomized into being single versus ever having married, 
including cases widowed or divorced, there was a significant association between 
remaining single and being aged nineteen years or less at onset of epilepsy (χ2(1)=78.816, 
p<0.001). 
Twenty-two (8.9%) individuals were divorced or separated, of whom fourteen (63.6%) 
provided information on the reason for marital difficulties, with eleven (78.6%) citing their 
epilepsy as the reason for marital breakdown (nine females, two males).  While females 
were more likely than males to be divorced or separated (χ2(1)=6.724, p=0.01), there was 
no significant difference between the sexes in the numbers of people citing epilepsy as the 
cause for their marital difficulties (χ2(1)=0.917, p=0.34). 
5.6.4 Occupation 
Data on occupation were available from 286 (98.3%) of 291 cases (Table 42).  Of note, 
sixty-nine individuals (24.1%) said that they were not working due to illness or disability.  A 
further forty-seven cases (16.4%) said that they were confined to small domestic tasks or 
housework with regards to any contribution that they made to the household economy.  
When all cases with cognitive or motor impairments were excluded the total number of 
cases not working due to disability was fifteen (5.2%), and the total number describing 





Female (n=130) Male (n=151) Total (n=281) 
n (% of females) n (% of males) n (% of total) 
Single 64 (58.2%) 81 (58.7%) 145 (58.5%) 
Married 24 (21.8%) 50 (36.2%) 74 (29.8%) 
Divorced/separated 16 (14.5%) 6 (4.3%) 22 (8.9%) 
Widowed 6 (5.5%) 1 (0.7%) 7 (2.8%) 
Total 110 (100.0%) 138 (100.0%) 248 (100.0%) 
Table 41: Marital status of all cases aged 19 years and over 
 
Occupational status 
Female (n=132) Male (n=154) Total (n=286) 
n (% of females) n (% of males) n (% of total) 
Farming/herding 41 (31.1%) 55 (35.7%) 96 (33.6%) 
Sick or disabled 31 (23.5%) 38 (24.7%) 69 (24.1%) 
Domestic tasks/housework 31 (23.5%) 16 (10.4%) 47 (16.4%) 
Trade/skill 5 (3.8%) 15 (9.7%) 20 (7.0%) 
Unemployed 6 (4.5%) 12 (7.8%) 18 (6.3%) 
Full-time education 11 (8.3%) 6 (3.9%) 17 (5.9%) 
Salaried/business  7 (5.3%) 6 (3.9%) 11 (4.5%) 
Retired 0 (0.0%) 3 (1.9%) 3 (1.0%) 
Other manual/unskilled 0 (0.0%) 3 (1.9%) 3 (1.0%) 
Total 132 (100.0%) 154 (100.0%) 286 (100.0%) 




All PWE identified in our study had ACE, with focal-onset seizures accounting for 71.5% of 
all cases.  High rates of focal onset seizures were also found in 71% of all cases identified 
in a recent community-based study of people with ACE in Kenya (Munyoki et al., 2010), 
and in 55% of all cases in a community-based study from Nigeria, although it is not clear 
how focal seizures with generalised clonic movements were classified in this latter study 
(Osuntokun et al., 1987).  Conversely, higher rates of generalised-onset seizures have 
previously been reported from community-based studies in SSA, accounting for between 
58% and 82% of diagnoses (Rwiza et al., 1992, Almu et al., 2006, Dent et al., 2005).  As 
discussed in the introduction to this chapter, differing approaches to case-ascertainment, 
differing diagnostic and classification criteria, and lack of EEG and CT to aid with 
classification make a strict comparison between studies difficult, although all authors in 
the above studies comment that focal seizures becoming rapidly generalised may have 
erroneously been classified as generalised onset seizures. 
The proportion of patients with inter-ictal epileptiform EEG findings in the HDSS 
population was 33.8% overall.  This is higher than a rate of 18% in 230 PWE previously 
reported from Ethiopia (Tekle-Haimanot et al., 1990b), in keeping with a more recent 
study from Kenya where epileptiform EEG abnormalities were reported in 33.8% of 408 
PWE (Munyoki et al., 2010), and lower than a rate of 49.1% reported in fifty-five PWE in 
western Uganda (Kaiser et al., 2000).  It is interesting to compare the influence of the 
availability of EEG in classifying epilepsy in these studies.  In our study investigations were 
suggestive of a focal onset to seizures in twenty-five cases in whom a clinical diagnosis of 
generalised seizures had been made: i.e. cases in whom a description of generalised 
convulsive seizures with no evidence of prodromal or focal-onset features had been 
obtained.  A diagnosis of focal epilepsy was therefore ultimately contingent on the 
availability of investigations, including EEG, in twenty-five (12.0%) of 208 cases, including 
eleven (5.3%) in which this distinction depended solely on the EEG.  By implication, 
without the availability of these diagnostic modalities the proportion of PWE diagnosed 
with focal-onset seizures would have been lower, at 62.9%.  This also conforms with 
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findings from Kenya, where EEG findings of focal abnormalities in 22% of PWE with 
convulsive epilepsy contributed to 71% of these cases finally being classified as 
generalised epilepsy with focal onset (Munyoki et al., 2010).  Similarly, in a rural area of 
west Uganda with a high prevalence of epilepsy and onchocerciasis, the addition of EEG 
findings to a purely clinical classification of seizures led to the proportion of focal 
epilepsies rising from 24% to 78% (Kaiser et al., 2000).  The high rate of focal onset 
seizures identified in our study suggests that a high proportion of epilepsy in this 
population may be due to identifiable, and possibly preventable, causes.  We know from a 
companion study that epilepsy in children from Hai is associated with adverse perinatal 
events (Burton et al., 2012a), while exposure to Taenia solium, the parasitic infection 
responsible for NCC, is associated with epilepsy in a number of African populations (Quet 
et al., 2010), including in Tanzania (Winkler et al., 2008a, Winkler et al., 2009b). 
In our cohort only 2.1% of cases overall had clinical and EEG evidence of a genetic 
generalised epilepsy (2.7% of cases who had EEG recordings made).  This is lower than the 
6.6% of PWE with EEGs in a similar population in Kenya (Munyoki et al., 2010), although 
this may be an underestimate, as no EEG was available in seventy-five cases (25.8%) and 
sixteen (7.4%) EEG recordings were degraded by artefact, rendering them unreadable. 
Clinical associations with or risk factors for epilepsy were identified in nearly half (43.6%) 
of the patients in this study, with the most commonly reported being febrile seizures in 
childhood, perinatal complications, febrile illnesses associated with loss of consciousness 
or convulsions, by implication referring to infections of the CNS, and head injury.  A recent 
review of epidemiologic studies of epilepsy in Africa over a ten year period found that out 
of 1,379 PWE identified, aetiology was determined in 879 (63.7%) (Quet et al., 2011).  Just 
over half of these (53.5%) were accounted for by symptomatic epilepsies, although the 
authors point out that most of these data are derived from hospital-based series rather 
than community-based cross-sectional studies.  In a more detailed review of thirty-five 
studies from SSA, including university theses and articles published in French, head 
injuries were implicated in between 0.3% and 15.8% of cases, perinatal complications in 
between 0.1% and 12%, infectious diseases in between 0.5% and 23.0% and a history of 
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febrile convulsions was ascertained in between 1.0% and 30.9% of cases (Preux and Druet-
Cabanac, 2005).  These wide variations serve to illustrate the difficulties of comparing and 
interpreting observational and descriptive data.  Case-controlled data on epilepsy from 
SSA that might further characterise the roles of various aetiologies are very limited.  This 
issue is further addressed in Chapter Six. 
In our cohort, a history of febrile convulsions was reported in 10.7% of cases, and one of 
non-specified febrile illness associated with loss of consciousness or convulsions in 6.9%.  
As far as possible, the nature of convulsions in the latter was explored in detail to try and 
exclude patients giving a history more in keeping with chills or rigors as opposed to 
seizures.  Febrile seizures have previously been associated with the subsequent 
development of epilepsy in Nigeria and Tanzania, with ORs of 2.9 to 11.0 in exposed 
groups (Ogunniyi et al., 1987, Matuja et al., 2001).  What is represented by these illnesses 
is a matter of much debate.  A widely held assumption is that cerebral malaria is 
responsible for a considerable amount of morbidity (Ngoungou and Preux, 2008), and ORs 
for developing epilepsy following exposure to cerebral malaria as high as 14.3 have been 
reported (Ngoungou et al., 2006).  In our study a history strongly suggestive of cerebral 
malaria was given in only 1.7% of PWE (five cases, all male).  This rate conforms with that 
of 1.2% reported from elsewhere in northern Tanzania (Winkler et al., 2009c), and the rate 
of cerebral malaria identified in our cohort may be an accurate reflection of an 
altitudinous region, where the transmission rate for malaria is low (Reyburn et al., 2004), 
although it cannot be discounted that the problem of recall bias in adults for distant 
events has depressed the reported rate.  In a Kenyan study of the clinical characteristics of 
convulsive seizures in adults and children, recall for febrile seizures and status epilepticus 
was greater in children, with the assistance of parents, in giving the history (Munyoki et 
al., 2010). 
Two studies from Tanzania have given details of the numbers of cases reporting a family 
history of epilepsy or seizures, with this being present in 33.3% and 41% of cases (Dent et 
al., 2005, Winkler et al., 2009c).  In our study 17.5% of cases reported a family history of 
epilepsy or seizures, with this being slightly more common in second-degree than first-
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degree relatives (11.3% vs. 6.2%).  Whether this points to a complex mode of inheritance 
is not clear, and would require more detailed further study, although it is interesting to 
note that in one of the two community-based studies from Tanzania to have reported on 
family history in epilepsy, this was recorded in up to third degree relatives (Winkler et al., 
2009c). 
Although our study did not systematically test for HIV, we did ask about HIV when taking a 
medical history, and a number of bedside tests were done in patients with and without 
epilepsy presenting with signs or symptoms that may have been markers of immune 
suppression.  Only one HIV test was positive, and this was in a patient who had revealed 
his status during the clinical interview.  Only one other patient was known to be HIV 
positive, giving a prevalence of 0.7%, which is well below the 5.6% that has previously 
been documented in a rural population within the Kilimanjaro region (Mmbaga et al., 
2007).  Up to 11% of patients with untreated HIV presenting with neurological problems 
may present with seizures (Bhigjee, 2005), and while the HIV positive patients we 
identified appeared to have acquired HIV subsequent to the development of epilepsy, this 
issue certainly warrants further study in this population. 
Over one-quarter (26.1%) of PWE identified in Hai had sustained burns during seizures: 
similar to a rate of 24.1% previously documented in a rural Tanzanian population (Rwiza et 
al., 1993b).  This phenomenon is well documented in SSA (Jilek-Aall and Rwiza, 1992, 
Birbeck, 2000b), and it has been observed that up to 50% of all patients presenting with 
burns have a history of epilepsy (Allorto et al., 2009).  Indeed, it has previously been noted 
in Malawi that a serious burn, rather than epilepsy itself, would be the event precipitating 
attendance at medical services, with epilepsy being more frequently diagnosed on surgical 
wards than in medical clinics (Watts, 1989).  In a UK series, burns have been found to be 
significantly associated with complex partial epilepsy with or without secondary 
generalisation (p=0.001) (Hampton et al., 1988), and with female sex (OR 2.2) (Buck et al., 
1997).  In our study, burns were more common in women (p=0.023), but were not 
associated with seizure type (p=0.631), although this latter distinction perhaps has less 
meaning as all PWE in this cohort were suffering with generalised convulsive epilepsy of 
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some description.  The determinants of burns in African patients have also been 
demonstrated to be environmental, being related to the presence of open cooking fires in 
the home (Rode et al., 2011), and the provision of safety stoves in at risk groups has been 
proposed as a public health intervention.  Further investigation into the risks for injuries 
and burns among PWE in the Hai population is warranted. 
A detailed assessment of the social impact of epilepsy or of associated stigma in this 
population was beyond the scope of this study, and the brief demographic and socio-
economic details presented here were collected for informative purposes and to facilitate 
later comparison with controls.  It is interesting to note, however, that analyses based on 
relating age of onset of epilepsy to ages at which people in Hai traditionally become 
eligible for marriage do appear to implicate epilepsy as a limiting factor.  These findings 
mirror those of an earlier study in a different rural population in Tanzania (Rwiza et al., 
1993b).  In this study 30.9% of 181 PWE of school age or older had never gone to school, 
and of those who had attended school, 62.9% stopped prematurely.  In the same study, 
42.2% of cases over the age of nineteen remained unmarried, with this proportion rising 
to 64.6% in individuals in whom epilepsy had started before this age, a difference that was 
statistically significant (p<0.005).  The findings from Hai presented here have since been 
further explored in a qualitative study of a purposefully selected sample of PWE from this 
cohort, in which themes of exclusion across major life domains were elaborated (Mushi et 
al., 2010).  In all, it is a sobering finding that these themes appear unaltered from 
commentary provided over the past two to five decades (Rwiza et al., 1993b), (Giel, 1968).  
In Chapter Eight of this thesis the issue of treatment for epilepsy and the ETG is 
considered, and it should be borne in mind that even a brief and crude quantitative 
assessment as has been presented here hints at the marginalised status of the person 




5.8 Summary and conclusions 
There is a high prevalence of focal-onset epilepsy among people with convulsive seizures 
living in the HDSS, suggesting the presence of acquired brain pathology in a considerable 
proportion of this group of patients.  Possible aetiological factors include perinatal 
complications, febrile seizures in childhood, CNS infections and head injuries.  The roles of 
HIV infection and of family history remain unclear, and warrant further investigation.  
Over one quarter of PWE living in the HDSS have suffered burns as a result of their 
epilepsy, and interventions to reduce this morbidity are warranted. 
PWE living in the HDSS are socially and economically disadvantaged.  The degree to which 
this relates to their epilepsy should be further explored through comparison with a control 




Chapter 6.  Case-control study of epilepsy in the HDSS 
Abstract 
Background 
There are few case-control data from SSA pertaining to either risk factors for epilepsy or 
the implications of living with this condition. 
Methods 
Following completion of case ascertainment of PWE in Hai, control subjects who did not 
have epilepsy were recruited from the adult population.  Clinical, demographic and socio-
economic variables were collected for comparison with cases.  Multivariable logistic 
regression models were constructed to look for predictors of epilepsy in this population. 
Results 
Clinical predictors of epilepsy were a history of febrile convulsions in childhood (OR 16.93; 
95% CI 2.14 to 134.26), a family history of epilepsy in second-degree relatives (OR 26.29; 
95% CI 3.36 to 205.99), and having cognitive impairment (OR 23.41; 95% CI 5.52 to 99.23) 
or motor impairment (OR 10.01; 95% CI 1.29 to 77.59).  When cognitive and motor 
impairments were excluded from the regression model a history of perinatal 
complications was associated with having epilepsy (OR 3.40; 95% CI 1.07 to 10.75).  Socio-
economic associations with epilepsy were being divorced or separated (OR 15.72; 95% CI 
3.15 to 78.61), being less likely to have completed primary education (OR 0.42; 95% CI 
0.25 to 0.73), and being less likely to be gaining an income through farming (OR 0.41; 95% 
CI 0.23 to 0.72). 
Conclusions 
The association with childhood illness and obstetric complications suggests that a 
proportion of epilepsy in the HDSS population could be prevented through better health 
care in early life.  PWE are socially and economically disadvantaged compared to people 





The difficulties associated with conducting large-scale community-based studies in SSA 
have meant that case-controlled data on epilepsy from this region remain sparse.  A 
comprehensive review of the literature from SSA published in 2005 identified only three 
case-control studies, conducted between 1989 and 2001, that searched for more than one 
exposure factor (Preux and Druet-Cabanac, 2005).  A Nigerian study from 1987 compared 
155 PWE identified from a hospital series with an equal number of age- and sex-matched 
controls with the aim of identifying risk factors for epilepsy (Ogunniyi et al., 1987).  Data 
on childhood immunisations, febrile convulsions, head injury, haemoglobinopathy, 
venereal diseases, psychotropic drug or alcohol use, and cerebrovascular disease were 
collected.  Of these, febrile convulsions and head injury were identified as predictors of 
epilepsy (ORs of 11.0 and 13.0 respectively).  In 2001, a study in a rural area of Burundi 
was conducted in 324 PWE and 648 age-matched controls to examine the link between 
sero-positivity for exposure to cysticercosis and epilepsy in the study population 
(Nsengiyumva et al., 2003).  Data on family history and childhood illness were also 
collected, and predictors of epilepsy in a multivariable model were sero-positivity for 
cysticercosis (OR 4.1), a family history of epilepsy (OR 3.3), and severe disease in 
childhood (OR 1.9).  The meaning of ‘severe disease in childhood’ is not elaborated, and it 
is not clear whether this should be taken to refer to a history of febrile seizures.  This 
study is discussed in more detail with regards to the issue of cysticercosis in Chapter Eight.  
In a community-based prevalence study from Tanzania conducted in 1989, a variation in 
prevalence of between 5.1 and 37/1,000 was observed between wards and divisions 
within one rural district (Rwiza et al., 1992).  To further investigate, 174 cases and an 
equal number of controls from the division with the highest prevalence were interviewed 
and examined (Matuja et al., 2001).  Controls were matched for age, sex and tribe, and 
data on family history, febrile convulsions, head trauma, birth complications and CNS 
infections were collected.  Multivariable analysis identified three of these factors as 
significant predictors of epilepsy: family history (OR 3.34), a history of febrile convulsions 
(OR 2.9) and a history of intrapartum complications (OR 4.5).  In this study, both cases and 
controls had EEG recordings, with epileptiform abnormalities being found in 22.9% of 
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cases and no controls (p<0.001), and abnormal background activity being seen in 25.8% of 
cases versus 11.5% of controls (p<0.001).  More recently a study from Kenya compared 
445 cases with 633 controls recruited during a large community-based prevalence survey 
in a rural population (n=151, 408) (Edwards et al., 2008).  Controls were frequency-
matched for age, data on family history of both febrile and non-febrile seizures and head 
injury were collected from all participants, and the mothers of children under the age of 
eighteen years were asked about perinatal complications.  Multivariable regression 
models for adults and children combined and children only were constructed; in adults 
and children, a family history of both febrile and non-febrile convulsions and previous 
head injury were both predictors of epilepsy (ORs 7.3 and 4.1 respectively).  When the 
analysis was restricted to children only, head injury was not found to be a predictor of 
epilepsy, while a history of perinatal complications was (OR 5.7).  Finally, and 
contemporaneous with the study described here, a case-control study of children with 
epilepsy identified in the HDSS found adverse perinatal events (OR 14.9), a family history 
of afebrile seizures (OR 5.7) and poor scholastic attainment (OR 8.6) all to be predictors of 
epilepsy in this population (Burton et al., 2012a). 
Other studies from SSA comparing cases with controls have focused on the link between 
particular infectious diseases and epilepsy rather than the general risk profile in the 
population, usually triggered by anecdotal observations of high prevalence rates of 
epilepsy in areas known to be endemic for the infectious disease in question.  Such studies 
have focused on the neuro-helminthoses which are endemic in many LMICs (Winkler et 
al., 2008a).  Studies of the link between exposure to onchocerciasis and epilepsy have 
been conducted in Cameroon, the Central African Republic and Burundi (Druet-Cabanac et 
al., 1999, Boussinesq et al., 2002, Newell et al., 1997b), with mixed findings.  In Burundi, 
evidence of onchocerciasis based on the presence of cutaneous nodules or antibody 
positivity on serological testing was found in 81.8% of 110 cases compared to 68.3% of 
eighty-two controls (p<0.05) (Newell et al., 1997b).  Similar findings were reported from 
Cameroon, where the prevalence of epilepsy and the community microfilarial load on 
skin-snip testing were significantly associated (p<0.02), with this being more marked when 
seventy-two PWE were compared with seventy-two controls for the same measure 
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(p<0.001) (Boussinesq et al., 2002).  A similar study conducted among 187 PWE and 374 
controls in the Central African Republic did not find skin-snip microfilarial load to be a 
predictor of epilepsy (OR 1.21; 95% CI 0.81 to 1.80) (Druet-Cabanac et al., 1999).  An 
association between infection with Toxocara canis and epilepsy has also been proposed 
(Arpino et al., 1990), with this having been supported by work done in Bolivia (Nicoletti et 
al., 2002).  In a study from Burundi, the presence of antibodies to T.canis was associated 
with epilepsy (OR 2.13), although this finding was not reproduced in a Tanzania 
population, where no association between epilepsy and anti-toxocaral antibodies was 
found in a small study of forty PWE and twenty controls (p=0.55) (Winkler et al., 2008a).  
Perhaps the most extensively researched of these conditions is Taenia solium infection, 
the causative agent of neurocysticercosis (NCC), which is well described as a cause of 
epilepsy in endemic regions of the world (Garcia and Del Brutto, 2005).  This issue, 
including a discussion of studies from SSA, is dealt with in depth in Chapter Seven. 
A small number of case-control studies of wider issues relating to epilepsy in SSA have also 
been performed.  In Benin anthropometric data were collected from 131 PWE and 262 
controls to look for any link between malnutrition and epilepsy, with the prevalence of 
malnutrition being higher in cases than controls (p=0.0006) (Crepin et al., 2007).  
Particular nutritional factors associated with epilepsy included low levels of cereal 
consumption (OR 4.2), tooth decay (OR 2.9), and food taboos due to perceived health 
status (OR 16.8).  Mean mid-upper-arm circumference was lower in cases than controls 
(p<0.0001).  In a study from Burundi, 352 PWE and 704 controls were compared to assess 
direct and indirect economic costs associated with epilepsy (Nsengiyumva et al., 2004).  
While no differences were observed between cases and controls in terms of marital or 
employment status, mean annual direct healthcare costs were greater in PWE than in 
controls (p=0.03), as were the mean number of days of disrupted family life (p=0.03).  
Finally, children with and without epilepsy from the Hai district have been studied with 
regards to physical and behavioural co-morbidities (Burton et al., 2011, Burton et al., 
2012b).  In a series of 112 children with epilepsy and 113 controls, one or more of 
cognitive impairment, behavioural disorder, motor difficulties, burns or other previous 
injuries were predictors of epilepsy (Burton et al., 2012b).  On multivariable regression 
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analysis factors associated with co-morbidity among cases in this series were age at onset 
of less than three years (OR 3.1), structural brain disease (OR 4.5) and having epileptiform 
abnormalities on EEG (OR 4.1). 
To summarise, risk factors implicated in the aetiology of epilepsy in populations from SSA 
have included febrile convulsions, head injuries, a family history of epilepsy or seizures, 
and a history of perinatal complications.  Specific infectious diseases affecting the CNS 
have also been studied, with mixed results.  The wider context of epilepsy also emerges 
from reading these studies, with malnutrition, reduced educational attainment and 
increased economic burden all being associated with epilepsy. 
In the Hai study, clinical and socio-economic associations with epilepsy identified during 
case ascertainment were further studied through comparison with controls that were 





6.2.1 Recruitment of controls 
Once case ascertainment was complete six age- and sex-matched controls for each case 
were identified from the census database using a random number sequence, providing a 
broadly matched pool of potential controls from which to recruit.  Names were compared 
with the census database to ensure that no positive responders had been included.  Lists 
of eligible controls in each HDSS village were then distributed to village enumerators, and 
during August and September 2010 individuals were approached and invited to participate 
in the study.  Those agreeing to participate were asked to complete a questionnaire pro-
forma similar to that used during case ascertainment along with the same socio-economic 
questionnaire completed by cases during follow-up visits.  Prior to inclusion all controls 
were assessed by the research doctor to confirm that they did not have a history 
suggestive of epilepsy.  The control interview pro-forma translated into Kiswahili was then 
completed by one of the field team, either enumerator or clinical supervisor. 
6.2.2 Statistical analysis 
All categorical predictor variables were either ordinal or dichotomous.  Dichotomous 
variables were coded according to the presence or absence of the characteristic in 
question; for ordinal variables where dichotomisation was not appropriate, a baseline 
comparator level was selected.  The outcome of interest for each predictor variable was 
‘case’ or ‘control’, with uni-variable odds ratios (ORs) with 95% confidence intervals being 
calculated for all predictor variables. 
Multivariable logistic regression was used to examine the joint effects of multiple 
predictors.  Regression models were constructed using a backwards stepwise elimination 
strategy based on the likelihood ratio test, with non-significant uni-variable predictor 
variables with a p-value of 0.1 or greater being excluded at each step.  Goodness-of-fit of 
final models was assessed using the Hosmer and Lemeshow statistic, with values closer to 
unity indicating a better fit with the data (Field, 2009a).  Separate regression models were 
constructed to examine for significant associations with epilepsy within two domains: 





By the end of the recruitment period a total of 182 controls had been recruited into the 
study: ninety-nine females (54.4%) and eighty-three males (45.6%).  Although controls 
were recruited from a pool that was broadly matched to cases for age and sex, they were 
not recruited on a strict matching basis.  Age and sex were therefore compared to assess 
the degree of match between the two series.  The final series of controls was significantly 
older than cases overall (Mann-Whitney U=21483.0, z=-3.457, p=0.001), with this holding 
true when the ages of cases and controls were compared by sex: U=5387.5, z=-2.614, 
p=0.009 for females; U=5238, z=-2.361, p=0.018 for males.  Although there were 
proportionally more male cases than controls (53.3% vs. 45.6%), there was no significant 
difference between cases and controls in proportions of males and females (OR for male 
sex and having epilepsy of 1.36, 95% CI 0.94 to 1.97).  The age distributions of cases and 
controls are given in Table 43, Table 44, Figure 26 and Figure 27. 
Data on tribal background were available for 275 (94.5%) of 291 cases and 179 (98.4%) of 
182 controls.  Data on religious background were available for 282 (96.9%) of 291 cases 
and 181 (99.5%) of 182 controls.  These data are summarized in Table 45.  There was no 
significant association with epilepsy in either case (Table 46). 
  Age (years) 
 n Median  
Range 
IQR Min Max 
Cases 291 30.0 15 85 21 
Controls 182 39.0 15 91 25 






Females Males Total 
Cases (n=136) Controls (n=99) Cases (n=155) Controls (n=83) Cases (n=291) Controls (n=182) 
n (%) n (%) n (%) n (%) n (%) n (%) 
15-19 23 (16.9%) 10 (10.1%) 19 (12.3%) 8 (9.6%) 42 (14.4%) 18 (9.9%) 
20-24 25 (18.4%) 13 (13.1%) 36 (23.2%) 13 (15.7%) 61 (21.0%) 26 (14.3%) 
25-29 23 (16.9%) 18 (18.2%) 14 (9.0%) 3 (3.6%) 37 (12.7%) 21 (11.5%) 
30-34 12 (8.8%) 5 (5.1%) 18 (11.6%) 9 (10.8%) 30 (10.3%) 14 (7.7%) 
35-39 9 (6.6%) 6 (6.1%) 13 (8.4%) 8 (9.6%) 22 (7.6%) 14 (7.7%) 
40-44 10 (7.4%) 8 (8.1%) 17 (11.0%) 11 (13.3%) 27 (9.3%) 19 (10.4%) 
45-49 13 (9.6%) 11 (11.1%) 11 (7.1%) 10 (12.0%) 24 (8.2%) 21 (11.5%) 
50-54 7 (5.1%) 11 (11.1%) 7 (4.5%) 4 (4.8%) 14 (4.8%) 15 (8.2%) 
55-59 6 (4.4%) 9 (9.1%) 8 (5.2%) 4 (4.8%) 14 (4.8%) 13 (7.1%) 
60-64 2 (1.5%) 3 (3.0%) 4 (2.6%) 5 (6.0%) 6 (2.1%) 8 (4.4%) 
65-69 4 (2.9%) 5 (5.1%) 4 (2.6%) 3 (3.6%) 8 (2.7%) 8 (4.4%) 
70+ 2 (1.5%) 0 (0.0%) 4 (2.6%) 5 (6.0%) 6 (2.1%) 5 (2.7%) 
Total 136 (100.0%) 99 (100.0%) 155 (100.0%) 83 (100.0%) 291 (100.0%) 182 (100.0%) 




Figure 26: Age distribution of controls 
 
 




Cases (n=291) Controls (n=182) 
n (%) n (%) 
Tribal group Chagga 220 (75.6%) 148 (81.3%) 
Other 55 (18.9%) 31 (17.0%) 
Not known 16 (5.5%) 3 (1.6%) 
Religion Christian 223 (76.6%) 149 (81.9%) 
Muslim 59 (20.3%) 32 (17.6%) 
Not known 9 (3.1%) 1 (0.5%) 
Table 45: Tribal and religious background of cases and controls 
 
Variable OR 95% CI p-value 
Tribal group other than Chagga (vs. Chagga) 1.19 0.73 to 1.94 0.474 
Muslim religion (vs. Christian) 1.23 0.76 to 1.98 0.389 
Table 46: Tribe and religion: uni-variable odds ratios for association with epilepsy 
194 
 
6.3.2 Risk factors for epilepsy 
Data on specific risk factors for epilepsy were available for all cases and controls (Table 
47).  Factors significantly associated with epilepsy on uni-variable analysis were a history 
of childhood febrile convulsions and a history of perinatal complications (Table 48).  No 
controls gave a history of meningitis, stroke or brain abscess, and therefore these 
categories could not be analysed using contingency tables to generate ORs.  As these are 
distinct clinical entities it was not appropriate to include them within any other categories 
to facilitate any further statistical analysis.  No controls reported being HIV +ve. 
6.3.3 Family history 
Data on a family history of epilepsy were available for all cases and controls.  
Proportionally more cases than controls reported a family history of epilepsy in both first- 
and second-degree relatives.  Proportionally more cases than controls reported a family 
history in a second-degree than in a first degree-relative (Table 49).  The uni-variable odds 
for cases reporting any family history (first- or second-degree relatives) were 5.31 (95% CI 
2.36 to 11.99; p<0.001).  When the categories of family history in either a first- or second-
degree relative were compared with the baseline comparator of having no family history 
there was a significant association between epilepsy and a family history in a second-
degree but not in a first-degree relative (Table 50). 
6.3.4 Cognitive and motor impairments 
The presence of cognitive or motor impairment was recorded for all cases and controls 
(Table 51).  Both were significantly associated with epilepsy, although the small numbers 
of controls with cognitive or motor impairments led to very wide confidence intervals 





Information on alcohol consumption was available for all 291 cases and 180 (98.9%) of 
182 controls.  The overall pattern of alcohol consumption amongst cases and controls is 
summarised in Table 53.  A higher proportion of cases than controls denied alcohol use 
(81.8% vs. 52.8%) and when this variable was dichotomised (drinks alcohol vs. abstinent 
from alcohol), this association was found to be significant (OR 0.25, 95% CI 0.16 to 0.38, 
p<0.001).  To further explore the pattern of alcohol consumption among those that did 
drink alcohol, ORs for each category of alcohol use (light, moderate or heavy) were 
calculated using abstinence as the baseline comparator.  A negative association with 




 Cases (n=291) Controls (n=182) 
n (%) n (%) 
Febrile convulsions in childhood  31 (10.7%) 1 (0.5%) 
Perinatal complication 23 (7.9%) 4 (2.2%) 
Head injury 20 (6.9%) 8 (4.4%) 
History of febrile illness with LOC/convulsion 20 (6.9%) 9 (4.9%) 
Meningitis 6 (2.1%) 0 (0.0%) 
History of malaria with LOC/convulsion 5 (1.7%) 3 (1.6%) 
Stroke 3 (1.0%) 0 (0.0%) 
Brain abscess 1 (0.3%) 0 (0.0%) 
Table 47: Risk factors for epilepsy reported by cases and controls 
 
Variable OR 95% CI p-value 
Febrile convulsions in childhood 21.58 2.92 to 159.52 <0.001 
Perinatal complication 3.82 1.30 to 11.23 0.005 
Head injury 1.61 0.69 to 3.73 0.258 
History of febrile illness with LOC/convulsion 1.42 0.63 to 3.19 0.389 
History of malaria with LOC/convulsion 1.04 0.25 to 4.42 0.954 






n (%) n (%) 
1st degree relative 18 (6.2%) 6 (3.3%)0 
2nd degree relative 33 (11.3%) 1 (0.5%) 
None 240 (82.5%) 175 (96.2%) 
Total 291 (100.0%) 182 (100.0%) 




Variable OR 95% CI p-value 
No family history 1.00 - - 
Family history in 2nd degree relative 24.06 3.26 to 177.61 0.002 
Family history in 1st degree relative 2.19 0.85 to 5.62 0.104 





 Cases (n=291) Controls (n=182) 
n (%) n (%) 
Cognitive impairment 88 (30.2%) 2 (1.1%) 
Motor impairment 48 (16.5%) 1 (0.5%) 




Variable OR 95% CI p-value 
Cognitive impairment 39.65 9.63 to 163.35 <0.001 
Motor impairment 35.75 4.89 to 261.45 <0.001 







n (%) n (%) 
None 238 (81.8%) 95 (52.8%) 
Light 22 (7.6%) 35 (19.4%) 
Moderate 11 (3.8%) 33 (18.3%) 
Heavy 20 (6.9%) 17 (9.4%) 
Total 291 (100.0%) 180 (100.0%) 
Table 53: Alcohol use (cases and controls) 
 
 
Variable OR 95% CI p-value 
Abstinent from alcohol 1.00 - - 
Light alcohol use 0.25 0.14 to 0.45 <0.001 
Moderate use 0.13 0.07 to 0.27 <0.001 
Heavy use 0.47 0.24 to 0.94 0.032 
Table 54: Uni-variable associations between epilepsy and alcohol use 
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6.3.6 Marital status 
Data on marital status were available for 281 (96.6%) of 291 cases and for all 182 controls 
(Table 55, Figure 28).  PWE were significantly less likely to be married or to be widowed 
(Table 56). 
6.3.7 Educational level 
Data on educational level were available for 275 (94.5%) of 291 cases and 180 (98.9%) of 
182 controls (Table 57, Figure 29).  Three individuals (all PWE with cognitive impairment) 
had attended non-mainstream education, and for the purposes of analysis were classed as 
having completed primary education.  The category “post-primary education” includes all 
individuals who were either in full-time secondary or further education at the time of the 
study or who had any level of prior secondary or further education.  Primary education is 
compulsory in Tanzania from the age of eight years, and access to and completion of 
primary education were therefore the outcomes of primary interest.  To generate uni-
variable ORs these data were dichotomised in three ways: any schooling vs. no schooling, 
completed primary education vs. incomplete or no primary education, and any secondary 
or further education vs. all lower levels combined.  PWE were less likely to have any 
schooling at all or to have completed their primary education (Table 58). 
Data on literacy were available for 276 (94.8%) of 291 cases and 181 (99.5%) of 182 
controls, with 48.9% of cases stating they could not read or write compared with 19.9% of 
controls (OR 3.86, 95% CI 2.50 to 5.96, p<0.001). 
6.3.8 Occupation 
Data on occupation were available for 286 (98.3%) of 291 cases and 181 (99.5%) of 182 
controls (Table 59).  Epilepsy was significantly associated with not working for health 
related reasons, and with contributions to the household economy being limited to 
domestic tasks only (Table 60).  Cases were also significantly less likely than controls to be 
engaged in farming or herding as their main source of income (Table 60).  Odds ratios 
were not calculated for the categories ‘other manual’ and ‘not working-retired/elderly’ as 





n (%) n (%) 
Single (never married) 178 (63.3%) 57 (31.3%) 
Married 74 (26.3%) 114 (62.6%) 
Divorced/separated 22 (7.8%) 2 (1.1%) 
Widowed 7 (2.5%) 9 (4.9%) 
Total 281 (100.0%) 182 (100.0%) 
Table 55: Marital status of cases and controls 
 
 
Variable OR 95% CI p-value 
Single (never married) 1.00 - - 
Married 0.21 0.14 to 0.32 <0.001 
Divorced/separated 3.52 0.80 to 15.44 0.095 
Widowed 0.25 0.09 to 0.70 0.008 










n (%) n (%) 
No schooling 57 (20.7%) 12 (6.7%) 
Incomplete primary education 75 (27.3%) 30 (16.7%) 
Completed primary education 111 (40.4%) 113 (62.8%) 
Any secondary/further education 32 (11.6%) 25 (13.9%) 
Total 275 (100.0%) 180 (100.0%) 
Table 57: Highest educational level (cases and controls) 
 
 
Variable OR 95% CI p-value 
Any schooling (vs. no schooling at all) 0.27 0.14 to 0.53 <0.001 
Completed primary education (vs. incomplete primary/no schooling) 0.33 0.22 to 0.50 <0.001 
Current or previous post-primary education (vs. lower levels combined) 0.82 0.47 to 1.43 0.48 
Illiterate (vs. literate) 3.86 2.50 to 5.96 <0.001 










n (%) n (%) 
Farming/herding 96 (33.6%) 126 (69.6%) 
Not working - sick or disabled 69 (24.1%) 3 (1.7%) 
Domestic tasks/housework only 47 (16.4%) 7 (3.9%) 
Trade/skill 20 (7.0%) 12 (6.6%) 
In full-time secondary/further education  17 (5.9%) 13 (7.2%) 
Not working - unemployed 18 (6.3%) 4 (2.2%) 
Private business 8 (2.8%) 10 (5.5%) 
Salaried employment 5 (1.7%) 6 (3.3%) 
Other manual 3 (1.0%) 0 (0.0%) 
Not working – retired/elderly 3 (1.0%) 0 (0.0%) 
Total 286 (100.0%) 181 (100.0%) 




Occupation OR 95% CI p-value 
Farming/herding 0.22 0.15 to 0.33 <0.001 
Not working – sick or disabled 18.87 5.84 to 60.96 <0.001 
Domestic tasks/housework only 4.89 2.16 to 11.07 <0.001 
Trade/skill 1.10 0.51 to 2.22 0.879 
In full-time education 0.82 0.39 to 1.72 0.597 
Not working - unemployed 2.97 0.99 to 8.93 0.033 
Private business 0.49 0.19 to 1.27 0.142 
Salaried employment 0.52 0.16 to 1.73 0.284 
Table 60: Univariable associations between epilepsy and occupation  
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6.4 Multivariable logistic regression analyses 
6.4.1 Clinical associations with epilepsy 
The uni-variable odds for all clinical associations and risk factors for epilepsy are 
summarised in Table 61, with the final regression model given in Table 62.  As there was 
incomplete matching for age and sex these variables were also entered into the regression 
model.  Predictors of epilepsy in the final model were a family history of epilepsy in a 
second-degree relative, presence of cognitive impairment, a history of febrile convulsions 
in childhood, and presence of motor impairment.  Epilepsy was negatively associated with 
light or moderate alcohol use (Table 62). 
Only small numbers of controls had either cognitive or motor impairments (two and one 
respectively).  To assess the effect this had on the sensitivity of the initial model the 
regression was reiterated with these variables omitted (Table 63).  When this was done, a 
family history of epilepsy in a second-degree relative and a history of febrile convulsions in 
childhood both remained as predictors of epilepsy, with a history of perinatal 
complication also now appearing as a predictor of epilepsy, although this model fitted the 
data less well (Hosmer & Lemeshow 0.82 vs. 0.96).  The negative associations with light 
and moderate alcohol use that were observed in the initial model were reproduced, with 
similar adjusted ORs as previously.
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Variable OR 95% CI p-value 
Demographic features 
Male sex 1.36 0.94 to 1.97 0.105 
Tribal group other than Chagga 1.19 0.73 to 1.94 0.474 
Muslim religion 1.23 0.76 to 1.98 0.389 
Clinical associations 
No family history of epilepsy 1.00 - - 
Family history of epilepsy in 1st degree relative 2.19 0.85 to 5.62 0.104 
Family history of epilepsy in 2nd degree relative 24.06 3.26 to 177.61 0.002 
Febrile convulsions in childhood 21.6 2.92 to 159.52 <0.001 
Perinatal complication 3.82 1.30 to 11.23 0.005 
Head injury 1.61 0.69 to 3.73 0.258 
History of febrile illness with LOC/convulsion 1.42 0.63 to 3.19 0.389 
History of malaria with LOC/convulsion 1.04 0.25 to 4.42 0.954 
No alcohol use 1.00 - - 
Light alcohol use (vs. no alcohol use) 0.25 0.14 to 0.45 <0.001 
Moderate alcohol use (vs. no alcohol use) 0.13 0.07 to 0.27 <0.001 
Heavy alcohol use (vs. no alcohol use) 0.47 0.24 to 0.94 0.032 
Cognitive impairment 39.65 9.63 to 163.35 <0.001 
Motor impairment 35.75 4.89 to 261.45 <0.001 




Variable B SE Adjusted OR* 
95% CI 
Lower Upper 
History of childhood febrile convulsions 2.829 1.057 16.93 2.14 134.26 
Family history of epilepsy  in 2
nd
 degree relative 3.269 1.050 26.29 3.36 205.99 
Cognitive impairment 3.153 0.737 23.41 5.52 99.23 
Motor impairment 2.303 1.045 10.01 1.29 77.59 
Light alcohol use (vs. none) -1.351 0.360 0.26 0.13 0.52 
Moderate alcohol use (vs. none) -1.823 0.434 0.16 0.07 0.38 
Goodness of fit (Hosmer & Lemeshow)=0.96   *adjusted for variables summarised in Table 61 and for age 
Table 62: Logistic regression model of clinical associations with epilepsy 
 
 
B S.E. Adjusted OR* 
95% CI 
Variable Lower Upper 
Febrile convulsions in childhood 3.017 1.050 20.42 2.61 159.86 
History or perinatal complication 1.223 0.588 3.40 1.07 10.75 
Family history of epilepsy (2
nd
 degree relative) 3.366 1.067 28.97 3.58 234.73 
Light alcohol use -1.622 0.338 0.20 0.10 0.38 
Moderate alcohol use -2.277 0.429 0.10 0.04 0.24 
Goodness of fit (Hosmer & Lemeshow)=0.82 *adjusted for variables in Table 61 but excluding cognitive and motor impairments, and for age 
Table 63: Logistic regression model (cognitive and motor impairments excluded) 
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6.4.2 Socio-economic associations with epilepsy 
A summary of all socio-economic uni-variable associations with epilepsy is given in Table 
64.  As for the modelling of clinical associations with epilepsy, age and sex were entered 
into the regression model as matching for these factors during recruitment had been 
incomplete.  Disability due to cognitive or motor impairments may affect socio-economic 
status independently of epilepsy, and these were therefore also included in the model as 
possible confounders.  The lower proportion of cases that drink alcohol may also be 
related to socio-economic status, and alcohol consumption was also included in the model 
for this reason.  Demographic features of tribe and religion were also entered.  In the final 
model, shown in Table 65, being divorced or separated was a predictor of epilepsy, with 
epilepsy being negatively associated with being engaged in farming or herding as a 
primary source of income, or having completed primary education.  The negative 
associations with light or moderate alcohol use were also reproduced in this model. 
As with the modelling of clinical associations, this model was reiterated to assess the 
sensitivity with cognitive and motor impairments excluded (Table 66).  In the revised 
model the occupational categories of being sick or disabled and of being limited to 
domestic tasks only now appeared as additional predictors of epilepsy.  The negative 
association with having completed primary education no longer appeared, while being 
illiterate now appeared as a predictor of epilepsy.  Finally, in addition to being divorced or 
separated, being currently married now appeared as a negative association with epilepsy.  
The Hosmer and Lemeshow statistic of 0.19 for this revised model indicates a poorer fit 




Variable OR 95% CI p-value 
Marital status    
Single 1.00 - - 
Married (vs. single) 0.21 0.14 to 0.32 <0.001 
Divorced/separated (vs. single) 7.65 1.78 to 32.92 <0.001 
Widowed (vs. single) 3.52 0.80 to 15.44 <0.095 
Educational level 
Any schooling (vs. no schooling at all) 0.25 0.09 to 0.70 0.008 
Completed primary education (vs. incomplete primary/no education) 0.33 0.22 to 0.50 <0.001 
Current or previous post-primary education (vs. all lower levels combined) 0.82 0.47 to 1.43 0.48 
Illiterate (vs. literate) 3.86 2.50 to 5.96 <0.001 
Occupation 
Farming/herding 0.22 0.15 to 0.33 <0.001 
Not working – sick or disabled 18.87 5.84 to 60.96 <0.001 
Domestic tasks/housework only 4.89 2.16 to 11.07 <0.001 
Trade/skill 1.10 0.51 to 2.22 0.879 
In full-time education 0.82 0.39 to 1.72 0.597 
Not working - unemployed 2.97 0.99 to 8.93 0.033 
Private business 0.49 0.19 to 1.27 0.142 
Salaried employment 0.52 0.16 to 1.73 0.284 




Variable B SE Adjusted OR* 
95% CI 
Lower Upper 
Divorced/separated 2.755 0.821 15.72 3.15 78.61 
Light alcohol use -1.450 0.405 0.24 0.11 0.52 
Moderate alcohol use -1.600 0.472 0.20 0.08 0.51 
Farming/herding -0.903 0.280 0.41 0.23 0.72 
Completed primary education -0.860 0.275 0.42 0.25 0.73 
Goodness of fit (Hosmer & Lemeshow)=0.62 *adjusted for age, sex, tribe, religion, cognitive and motor impairment, and all variables in Table 64 
Table 65: Logistic regression model of socio-economic associations with epilepsy 
 
Variable B S.E. Adjusted OR* 
95% CI 
Lower Upper 
Marital status – married -0.563 0.271 0.57 0.34 0.97 
Marital status - divorced/separated 2.588 0.816 13.30 2.69 65.84 
Light alcohol use -1.401 0.385 0.25 0.12 0.52 
Moderate alcohol use -1.691 0.459 0.18 0.08 0.45 
Farming/herding -0.736 0.288 0.48 0.27 0.84 
Sick/disabled 1.871 0.663 6.50 1.77 23.80 
Domestic tasks only 1.110 0.496 3.04 1.15 8.02 
Illiterate 0.914 0.285 2.49 1.43 4.36 
Goodness of fit (Hosmer & Lemeshow)=0.19 *adjusted for age, sex, tribe, religion and all variables in Table 64 




After controlling for the demographic features of age, sex and tribal and religious groups, 
predictors of epilepsy in the HDSS adult population were a history of febrile convulsions, a 
family history of epilepsy in a second-degree relative, and the presence of cognitive or 
motor impairments.  These findings correlate in part with those of the few other case-
control studies from SSA to have used multivariable analyses to control for confounding.  
In rural Kenya family history was also found to be a predictor of epilepsy (Edwards et al., 
2008), and it is interesting to note that in this study a stronger uni-variable association was 
found with a family history in extended relatives (p<0.0001) than in first-degree relatives 
(p=0.0332).  A complex, non-Mendelian hereditary pattern for some epilepsy in SSA has 
previously been proposed (Neuman et al., 1995), and these findings from Hai and 
elsewhere may lend support to this theory.  At the same time, it could be argued that the 
high rates of focal-onset seizures along with high rates of clinically apparent structural 
brain disease, as evidenced by cognitive and motor impairments, would point more 
towards a predominance of environmental causes in the Hai population.  Family history 
has also been identified as a predictor of epilepsy in the two other studies to have used 
these techniques (Nsengiyumva et al., 2003, Matuja et al., 2001), although details 
available from the latter of these studies, conducted in Tanzania, implicate first-degree 
relatives as opposed to extended family members.  The authors of the Tanzanian study 
also comment that the meaning of this finding is not clear, as there was also a high rate of 
focal-onset epilepsy identified in that study (Matuja et al., 2001).  In the recent Kenyan 
study mentioned above, the authors sought to make the distinction between a family 
history of febrile and non-febrile seizures, but acknowledge that problems with recall may 
have limited the power and precision of these observations (Edwards et al., 2008).  In our 
study we did not attempt to make this distinction, and acknowledge that in a study of 
adults that utilises data derived from reported events problems with recall are likely to be 
a major limitation. 
A childhood history of febrile convulsions and the presence of cognitive and motor 
impairments were also predictors of epilepsy in the Hai population, also reflecting 
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observations made elsewhere in SSA (Ogunniyi et al., 1987, Matuja et al., 2001).  In two 
different Tanzanian cohorts of PWE, 9.6% and 22% of cases were described as having 
mental retardation or of being of impaired intelligence (Winkler et al., 2009c, Matuja et 
al., 2001).  In our study, when the regression model was reiterated with these variables 
removed it was interesting to note that a history of adverse perinatal events appeared as 
a predictor of epilepsy.  Again, this mirrors case-control data from elsewhere in SSA, 
including Tanzania (Edwards et al., 2008, Matuja et al., 2001, Nsengiyumva et al., 2003).  
The issue of obstetric complications and their contribution to the burden of mortality and 
morbidity is of particular interest in SSA where most children are born at home without 
professional help, and where maternal and infant mortality rates are generally high 
(Kitange et al., 1996, Janson, 2007). 
Case-control studies from SSA have also previously identified head injury as a significant 
cause of epilepsy (Ogunniyi et al., 1987, Edwards et al., 2008).  While head injury was 
clearly implicated in a number of cases of epilepsy in Hai, it was not found to be a 
significant predictor of epilepsy in the HDSS population.  This may be a reflection of the 
rural nature of the district, with few paved roads carrying motorised transport, or possibly 
of the peaceful nature of the local society, with the prevailing influence on the rates of 
serious and penetrating head injury of road traffic accidents and civil unrest and conflict 
that are seen in other parts of SSA not being present (Preux and Druet-Cabanac, 2005, 
Adamolekun, 1995). 
With regards to socio-economic associations with epilepsy, we found that cases were less 
likely to have completed primary education, and were less likely to be engaged in farming.  
These predictors were present in the final regression model which adjusted for cognitive 
and motor impairments, suggesting that these negative associations are reflective of 
epilepsy, rather than the presence of other disabilities with which epilepsy may be 
associated.  With primary education being compulsory in Tanzania, and subsistence 
agriculture being the chief economic activity in this population, this finding suggests that 
any social marginalisation experienced by PWE in this population, as evidenced by a 
greater likelihood of divorce or marital separation, is further compounded by educational 
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and economic disadvantage.  There are very few case-control data from SSA of which we 
are aware which specifically examine the degree of association between epilepsy and 
similar socio-economic outcomes.  A study in Burundi compared 352 PWE identified from 
the general population with 704 controls to ascertain the direct and indirect economic 
costs of epilepsy (Nsengiyumva et al., 2004).  While there was no comparison between 
cases and controls with regards to the socio-demographic indicators that we have 
examined here, the authors do state that there were no differences between treated and 
untreated PWE in terms of marital or employment status.  Our findings are consistent, 
however, with those of a number of observational studies that have documented the 
experience of PWE living in Tanzania and elsewhere in SSA.  In a clinic-based series of 231 
PWE from Nigeria, nearly 20% of cases had suffered marital breakdown or had been 
withdrawn from education as a result of their epilepsy (Nuhu et al., 2010).  Observational 
studies from Nigeria, Zambia and Tanzania have all described children with epilepsy being 
expelled from school solely because of their seizures (Osuntokun and Odeku, 1970, 
Birbeck and Kalichi, 2003, Matuja and Rwiza, 1994).  In a survey of 276 health care 
workers in rural Zambia one quarter of respondents stated that they would not allow their 
child to marry someone with epilepsy and one fifth thought that PWE should not marry or 
hold employment (Chomba et al., 2007).  A survey of 171 teachers drawn from the same 
population found that between 16.8% and 28.2% of respondents thought that epilepsy 
was due to possession by spirits, witchcraft or contagion, with aberrant beliefs about 
epilepsy correlating with stigmatising practices such as excluding children with seizures 
from school (Birbeck et al., 2006).  In a qualitative study conducted in the HDSS epilepsy 
cohort, forty-one PWE and nineteen relatives or carers were interviewed in depth, with 
themes of social exclusion across the spheres of marriage, work and education emerging 




6.6 Summary and conclusions 
The identification of febrile seizures, perinatal complications, and evidence of structural 
brain disease as predictors of epilepsy in the HDSS population points to a considerable 
burden of acquired epilepsy.  By implication, improved obstetric care and improved 
recognition and management of febrile seizures in childhood may lead to a measurably 
reduced morbidity with epilepsy in later life in this population.  Epilepsy appears to be 
associated with adverse socio-economic outcomes in this population, indicating that the 
burden of epilepsy extends beyond the morbidity and costs associated with purely the 
medical aspects of the disease.  The degree to which reduced educational attainment and 
economic productivity pertains to the physical burden of disease or to enacted stigma 
warrants further investigation. 
217 
 
Chapter 7.  Cysticercosis and epilepsy in Hai 
Abstract 
Background 
Neurocysticercosis (NCC) results from infection with the larval form of the human 
tapeworm Taenia solium.  NCC has been described as a major cause of symptomatic 
epilepsy in endemic regions around the world, including Latin America, India and China.  
NCC has been postulated as an important cause of epilepsy in SSA, although there have 
been few comprehensive studies. 
Methods 
Blood samples from adult PWE and healthy controls living in the HDSS were tested for the 
presence of antibodies to T.solium using an EITB assay to two different cysticercal 
antigens.  All PWE were offered a CT head scan to look for evidence of active or calcified 
cystic lesions suggestive of NCC.  Questionnaire data on pig keeping, household sanitation 
and pork consumption were collected from cases and controls. 
Results 
Antibodies to T.solium were detected in six out of 218 cases (2.8%) and in none of 174 
controls (p=0.036).  Lesions suggestive of NCC were seen in eight out of 200 CT scans 
(4.0%).  Taking CT as the gold standard for diagnosis, EITB serology performed with a 
positive predictive value of 40.0%, sensitivity of 33.3% and specificity of 98.2%.  No 
correlation with household sanitation, pig keeping or pork consumption was identified on 
comparing either cases and controls, or cases with and without NCC. 
Conclusions 
NCC is present in Hai, but with very low endemicity.  EITB serology does not appear to 





7.1.1 Cysticercosis, neurocysticercosis and epilepsy 
Taenia solium is a zoonotic human cestode that depends on the pig as an intermediate 
host.  Infection of human tissue with the larval stage of the parasite is known as 
cysticercosis: the term neurocysticercosis (NCC) specifically refers to infection of the CNS.  
NCC is the commonest helminthic disease of the CNS worldwide (Winkler et al., 2009a), 
and is increasingly recognised as a leading cause of epilepsy in endemic countries (de 
Bittencourt et al., 1996a).  Up to fifty million people worldwide may be affected by 
cysticercosis (World Health Organisation, 2006), which may be implicated in up to 50,000 
deaths per year (Roman et al., 2000).  The WHO has estimated that up to 30% of all 
epilepsy worldwide may be associated with NCC, with ten million of these individuals 
living in Africa (World Health Organisation, 2011). 
Humans are the definitive host for T.solium, with individuals becoming infected through 
the consumption of undercooked pork that contains cysticerci, the larval stage of the 
parasite.  Ingested cysticerci become attached to the wall of the small intestine, 
developing into adult worms of up to three metres in length over a period of 
approximately two months.  Individuals infected in this way will excrete proglottid 
tapeworm segments in their faeces from which the immediate environment is 
contaminated with viable Taenia eggs.  When eggs are ingested by a pig they hatch into 
active entities known as oncospheres; these are able to cross the gut lumen to become 
lodged in extra-intestinal tissues where they develop into the cystic larval stage of the 
parasite.  The life-cycle is completed when undercooked encysted pork is consumed and 
viable cysts develop into adult worms in the gut of the next human host.  Human 
cysticercosis therefore occurs when Taenia eggs are accidentally consumed by humans, 
through faecal-oral transmission or through auto-infection, with human tissue 
subsequently becoming infected with the encysted larval stage of the tape worm (King, 
2005).  The tissues most commonly affected in this way include subcutaneous tissue, 
striated muscle, the eye and the CNS (Winkler et al., 2009a).  Four developmental stages 
in NCC are recognised.  In the first stage immature cysts appear in the tissues within one 
to four weeks (stage 1).  Cysts then mature and become viable after approximately two 
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months (stage 2); this stage is generally asymptomatic and may persist for ten years or 
more.  Loss of host immune control after between two and ten years leads to cyst 
degeneration and associated inflammation (stage 3); involvement of parenchymal brain 
tissue at this stage can present with signs and symptoms of raised intracranial pressure 
and can be associated acutely with seizures and a reduced conscious level.  In the final 
stage there is involution and calcification of the cyst, with eventual resolution of any 
associated inflammation (stage 4).  Calcified parenchymal foci and associated scarring 
have the potential to act as epileptogenic foci, giving rise to acquired focal-onset epilepsy 
in affected individuals (King, 2005). 
A number of epidemiological insights are gained from this description of the natural 
history of human T.solium infection and human cysticercosis.  Firstly, the conditions for 
the perpetuation of T.solium infections in humans depend on two chief factors: there 
being a pig population that is routinely exposed to human faecal matter, e.g. in water, 
contaminated vegetable matter or directly from night soil or through defecation in pig 
pens, and there being insufficient food hygiene standards, in abattoirs or at the food 
preparation stage, to protect humans from the consumption of undercooked encysted 
pork.  These conditions hold sway in many LMICs, particularly where free-range pig rearing 
is practiced and where public sanitation is limited, and it is well recognised that 
cysticercosis is strongly associated with poverty (Willingham III and Engels, 2006).  
Secondly, the risk factor for human cysticercosis is faecal-oral exposure in an environment 
where individuals are carrying adult T.solium worms in their guts and are excreting eggs 
into the environment.  Each proglottid segment contains between 50,000 and 60,000 
eggs, and infected humans may shed a few proglottids per day (Garcia et al., 2003).  In this 
way a single carrier may be responsible for the infection of numerous individuals in a 
community, and neither pig-rearing nor pork consumption are therefore necessary to the 
acquisition of cysticercosis (Schantz et al., 1992, Hira et al., 2004). 
While post-mortem evidence suggests that NCC may be asymptomatic in up to 80% of 
infected individuals (Bern et al., 1999), the relationship between NCC and epilepsy has 
also been clearly established.  In Latin-American countries cerebral calcifications are a 
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common finding in persons with seizures or epilepsy in populations where T.solium is 
endemic (Nash et al., 2004).  The prevalence of cerebral calcification consistent with NCC 
in randomised studies of endemic populations ranges from 9% to 18%, and rates as high 
as 83% have been documented in selected populations with seizures (Nash et al., 2004).  
For example, typical calcifications were found in 36% and 35% of persons with seizures in 
two different villages in Guatemala compared to 15% and 9% in matched controls without 
a history of seizures (Garcia-Noval et al., 2001).  Cysts or degenerating cysts in this study 
were responsible for about 25% of the seizures in patients with cysticercosis. 
An estimated 80 to 90% of people with symptomatic NCC will develop seizures at some 
point (Bern et al., 1999), although the proportion of people with acute symptomatic 
seizures associated with NCC who go on to develop epilepsy is unknown (Foyaca-Sibat et 
al., 2009).  While NCC is widely considered to be the leading preventable cause of epilepsy 
in LMICs (Preux and Druet-Cabanac, 2005, Roman et al., 2000), studies have not always 
discriminated between acute symptomatic seizures and epilepsy, and some studies have 
included patients with seizures and positive serology without the support of neuro-
imaging (Garcia et al., 1993, Nsengiyumva et al., 2003).  In endemic areas many people 
may be exposed to T.solium eggs, including exposure after the onset of epilepsy, leading 
to high false-positive rates on serological testing (Foyaca-Sibat et al., 2009). 
7.1.2 Diagnosing cysticercosis and neurocysticercosis 
Although NCC is the most common helminthic infection of the CNS, its diagnosis is 
rendered difficult by non-specific clinical manifestations, including seizures, headaches, 
focal neurological deficits, by imaging findings that are often abnormal but seldom 
pathognomic (Garcia and Del Brutto, 2003, Coyle and Tanowitz, 2009, Martinez et al., 
1989), and by the variable sensitivity and specificity of serological tests, particularly in 
patients with single lesions (Coyle and Tanowitz, 2009, Wilson et al., 1991). 
Infection with T.solium is associated with specific IgG antibody responses, with multiple 
antibodies of different specificities appearing at different intervals after infection 
reflecting the varying antigenic signatures of the different stages of parasitic development 
(Dorny et al., 2003).  Various tests to detect the presence of T.solium antibodies have 
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been developed, making use of either crude antigen preparations or purified 
glycoproteins (Ito et al., 2003).  An enzyme-linked immuno-transfer blot (EITB) of seven 
purified cysticercal glycoproteins has been shown to have a specificity approaching 100% 
and sensitivity of between 70% and 90% (Tsang et al., 1989).  EITB is an expensive 
technique, however, and in LMICs the simpler, more affordable and more widely available 
technique of the enzyme-linked immunosorbent assay (ELISA) is preferable (Rosas et al., 
1986).  An ELISA using purified glycoproteins obtained from cyst fluid has been shown to 
have a sensitivity and specificity similar to that of EITB in experimental conditions (Dorny 
et al., 2003). 
Serological tests alone can be difficult to interpret.  For example, the utility of antibody-
based serological techniques may be limited in cases with small numbers of lesions or 
solitary cysticerci (Garcia et al., 2003, Dorny et al., 2003), and sensitivities as low as 28% 
have been reported in cases with single cysts in the brain (Wilson et al., 1991).  
Conversely, a positive antibody test may merely indicate prior exposure rather than active 
infection or disease (Garcia et al., 2001), and in endemic populations 10% or more of the 
general population may have antibodies to T.solium (Bern et al., 1999).  Reliance on 
serological tests alone may thus lead to missed diagnoses in individuals truly suffering 
with NCC or to an overestimation of the extent of disease related to cysticercosis in 
communities where T.solium is endemic.  Correlation with clinical details and imaging is 
therefore imperative wherever possible, although the latter of these modalities is seldom 
routinely available in resource-limited settings. 
Antigen detection has been proposed as a suitable alternative to antibody testing, 
particularly in the detection of viable cysts that may be amenable to anti-helminthic 
treatment.  Several assays have been developed (Dorny et al., 2003), and a high level of 
agreement between an antigen ELISA, CT scanning and histological examination have been 
reported (Erhart et al., 2002).  As with antibody serology, however, lower sensitivities 
have been reported in patients with single viable lesions or enhancing lesions only (Garcia 
et al., 2000), and the sensitivity and specificity of antigen testing were both found to be 
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poorer than that of antibody testing in a South African population (Foyaca-Sibat et al., 
2009). 
A diagnosis of NCC is usually based on neuro-imaging with either CT or magnetic 
resonance imaging (MRI) (Garcia and Del Brutto, 2005).  CT imaging of the brain has a 
sensitivity and specificity in excess of 95% for the diagnosis of NCC, and although 
characteristic patterns associated with each stage in the development and subsequent 
involution of cysts have been described, findings are rarely pathognomonic (Garcia and 
Del Brutto, 2003), and the differential diagnosis on neuro-imaging in endemic regions 




7.1.3 Clinical diagnostic criteria for NCC 
To account for these difficulties, and to help clinicians with arriving at a diagnosis, a set of 
diagnostic criteria comprising four categories has been proposed (Del Brutto et al., 2001).  
These take into account clinical, imaging and serological findings along with 
epidemiological factors, as follows: 
Absolute criteria: histological demonstration of the parasite, CT imaging demonstrating 
the scolex, direct visualisation of sub-retinal parasites on fundoscopy. 
Major criteria: lesions highly suggestive of NCC on neuro-imaging, positive serum EITB for 
anti-cysticercal antibodies, resolution of intracranial lesions after specific anti-helminthic 
therapy, spontaneous resolution of single enhancing lesions. 
Minor criteria: lesions compatible with NCC on neuro-imaging, clinical manifestations 
suggestive of NCC, positive CSF ELISA for anti-cysticercal antibodies or cysticercal antigens, 
cysticercosis present outside the CNS. 
Epidemiologic criteria: evidence of a household contact with T.solium infection, individuals 
coming from or living in endemic areas, and a history of frequent travel to endemic areas. 
Diagnoses made using these criteria are accorded one of four degrees of certainty (Table 
67). 
Diagnostic certainty Criteria 
Definitive 1. Presence of one absolute criteria 
2. Presence of two major plus one minor and one 
epidemiologic criterion 
Probable 1. Presence of one major plus two minor criteria 
2. Presence of one major plus one minor and one 
epidemiologic criterion 
3. Presence of three minor plus one epidemiologic criterion 
Table 67: Degrees of certainty for the diagnosis of NCC 
(Del Brutto et al., 2001) 
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7.1.4 Neurocysticercosis and epilepsy in Africa 
While NCC is recognised as a leading cause of epilepsy in LMICs worldwide (de Bittencourt 
et al., 1996b, de Bittencourt et al., 1996a, Roman et al., 2000), there have been relatively 
few studies of human cysticercosis and NCC from SSA.  A recent review identified thirteen 
studies in eight countries (excluding South Africa) between 1989 and 2009 (Winkler et al., 
2009a), with only eleven of these being suitable for inclusion in a meta-analysis that 
specifically examined the relationship between NCC and epilepsy in SSA (Quet et al., 
2010).  The sero-prevalence of anti-cysticercal antibodies in PWE has been documented as 
being as high as 40% in Cameroon (Zoli et al., 2003a), has been shown to be significantly 
associated with epilepsy in Burundi (Nsengiyumva et al., 2003), and the overall association 
between cysticercosis and epilepsy in SSA based on serological studies has been estimated 
to have a significant common odds ratio of 3.4 (95% CI 2.7 to 4.3) (Quet et al., 2010).  This 
picture is not universal, however; in The Gambia cysticercal antigen was detected by ELISA 
in 1.4% of 210 PWE and 1.9% of 420 controls, with none of the sero-positive individuals 
demonstrating cysts or other lesions suggestive of NCC on CT imaging (Secka et al., 2010). 
Studies of NCC and epilepsy from SSA which benefit from both imaging and serology have 
been very limited.  Outside of South Africa there has been only one set of published 
studies to date, in a cohort of 212 PWE from northern Tanzania, with only limited data on 
the sero-prevalence of cysticercosis among controls (Blocher et al., 2011, Winkler et al., 
2008a, Winkler et al., 2009b). 
To date there have been no systematic studies of which we are aware that have examined 





All 291 adult PWE identified during the HDSS prevalence survey were offered CT imaging 
of the brain and were asked to provide a blood sample.  CT scans with contrast were 
performed as described in Chapter Five and healthy controls were recruited as described 
in Chapter Six.  Controls were also asked to provide a blood sample to be analysed 
alongside those from cases.  Blood samples were collected from cases either when they 
attended KCMC for investigations or in the community during follow-up visits.  All blood 
samples from controls were collected in the community during the control recruitment 
phase of the study.  Samples were centrifuged in daily batches to separate plasma from 
serum before storage at -80oC.  Plasma samples were shipped to the KEMRI-Wellcome 
research laboratory in Kilifi, Kenya where they were analysed for the presence of anti-
cysticercal antibodies using the EITB method with purified r24 and rES33 T.solium 
antigens.  The sensitivity and specificity of this serological method in an endemic area of 
South Africa have been shown to be 54.5% and 69.2% respectively (Foyaca-Sibat et al., 
2009). 
Diagnoses of NCC in PWE were made according to clinical, neuro-imaging, serological and 
epidemiologic diagnostic criteria (Del Brutto et al., 2001).  For the purposes of this study 
the HDSS was considered to be an endemic region for T.solium infection, by extrapolation 
from work done elsewhere in Tanzania (Quet et al., 2010, Winkler et al., 2008a, Mafojane 
et al., 2003).  The number of households in the district that keep pigs was ascertained 
during the census, and additional demographic data on household occupancy, pork 
consumption and access to domestic sanitation were collected during the clinical follow-
up and control recruitment phases of the study. 
Comparisons were made between all cases and controls, and between cases with 
definitive or probable NCC and those without NCC.  Categorical variables were compared 
using Chi-square and Fisher’s exact tests; non-normally distributed continuous variables 
were compared using the Mann-Whitney U test.  A p-value of 0.05 or less was used as the 
threshold for significance throughout. 
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With regards to sero-prevalence of antibodies to T.solium, sample size calculations were 
made based on data derived from two case-control studies of cysticercosis in epilepsy 
performed in Burundi.  In a 1997 study, antibodies were detected in 11.7% of 103 PWE 
versus 2.8% of 72 controls using EITB (Newell et al., 1997a).  To detect a similar difference, 
i.e. least extreme OR of 4.60, with 95% confidence and 80% power using a one-to-one 
matching stratagem would require a sample of 134 cases and controls (i.e. a total sample 
size of 268).  A more recent study in a population with an apparently higher endemicity of 
human cysticercosis identified antibodies in 58.7% of 303 PWE compared with 38.3% of 
606 controls using an antibody ELISA (Prado-Jean et al., 2007).  If such a situation was the 
case in the HDSS population a similar difference could be detected, again with 95% 
confidence and 80% power, with one-to-one matching of ninety-five cases and controls, 
i.e. a total sample size of 190.  With a prevalent cohort of 291 PWE willing to participate in 
the study, we were therefore confident that similar differences could be detected in our 






CT head scans were available from 200 (68.7%) of 291 cases.  There was no difference in 
the proportions of males and females among cases who did and did not have a CT scan 
(χ2(1)=0.18, p=0.89), although cases who did have scans were older than those who did 
not (Mann-Whitney U=7733.5, z=-2.054, p=0.040; Table 68).  Lesions suggestive of NCC 
were seen in eight (4.0%) of 200 scans: seven (7.4%) of ninety-four females and one (0.9%) 
of 106 males (Fisher’s Exact Test, p=0.027).  A full description of all imaging findings other 
than NCC is given in Chapter Five, section 5.4.2. 
7.3.2 Serology 
Blood samples were taken from 231 (79.4%) of 291 cases: 109 (80.1%) of 136 females and 
122 (78.7%) of 155 males.  There was no difference in gender distribution between cases 
that did and did not give a blood sample (χ2(1)=0.091, p=0.762), and the ages of these two 
groups were similar (Mann-Whitney U=6570.50, z=-0.619, p=0.536; Table 69).  Blood 
samples were available from all 182 controls. 
When laboratory results became available it was found that twenty-one samples were 
missing: thirtee n (5.6%) of 231 cases and eight (4.5%) of 182 controls (χ2(1)=0.32, 
p=0.572; Table 70).  A total of 392 samples were therefore analysed: 218 from cases and 
174 from controls.  The demographic characteristics of these groups are summarised in 
Table 71 and Table 72.  While controls were significantly older than cases (Mann-Whitney 
U 15833.0, z= -2.812, p=0.005), the proportions of males and females among cases and 
controls were similar (χ2(1)=2.65, p=0.104). 
Antibodies to T.solium were identified in six (2.8%) of 218 cases and in none of 174 
controls (Table 73).  Of the six seropositive cases, three (50%) had antibodies to the T24 
antigen only, one (16.7%) had antibodies to the ES33 antigen only, and two (33.3%) had 
antibodies to both.  The overall sero-positivity rate among cases and controls combined 
was 1.5% (95% CI 0.3 to 2.8), and the sero-positivity rate amongst cases only was 2.8% 
(95% CI 0.6 to 4.9).  Although sero-positivity rates were low, there was a statistically 
significant association between seropositivity and having epilepsy (Fisher’s Exact Test, 
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p=0.036).  There was no association between seropositivity and sex (Fisher’s Exact Test, 
p=1.00). 
There were no significant differences between sero-negative and sero-positive cases with 
regards to either age on prevalence date (Mann-Whitney U 423.5, Z= -1.395; p=0.168), or 
age at onset of epilepsy (Mann-Whitney U 438.5, Z= -1.255; p=0.216).  These data are 
summarised in Table 74 and Table 75.  In addition, no significant associations between 




Age on prevalence date (years) 
Median Min Max IQR 
CT scan 200 31.5 15 85 22 
No CT scan 91 26.0 15 81 21 
Total 291 30.0 15 85 21 




Age on prevalence date (years) 
Median Min Max IQR 
Blood sample taken 231 30.0 15 81 21 
No blood sample 60 28.5 15 62 25 
Total 291 30.0 15 85 21 




 Cases Controls Total 
n (%) n (%) n (%) 
Not taken 60 (20.6%) 0 (0.0%) 60 (12.7%) 
Taken and analysed 218 (74.9%) 174 (95.6%) 392 (82.9%) 
Taken but missing 13 (4.5%) 8 (4.4%) 21 (4.4%) 
Total 291 (100.0%) 182 (100.0%) 473 (100.0%) 
Table 70: Blood samples taken during field work 
 
 n 
Age on prevalence date (years) 
Median Min Max IQR 
Case 218 31.0 15 85 22 
Control 174 39.0 15 91 25 
Total 392 33.5 15 91 23 
Table 71: Analysed blood samples, by age (cases and controls) 
 
 Female Male Total 
n (%) n (%) n (%) 
Case 101 (46.3%) 117 (53.7%) 218 (100.0%) 
Control 95 (54.6%) 79 (45.4%) 174 (100.0%) 
Total 196 (50.0%) 196 (50.0%) 392 (100.0%) 
Table 72: Analysed blood samples by sex (cases and controls) 
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 Cases Controls Total 
n (%) n (%) n (%) 
Sero-negative 212 (97.2%) 174 (100.0%) 386 (98.5%) 
Sero-positive 6 (2.8%) 0 (0.0%) 6 (1.5%) 
Total 218 (100.0%) 174 (100.0%) 392 (100.0%) 
Table 73: Outcomes of serological testing 
 
 Age on prevalence date (years) 
 n Median Min Max IQR 
Sero-positive 6 41 22 74 30 
Sero-negative 212 34 15 85 21 
Total 218 31 15 85 22 
Table 74: Age of cases and sero-status for antibodies to T.solium 
 
 Age at onset of epilepsy (years) 
 n Median Min Max IQR 
Sero-positive 6 27.5 4 70 41 
Sero-negative 209 13 0 81 19 
Total 215* 13 0 81 19 
*data missing for 3 sero-negative cases 





Total Fisher’s exact Positive Negative 
Gender: Male n (%) 3 (50.0) 114 (53.8) 117 (53.7)  
 Female n (%) 3 (50.0) 98 (46.2) 101 (46.3) n=218; p=1.00 
Chagga tribe (vs. other group) n (%) 5 (83.3) 168 (80.8) 173 (80.8) n=214; p=1.00 
Religion: Christian n (%) 6 (100.0) 169 (80.9) 175 (81.4)  
 Muslim n (%) 0 (0.0) 40 (19.1) 40 (18.6) n=215; p=0.596 
Any education (vs. none) n (%) 6 (100.0) 165 (96.5) 171 (81.8) n=209; p=0.595 
Completed 1o education (vs. none/incomplete) n (%) 2 (33.3) 107 (53.5) 109 (52.4) n=206; p=0.423 
Focal onset seizures (vs. generalised/undefined) n (%) 5 (83.3) 154 (72.6) 159 (72.9) n=218; p=1.00 
Family history of epilepsy n (%) 0 (0.0) 34 (16.0) 34 (15.6) n=218: p=0.593 
Cognitive impairment n (%) 2 (33.3) 55 (25.9) 57 (26.1) n=218; p=0.653 
Motor impairment n (%) 0 (0.0) 28 (13.2) 28 (12.8) n=218; p=1.00 
Table 76: Demographic and clinical characteristics of cases by sero-status 
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7.3.3 Diagnosis of neurocysticercosis in people with epilepsy 
All 291 PWE were considered to have at least one minor diagnostic criterion (i.e. seizures) 
and one epidemiologic criterion (i.e. coming from an area endemic for cysticercosis).  
Investigations potentially diagnostic of NCC were available in 252 (86.6%) of 291 cases: 
176 (69.8%) with both CT and serology, twenty-four (9.5%) with CT only, and forty-two 
(16.7%) with serology only.  Blood samples were available for six (75%) of eight cases in 
which lesions suggestive of NCC were seen on CT, of which two (33.3%) were positive for 
T.solium antibodies and therefore fulfilled the criteria for definitive NCC (two major plus 
one minor criteria and one epidemiologic criterion); both of these cases had multiple 
lesions on CT.  A further four (50%) of eight cases with lesions suggestive of NCC on CT 
were sero-negative and considered as probable NCC (one major plus one minor and one 
epidemiologic criterion).  Of these, one (25.0%) had a single lesion, one (25.0%) had 
multiple lesions and two (50.0%) had diffuse calcification.  Two cases with CT suggestive of 
NCC, both with single lesions, from whom no blood sample was available were also 
considered as probable NCC, with one major plus one minor and one epidemiologic 
criterion.  Finally, three cases who were sero-positive but with no evidence of NCC on CT 
and one case who was sero-positive but with no CT scan available were also considered as 
probable NCC, again with one major plus one minor and one epidemiologic criterion.  In 
summary, a total of twelve (4.8%) of 252 PWE in whom appropriate investigations were 
available were diagnosed with NCC: two with definitive NCC and ten with probable NCC 
(Table 77).  In the absence of a gold standard diagnosis, but taking CT evidence of NCC as a 
proxy , the PPV of the EITB anticysticercal antibody serology in this setting was 40.0%, the 




 Absolute criteria Major criteria Minor criteria 
Epidemiologic 
criteria 
n (%)  CT suggestive Sero-positive (seizures) (endemic region) 
Definitive 2 (16.7%) No Yes Yes Yes Yes 
Probable 4 (33.3%) No Yes No Yes Yes 
 2 (16.7%) No Yes N/A* Yes Yes 
 3 (25.0%) No No Yes Yes Yes 
 1 (8.3%) N/A* N/A* Yes Yes Yes 
Total 12 (100%) 0 8 6 12 12 
*N/A=investigation not available 
Table 77: Criteria used in the diagnosis of NCC in PWE from Hai 
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7.3.4 Neurocysticercosis: demographic and clinical characteristics 
Eleven (91.7%) of the twelve PWE with definitive or probable NCC had focal-onset 
seizures, with the seizure-type remaining undefined in one (8.3%).  No significant 
associations with any demographic or clinical variables were identified among cases with 
and without NCC (Table 78).  In 176 cases for whom both sets of investigations were 
available, two (33.3%) out of six with CT scans suggestive of NCC were sero-positive, 
compared to three (1.8%) of 170 in whom NCC was not seen on CT scanning (OR 27.8; 95% 
CI 3.6 to 215.3; Fisher’s Exact p=0.009).  With such small numbers involved further 
examination for confounding and interaction with covariates was unlikely to be 
meaningful and was therefore not performed. 
7.3.5 Risk factors for neurocysticercosis in Hai 
Results from the 2009 HDSS census indicated that 2,270 (5.2%) of 43,794 households kept 
pigs; twenty (8.4%) of 237 PWE for whom there were data and eleven (6.0%) of 182 
controls came from households that kept pigs (χ2(1)=0.862, p=0.353).  From interviews 
with cases and controls and visits to households that kept pigs, it became apparent that 
the predominant pig husbandry technique employed in Hai was that of ‘zero grazing’, 
whereby livestock are kept in pens within the homestead and fodder brought to them 
(Figure 31), with fodder for pigs consisting of a combination of household vegetable 
waste, night soil and chaff from the fields (this is an anecdotal finding gleaned during field 
work that we do not have formal data to support). 
Data on pork consumption were available from 161 (55.3%) of 291 cases and 178 (97.8%) 
of 182 controls, with seventy-eight (48.4%) cases and eighty-eight (49.4%) controls stating 
that they consumed pork at times (χ2(1)=0.033, p=0.855).  All cases and controls that were 
Muslim stated that they never ate pork. 
Regarding domestic sanitation, 123 (75.9%) of 162 cases and 128 (73.6%) of 174 controls 
used piped water as their main domestic water source.  The remainder took their water 
from wells or open sources such as rivers or springs (Table 79).  The majority of both cases 
and controls used pit latrines for domestic sewage: 153 (95.0%) of 161 cases and 166 
(93.3%) of 178 controls; a small minority had access to an indoor flushing toilet or had no 
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formal sewerage within their home (Figure 30, Table 80).  While there were no 
appreciable differences in domestic toilet facilities between cases and controls 
(χ2(2)=1.55, p=0.461), the greater numbers of cases using a well and controls using open 
water sources was significant (χ2(2)=8.74, p=0.013); the clinical significance of this 
statistical finding is not clear.  Possible risk factors for NCC were compared between cases 
and controls (Table 81), and between cases with and without NCC (Table 82); no 
significant associations were identified among any groups. 
 
 





Figure 31: Zero-grazing pig husbandry in Hai 




Characteristics NCC No NCC Total Statistics 
Age (years) n 12 240 252  
 Mean (SD) 34.4 (17.6) 34.5 (15.0) 34.5 (15.1)  
 Median (range) 30 (17 to 74) 30 (15 to 85) 30 (15 to 85) U=1374.5; p=0.790† 
Age at onset (years) n 12 236 248  
 Mean (SD) 24.4 (20.8) 16.9 (15.3) 17.3 (15.7)  
 Median (range) 15 (1 to 70) 12 (0 to 81) 13.0 (0 to 81) U=1093.0; p=0.182† 
Gender: Male n (%) 4 (33.3) 129 (53.8) 133 (52.8)  
 Female n (%) 8 (66.7) 111 (46.3) 119 (47.2) Χ2(1)=1.911; p=0.167 
Chagga tribe (vs. other group) n (%) 9 (75.0) 187 (80.6) 196 (80.3) n=244; p=0.708* 
Religion: Christian n (%) 8 (66.7) 192 (81.4) 200 (80.6)  
 Muslim n (%) 4 (33.3) 44 (18.6) 48 (19.4) p=0.255* 
Any education (vs. none) n (%) 11 (91.7) 184 (80.7) 195 (81.3)  
Completed 1o education (vs. none/incomp.) n (%) 7 (58.3) 116 (51.6) 123 (51.9) n=237; p=0.647* 
Focal-onset seizures (vs. generalised/undef.) n (%) 11 (91.7) 173 (72.1) 184 (73.0) n=252; p=0.190* 
Family history of epilepsy n (%) 3 (25%) 41 (17.1) 44 (17.5) n=252; p=0.445* 
Cognitive impairment n (%) 4 (33.3) 68 (28.3) 72 (28.6) n=252; p=0.746* 
Motor impairment n (%) 1 (8.3) 36 (15.0) 37 (14.7) n=252; p=1.000* 
* Fisher’s Exact Test †Mann-Whitney U Test 
Table 78: Characteristics of PWE with and without NCC 
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 Main domestic water source 
Piped water Well River/open source Total 
n (%) n (%) n (%) n (%) 
Case 123 (75.9%) 12 (7.4%) 27 (16.7%) 162 (100.0%) 
Control 128 (73.6%) 3 (1.7%) 43 (24.7%) 174 (100.0%) 
Total 251 (74.7%) 15 (4.5%) 70 (20.8%) 336 (100.0%) 
Table 79: Main domestic water source (cases and controls) 
 
 
 Domestic toilet arrangements 
Indoor flushing toilet Pit latrine No toilet Total 
n (%) n (%) n (%) n (%) 
Case 5 (3.1%) 153 (95.0%) 3 (1.9%) 161 (100.0%) 
Control 10 (5.6%) 166 (93.3%) 2 (1.1%) 178 (100.0%) 
Total 15 (4.4%) 319 (94.1%) 5 (1.5%) 339 (100.0%) 




Characteristics Case Control Total Statistics 
No. of household occupants n 162 180 342  
 Mean (SD) 5.0 (2.1) 5.6 (2.6) 5.3 (2.4)  
 Median (range) 5 (1 to 13) 5 (2 to 18) 5 (1 to 18) U=13172.5; p=0.119† 
Keeps pigs n (%) 4 (33.3) 129 (53.8) 133 (52.8) n=419; Χ2(1)=0.862, p=0.353  
Eats pork n (%) 78 (47.0) 88 (53.0) 166 (49.0) n=339; Χ2(1)=0.033, p=0.855 
No piped water n (%) 39 (24.1) 46 (26.4) 85 (25.3) n=336; Χ2(1)=0.248, p=0.619 
Pit latrine/no domestic toilet n (%) 11 (91.7) 184 (80.7) 195 (81.3) n=339; p=0.473* 
*Fisher’s Exact Test †Mann-Whitney U Test 




Characteristics NCC No NCC Total Statistics 
No. of household occupants n 162 180 159  
 Mean (SD) 5.3 (2.0) 5.0 (2.1) 5.0 (2.1)  
 Median (range) 5 (3 to 8) 5 (1 to 13) 5 (1 to 13) U=546.5; p=0.647† 
Keeps pigs n (%) 2 (20.0) 18 (8.8) 20 (9.3) n=215, p=0.235* 
Eats pork n (%) 2 (25.0) 75 (49.7) 77 (48.4) n=159; p=0.278* 
No piped water n (%) 0 (0.0) 39 (25.7) 39 (24.4) n=160; p=0.201* 
Pit latrine/ no domestic toilet n (%) 8 (100.0) 146 (96.7) 154 (96.9) n=159; p=1.000* 
*Fisher’s Exact Test †Mann-Whitney U 




NCC is recognised as a major cause of both acute seizures and of epilepsy in many LMICs, 
being demonstrated in up to 80% of PWE in endemic areas (Nash et al., 2004).  In SSA 
there have been few epidemiological studies of NCC in epilepsy, with a recent meta-
analysis identifying eleven studies from eight countries in which diagnostic criteria and 
control groups were described (Quet et al., 2010).  Furthermore, while serological testing 
provides indirect evidence, to date there have been few imaging studies describing the 
prevalence of NCC in PWE from SSA.  Two studies from South Africa presented CT findings 
without serology in clinic-based series (van As and Joubert, 1991, Cambell and Farrell, 
1987), and one more recent study used CT scanning in a random sample of PWE attending 
a clinic to validate serological findings (Foyaca-Sibat et al., 2009).  Outside of South Africa 
only two studies have presented both CT and serology findings: one, published in French, 
from Reunion Island (Mignard et al., 1986), and one from northern Tanzania (Blocher et 
al., 2011, Winkler et al., 2008a, Winkler et al., 2009b).  The work from Hai presented here 
therefore represents only the second study from mainland SSA outside of South Africa to 
present both neuro-imaging and serological data on NCC in PWE in this region.  
Furthermore, this is the only study we are aware of to have collected imaging and 
serological data in parallel from a community-based prevalent cohort. 
There is a low prevalence of NCC on neuro-imaging among PWE from the Hai district 
(4.0%), suggesting that this is a population with low-endemicity for T.solium infection.  
This contrasts with findings from elsewhere in northern Tanzania, where 17.9% of 212 
PWE were found to have lesions either definitive for, suggestive of or compatible with 
NCC on CT scanning (Winkler et al., 2009b).  In the same study 5.1% of 198 consecutive CT 
scans done for various clinical indications in people without epilepsy were also found to 
have evidence of NCC according to the same criteria. 
The low prevalence of NCC on neuro-imaging in PWE in Hai correlates with a low 
seroprevalence, with only 2.8% of PWE and 1.5% of all individuals who were tested being 
sero-positive for the presence of T.solium antibodies (p=0.036).  An odds ratio was not 
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calculated as none of our controls were seropositive.  This contrasts to other parts of SSA, 
where up to one third of all individuals may be seropositive for anti-cysticercal antibodies, 
rising to nearly 60% in PWE (Quet et al., 2010, Mafojane et al., 2003).  A clinic-based study 
from northern Tanzania found anti-cysticercal antibodies in 30% of twenty PWE who had 
NCC on and in none of twenty PWE without NCC on CT scanning; the overall sero-
prevalence in PWE in this study was 15%, and no antibodies were detected in sera from 
twenty healthy controls (Winkler et al., 2008a).  Commercially available ELISA and 
Western blot (WB) assays were used initially, but more recently the same samples were 
re-analysed as part of a larger study using both WB and EITB assays, with serology results 
being correlated with CT findings (Blocher et al., 2011).  The EITB performed with greater 
sensitivity, identifying 52.2% of twenty-three PWE with NCC on CT scan, although with an 
apparently lower specificity, giving a positive result in 8.7% of forty PWE with no CT 
evidence of NCC; no control samples were analysed in this larger study. 
Elsewhere in Africa higher rates of seropositivity in PWE and controls have been observed.  
Two studies from Burundi have examined anti-cysticercal antibody sero-positivity rates in 
PWE and controls.  In the first of these a community-based study examined 103 PWE and 
seventy-two household controls in three different administrative zones for the presence 
of cysticercal antigen and anti-cysticercal antibodies (Newell et al., 1997a).  Antibodies 
were detected by EITB in 11.7% of PWE overall and in 2.8% of controls, although the 
difference that was not statistically significant.  Between 10% and 40% of households in 
the study kept pigs, although no further statistical correlation is offered.  In another 
community-based study of epilepsy in a different province of Burundi, 58.7% of 303 PWE 
were had anti-cysticercal antibodies on ELISA, compared to 31.4% of controls (OR 3.6; 95% 
CI 2.5 to 4.9) (Prado-Jean et al., 2007).  Controls were recruited from among neighbours of 
PWE identified during the study.  Sero-epidemiological studies of human cysticercosis 
have also been performed in Cameroon (Zoli et al., 2003a, Nguekam et al., 2003), although 
only one of these specifically involved PWE (Zoli et al., 2003a).  In this study the overall 
ELISA antibody sero-prevalence in 504 PWE from three rural localities in West Cameroon 
was 44.6%, rising to 56.2% in cases of late-onset epilepsy (difference not statistically 
significant) (Zoli et al., 2003a).  In a hospital-based matched case-control study from 
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Madagascar 31.7% of 104 PWE had anticysticercal antibodies on EITB compared to 13.5% 
of 104 controls (OR 3.4; 95% CI 1.5 to 8.6) (Andriantsimahavandy et al., 1997). 
This picture of high seroprevalence rates is by no means uniform, however, with lower 
rates also having been previously observed in SSA.  A study from Togo, in a population 
where the prevalence of epilepsy was 16.7 per 1,000, used a combination of clinical 
findings, antibody ELISA, skull and soft tissue X-rays and biopsies of subcutaneous nodules 
to examine the link between cysticercosis and epilepsy (Dumas et al., 1989).  Cysticercosis 
was diagnosed in 2.7% of the total population, with 9.9% of eighty-one PWE being sero-
positive for anti-cysticercal antibodies compared to 6.8% of all 1,527 people who were 
tested; no statistical comparison between groups is offered.  The authors observed that 
81% of the study population ate pork, and that this was usually poorly prepared.  In a 
clinic-based series from two areas close to Nairobi in Kenya (rural and urban), anti-
cysticercal antibodies were detected in 5% of ninety-nine PWE and 2.4% of controls using 
an ELISA assay (Macharia et al., 2002). 
While these various findings suggest that cysticercosis is indeed important as a cause of 
epilepsy in parts of SSA, the picture is by no means uniform, and detailed assessments of 
the socio-economic and environmental circumstances in which different communities live 
will be necessary to inform any public health interventions designed to tackle this issue. 
We combined clinical, serological and imaging findings to arrive at a diagnosis of NCC in 
PWE from Hai, based on a set of diagnostic criteria that have been used in Africa and 
elsewhere in the developing world (Del Brutto et al., 2001).  All diagnoses of NCC 
depended on the a priori assumption that Hai was a region likely to be endemic for 
cysticercosis.  The prevalence of NCC on imaging was 4.0%, and based on these cases the 
EITB serology used in our study performed with a sensitivity of only 33.3%, which is 
considerably lower than that of 54.5% seen with ELISA antibody serology in an endemic 
area of South Africa, where the prevalence of NCC in PWE on CT imaging was 37% 
(Foyaca-Sibat et al., 2009).  In the only other study outside of South Africa to correlate 
imaging and serology to diagnose NCC in PWE, the sensitivity was very variable between 
two different assays: 52.2% for EITB compared with only 13.3% when a commercial 
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Western Blot was used (Blocher et al., 2011).  In this study the overall prevalence of NCC 
on CT in PWE, either ‘definite’, ‘suggestive’ or probable’, was 17.9%.  It may be that the 
lower sensitivity of serological testing seen in the Hai district is a reflection of a lower 
endemicity and prevalence of human cysticercosis in this population.  The use of different 
assays makes the comparison of different studies difficult, with sensitivities and 
specificities varying according to assay and epidemiological context (Dorny et al., 2003).  
For example, EITB has performed with sensitivity and specificity as high as 98% and 100% 
respectively in experimental conditions, compared to lower sensitivities of between 47% 
and 95% and specificities of between 67% and 100% for ELISAs (Tsang et al., 1989).  
Differences between different T.solium genotypes have also been observed (Ito et al., 
2003), and it has been suggested that these may influence both clinical presentation and 
serological diagnostic accuracy (Quet et al., 2010, Winkler et al., 2009a).  While it is 
difficult to draw any firm conclusions from the limited findings from Hai, it would seem 
that serological screening is unlikely to be either clinically useful or cost-effective in an 
area of low-endemicity for T.solium.  It should also be borne in mind that the mainstay of 
treatment for NCC is the control of seizures with AEDs; only when viable cysticerci are 
visualised on CT or MRI should anti-helminthic drugs be given, in combination with 
steroids to reduce peri-lesional inflammation may confer an improved prognosis (Singh 
and Prabhakar, 2008, Garcia et al., 2004, Abba et al., 2010).  No such lesions were 
indentified in the Hai study. 
The authors of the studies discussed above generally comment that their findings should 
be seen in the context of exposure to observed risk factors for cysticercosis, such as pig-
rearing, pork consumption, poor sanitation, and of the high prevalence of porcine 
cysticercosis (up to 50%) that is known to exist in much of SSA, including Tanzania (Phiri et 
al., 2003, Mafojane et al., 2003, Zoli et al., 2003b).  While at least some of the potential 
risk factors for cysticercosis would appear to be present in the Hai district, the reasons for 
the apparently low prevalence of NCC compared to elsewhere in Tanzania warrant further 
investigation.  Possible factors may be the use of zero-grazing animal husbandry 
techniques, the quality of meat inspection and food preparation locally, or the source of 
pork that is consumed within the district.  Investigation of these factors is beyond the 
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scope of this study, although may yield insights important to public health if pursued.  
With regards to sanitation it has previously been observed that high mortality rates in 
children under five years in Hai are associated with diarrhoeal disease, unsafe drinking 
water and poor sanitation (Kissima, 1995).  More recently, a contemporaneous cross-
sectional study used microscopy to assess the prevalence of enteric pathogens in stool 
samples from Hai residents (Mziray, 2009).  Cysts and parasites were seen in 45.3% of 
samples taken from 775 individuals in twenty-nine different villages.  The most commonly 
identified organisms were entamoeba species, seen in 35% of samples overall and in 
nearly 50% of samples in the thirty-one to forty years age-group, while the prevalence of 
eggs from taenia species was very low (0.5%).  Unfortunately it was not possible to 
correlate the findings of this study with the epilepsy study more closely. 
There are some important limitations in our study.  While socio-demographic data were 
collected from controls in the field during recruitment under supervision from the 
research doctor, these data were collected from cases independently by field workers 
during the follow-up phase of the study when patients were attending KCMC for 
investigations; non-attendance and other operational difficulties meant that these data 
were missing from nearly half of cases overall (44.3%), reducing the validity of this aspect 
of comparison with controls.  It is also difficult to comment on what biases may have been 
introduced by this loss of data.  Furthermore, there is no control series of CT scans.  For 
ethical reasons controls could not be exposed to CT radiation without a clear clinical 
indication, and for technical and administrative reasons it proved unfeasible to access a 
series of consecutive CT images at KCMC from patients attending from the Hai district that 
might have served as a proxy control series.  Finally, the prevalence study in Hai only 
identified cases with generalised convulsive epilepsy, whether focal or generalised in 
onset, and more subtle focal-onset seizures without secondary generalisation which were 




7.5 Summary and conclusions 
Cysticercosis and NCC appear to be present in Hai but with a low endemicity.  In this 
epidemiological context, while the utility of serological testing with antibody EITB for 
cysticercosis is not proven, the presence of NCC as an aetiology of epilepsy needs to be 
considered, especially in the assessment and management of any individual presenting 
with late-onset epilepsy or incident seizures.  The conditions for the ongoing transmission 
of human and porcine cysticercosis appear to be present in the district, although few 
households keep pigs, and pigs are generally not free-ranging.  Although these aspects 
have not been formally studied here, a clearer understanding of the social and 
environmental factors that distinguish Hai from other areas of Tanzania and SSA where 
NCC is more endemic may help to inform public health initiatives designed to reduce the 
burden of acquired epilepsy. 
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Chapter 8.  Management of epilepsy in Hai 
Abstract 
Background 
The ETG is high in countries in SSA, including Tanzania, often being close to 100%.  Few 
published studies from SSA have examined patient- and healthcare-related factors 
associated with lack of treatment or default from follow-up. 
Methods 
We collected self-reported data on access to treatment for epilepsy from 291 PWE 
identified during a community-based study in a rural district of northern Tanzania.  
Multivariable logistic regression analyses were used to identify significant associations 
with accessing treatment and remaining under follow-up. 
Results 
The majority (89.0%) of cases had previously presented to medical services.  Cases more 
likely to have presented were those who had completed primary education (OR 2.55; 95% 
CI 1.09 to 5.98) and those who experienced a prodromal aura with their seizures (OR 2.83; 
95% CI 1.12 to 7.12).  Cases less likely to have presented were those who drank alcohol 
(OR 0.32; 95% CI 0.13 to 0.80) and those who had attended a traditional healer (OR 0.36; 
95% CI 0.16 to 0.85).  59.8% of cases overall were under follow-up at the time of the 
study.  Predictors of remaining under follow-up were having any education (vs. none) (OR 
2.46; 95% CI 1.20 to 5.05) and having previously received a diagnosis of epilepsy (OR 3.09; 
95% CI 1.56 to 6.15).  The ETG based on AED usage was 68.6% (95% CI 63.6 to 73.7). 
Conclusions 
The ETG among adult PWE in the HDSS is in line with recent estimates from elsewhere 
SSA.  The protective effects of education and of receiving a formal diagnosis suggest that 
interventions focusing on these factors may serve to increase levels of sustained access to 




An estimated 68.8 million people worldwide have been affected by epilepsy during their 
lifetimes, with up to sixty-two million (90.1%) of these living LMICs (Ngugi et al., 2010).  
Although the prevalence of epilepsy in these countries is generally thought to be higher 
than in HICs, the majority of PWE in LMICs may not receive appropriate treatment for 
their condition, leading to the concept of the epilepsy treatment gap (ETG), defined as the 
proportion of PWE with active epilepsy and requiring treatment who are not receiving it 
(Meinardi et al., 2001, Scott et al., 2001).  The concept of the ETG can be applied not just 
to drug treatment, but also to areas of healthcare on which treatment may be contingent, 
including failure to diagnose all patients presenting with a given illness (diagnostic gap), or 
failure to provide the investigations required to diagnose or manage an illness 
(investigations gap) (Kale, 2002). 
The ETG may be measured indirectly, extrapolating from data on prevalence and on total 
AED acquisition and use at national or population level (Shorvon and Farmer, 1988), or 
directly during the course of a prevalence study when the number of detected cases who 
are not receiving treatment can be ascertained (Kale, 2002).  The latter of these 
approaches has been the most frequently employed in studies from LMICs, and has the 
added advantage that it may also identify the number of PWE who may have been advised 
on treatment but who either did not take it or discontinued, thus yielding information on 
the contribution of non-adherence to the ETG.  This may be important as it is thought that 
in LMICs a large proportion of patients who are diagnosed with epilepsy discontinue 
treatment soon after initiation, and the term ‘secondary treatment gap’ has been coined 
to describe this phenomenon (Das et al., 2007).  Although the indirect method is crude 
and relies on data that may not be readily available or robust in many LMICs, it has the 
advantages of being convenient, of having the potential for validation against direct 
estimates, and may also be repeated regularly to monitor any reductions in the ETG in 
response to interventions (Kale, 2002).  The direct method is not without its difficulties, 
however, not least of which is the cost associated with conducting community-based 
studies.  Most studies of ETG that employ the direct method also rely on self-reported use 
of AEDs, which may not be reliable: for example, a study in rural Kenya that analysed 
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blood samples for the presence of AEDs reported a sensitivity of 58% and specificity of 
87% for self-reported AED use (Edwards et al., 2008).  
Studies estimating the ETG in LMICs have consistently identified very high rates, with 
anecdotal and descriptive estimates reporting gaps in excess of 80% in many countries 
(Diop et al., 2003), and recent reviews using systematic or meta-analytic approaches have 
reported rates from 56% to over 75% in most LMICs, albeit with wide confidence intervals 
and considerable heterogeneity between studies (Mbuba et al., 2008, Meyer et al., 2010).  
A review of data on treatment from thirteen epidemiological studies of epilepsy 
conducted in Africa using a standardised questionnaire summarised findings from 2,269 
PWE, with the overall ETG from seven community-based studies being 55.7% (95% CI 52.7 
to 58.7) (Quet et al., 2011).  The most frequently cited reasons for lack or irregularity of 
treatment were unavailability of drugs (41.3%) and cost (27.2%).  A multivariable logistic 
regression analysis also identified a number factors associated specifically with non-
utilisation of phenobarbital: younger age, presence of focal-onset seizures with secondary 
generalisation, a generally good state of health, age at onset of epilepsy greater than six 
years, having no family history of epilepsy, and also not having accessed traditional 
treatment. 
Why does the ETG exist to the magnitude that it does?  Despite estimates of the ETG 
being consistently high, there remains a paucity of data examining the causes of or 
potential solutions to the gap.  A recent systematic review of the magnitude and causes of 
the ETG included studies that met the inclusion criteria of either using direct methods to 
estimate the gap, presenting observational or qualitative data to identify potential causes, 
or describing interventions designed to address attributed causes of the ETG (Mbuba et 
al., 2008).  Only eight studies were identified which presented data on possible cause, of 
which three were from countries in SSA (Preux et al., 2000, El Sharkawy et al., 2006, 
Elechi, 1991).  The most frequently identified contributor to the ETG was the cost 
associated with seeking epilepsy care, with a lack of medically skilled personnel also 
correlating to a higher median ETG.  Patient-centred factors included non-adherence 
(Elechi, 1991), and social and cultural beliefs that lead PWE to seek traditional rather than 
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modern biomedical treatments (Preux et al., 2000, El Sharkawy et al., 2006).  This 
phenomenon is well-described in observational studies from SSA in general, including 
from Tanzania, and is often associated with considerable costs being incurred to the 
patient (Birbeck et al., 2007, Winkler et al., 2010b, Shorvon and Farmer, 1988). 
The diagnosis of epilepsy is fundamentally a clinical judgement; the accuracy of diagnosis 
therefore depends on the skill and experience of the physician or other healthcare worker 
and the quality and reliability of the information provided by the witness.  LMICs have an 
average of one neurologist for every three to five million people, with many countries in 
Africa having no neurologists at all (WHO, 2005).  To put this in context, people with 
epilepsy have potential access to specialist care in 56% of LMICs compared with 89% of 
HICs (Dua et al., 2006).  Furthermore, two thirds or more of people in LMICs live in rural 
areas while nearly all the neurologists working in these countries are to be found in urban 
centres, meaning that most PWE in LMICs rely exclusively on primary care services for 
diagnosis and treatment (Radhakrishnan, 2009). 
In addition to the difficulties associated with accessing effective treatment, epilepsy in SSA 
is also associated with psychosocial problems, reduced life-expectancy and social isolation 
(Matuja, 1990, Jilek-Aall and Rwiza, 1992, Mushi et al., 2010).  All of these factors may be 
exacerbated by having uncontrolled seizures, making the condition both more dangerous 
and more visible.  In 2005 the WHO in conjunction with the ILAE published the Atlas of 
Epilepsy Care, which describes the medical, sociological, psychological and financial 
consequences of living with epilepsy, highlighting the importance of delivering epilepsy 
treatment not just to gaining control of seizures, but also to reducing the burden of 
morbidity and other harms experienced by PWE across these dimensions (WHO, 2005).  In 
the face of these complex issues, resource-poor countries share a number of traits that 
compound the difficulties associated with addressing these challenges as well as dictating 
the types of interventions that are appropriate or feasible, with treatment programmes 




While epilepsy in LMICs may potentially be prevented through public health strategies 
that tackle identified risk factors such as head injury, CNS infection, febrile seizures and 
obstetric complications, the primary focus of care for PWE is the control and prevention of 
further seizures (Kwan and Brodie, 2002).  Given access to appropriate and consistent 
drug therapy, the prognosis of epilepsy can be favourable, with seizure-freedom being 
achievable in up to 75% of PWE within five years of diagnosis (Feksi et al., 1991, Kale, 
1997).  It is also important to note that these outcomes are achievable in LMICs as well as 
HICs (Shorvon and Farmer, 1988, Coleman et al., 2002), and first-line AEDs including 
phenobarbital (PB), phenytoin (PHT) and, to a lesser extent, carbamazepine (CBZ) are 
affordable and widely available, appearing on between 86% and 95% of national essential 
drugs lists (WHO, 2005, Mbuba and Newton, 2009). 
The older AEDs, particularly PB, are both affordable and effective, costing as little as five 
USD a year for an adult in 2005 (Chisholm, 2005).  Supply and quality vary, however, and 
in the case of PB the former of these issues may have been exacerbated by the drug being 
classified as a controlled drug in some countries (Meyer et al., 2010).  Despite these 
issues, its low cost and widespread availability mean that PB continues to be commonly 
prescribed in LMICs, while in most HICs it has largely fallen out of use (Kale and Perucca, 
2004).  Reasons for this, despite its efficacy and broad spectrum of anti-convulsant activity 
against both focal and generalised tonic-clonic seizures, may relate to documented 
disadvantages including hepatic enzyme induction and adverse cognitive and behavioural 
effects, particularly in children (Kwan and Brodie, 2004).  Although most of the evidence-
base supporting the use of PB comes from observational studies rather than controlled 
trials, meta-analysis data from four randomised controlled trials comparing PB and PHT, 
and four trials comparing PB and CBZ are available (Taylor et al., 2001, Tudur Smith et al., 
2003).  From these studies it is known that while PB is associated with higher 
discontinuation rates than both PHT and CBZ, efficacy, in terms of time to twelve-month 
remission and time to first seizure, is similar when comparing PB with either PHT or CBZ.  
The only trial data on the efficacy of AEDs in SSA come from a large open-label study 
conducted in Kenya in which 302 untreated children and adults with epilepsy were 
randomised to receive either PB or CBZ for twelve months (Feksi et al., 1991).  No 
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differences between treatment groups were identified in the proportions of patients 
remaining seizure-free at six and twelve months, and although the absolute number of 
patients experiencing side-effects was greater in the PB group, there were no statistically 
significant differences between treatment groups with regards to this outcome.  
Observational studies on the use of PB in clinical rather than trial settings are also 
available, from Mali, Nigeria and Tanzania.  In Mali, in a community-based study 
conducted in a poor and remote rural area, PB was given to ninety-six adults and children 
with a mix of partial and generalised seizures who were then followed-up for an average 
of twelve months (Nimaga et al., 2002).  High levels of drug adherence and seizure-control 
were observed, with only 3% of patients reporting adverse effects after one year of 
treatment and with none of these being severe enough to discontinue treatment.  In a 
clinic-based study from Nigeria complete seizure control was reported in 50.6% of 344 
children with epilepsy who were treated with PB (Sykes, 2002).  Only two patients 
discontinued treatment due to side-effects, although nearly one third of patients (27%) 
were lost to follow-up.  Finally, a retrospective study conducted in rural Tanzania reported 
that 52.4% of 164 PWE who were started on AED therapy (158 of them on PB) between 
1959 and 1963 achieved seizure control while maintained on treatment (Jilek-Aall and 
Rwiza, 1992).  Patients were treated for up to ten years until 1971, when the AED supply 
ended.  From these few studies, it would seem that PB appears to be efficacious and well-
tolerated as a treatment for epilepsy in SSA populations.  It is important to note, however, 
that these data are not strictly comparable in terms of follow-up duration or approaches 
to data collection for adverse events, and the low rates of treatment withdrawal may be a 
reflection of the lack of treatment options rather than tolerability (Kwan and Brodie, 
2004); in resource-poor settings the treatment options for PWE generally lie between 
using the cheapest treatment available or receiving no treatment at all.  Given this stark 
choice it is generally accepted that PB should be used, particularly in adults; a position 
that is endorsed by the ILAE and encompassed within their demonstration projects (Kale 
and Perucca, 2004, De Boer, 2002). 
Comprehensive interventions at national levels to improve drug supply and increase 
human and material resources to reduce the ETG would incur significant costs, and 
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economic assessments of the burden of epilepsy are therefore important.  Such 
assessments have been conducted in the UK, the USA, and in India (Begley et al., 2000, 
Cockerell et al., 1994, Thomas et al., 2001), although to the best of our knowledge have 
yet to be conducted in SSA.  Where assessments have been performed, the economic 
implications of epilepsy in terms of health service needs, increased morbidity and 
mortality, and reduced economic productivity have all been demonstrated.  In 2005, in a 
bid to redress the relative paucity of cost-effectiveness data on epilepsy treatments in 
LMICs, the WHO estimated the cost-effectiveness of four first-line AEDs (PB, PHT, CBZ and 
SV) specifically in terms of their potential impact at a primary care level in resource-poor 
regions of the world (Chisholm, 2005).  An economic model was applied to nine WHO 
developing sub-regions including two African regions encompassing Nigeria, Senegal, 
Botswana and Kenya.  Efficacy of treatment was gauged in terms of reduction in disability, 
with adjustments for coverage, response and adherence, and treatment costs and cost-
effectiveness ratios were measured in international dollars.  Only primary or idiopathic 
were considered for the analysis.  The authors concluded that by extending AED treatment 
coverage to 50% of all cases, up to 40% of the current burden of DALYs could be averted, 
and that this could be achieved at an annual cost per capita of between 0.20 to 1.33 
international dollars, which falls below the average income per capita for these regions.  
The countries that stood to gain the most were Kenya and Botswana, with 646 DALYs 
averted per one million people; the cost per DALY specifically associated with PB in these 
countries was 844 international dollars.  These two countries were considered together on 
the basis of having high mortality rates among children and adults compared to other 
countries in the analysis. 
To summarise, while the prognosis for seizure-freedom given access to regular and 
adequate AED therapy is good, the majority of PWE in LMICs do not receive treatment.  
The reasons for this are largely but not solely associated with cost, both to the patient and 
to the health system providing treatment.  Older and more affordable AEDs, in particular 
PB, are widely available and efficacious, and economic modelling suggests that increasing 
the availability of PB in LMICs would be a cost-effective means of achieving a considerable 
reduction in the morbidity and disability associated with epilepsy. 
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Having established a prevalent cohort of PWE in the HDSS population we sought to 
quantify the levels of access to treatment for epilepsy in this community and to identify 






8.2.1 Procedures and variables 
All 291 cases identified during the prevalence survey were asked about current or 
previous access to medical care, including any drug treatment for epilepsy.  For any cases 
using AEDs we sought to ascertain the identity, dose and pattern of use of the drug(s), and 
any side-effects experienced.  We also asked about source and cost of treatment and in all 
cases who had been in contact with medical services because of their seizures we asked 
about any diagnoses for the problem that had been given previously.  In addition to asking 
about biomedical treatments we also asked about any use of traditional healers or 
traditional medications, and about the costs of these. 
8.2.2 Statistical analyses 
Continuous variables with non-normal distributions were compared non-parametrically 
using the Mann-Whitney U test; distributions of categorical variables were examined using 
the Chi-square test.  The ETG was estimated as a percentage based on self-reported AED 
use and where the choice of drug, dosage and adherence were considered to be adequate 
and appropriate.  The 95% confidence interval for the ETG was calculated based on a 
Poisson assumption. 
To further explore the data, uni-variable analyses of two binary outcomes were 
performed: PWE who had previously presented to medical services were compared to 
those who had never presented; for PWE who had previously presented to services, those 
remaining under follow-up were compared with those who had defaulted from follow-up.  
To examine for the joint effects of multiple predictors, logistic regression models were 
constructed using a backwards stepwise elimination strategy based on the likelihood ratio 
test (LRT); predictor variables with a p-value of 0.1 or greater were excluded at each step.  
The goodness of fit to the data of final models was assessed using the Hosmer and 
Lemeshow statistic, with values closer to unity indicating a better fit (Field, 2009a).  A p-





8.3.1 Access to medical care 
A total of 253 (86.9%) of 291 cases with active epilepsy had previously sought medical 
attention for their seizures, with 174 (68.8%) of these remaining under follow-up at the 
time of initial assessment by the epilepsy study (59.8% of all cases; Table 83).  While there 
was no difference between the sexes in the proportion of individuals seeking medical help 
at any point (χ2(1)=0.926; p=0.336), of those who had previously sought help females were 
more likely than males to remain under follow-up at the time of the study (χ2(1)=5.381; 
p=0.02).  Thirty-eight (13.1%) of 291 cases denied ever having sought help for their 
seizures, or ever having been on any form of AED treatment. 
The distributions of age at onset of epilepsy and age on prevalence date within these 
treatment groups are summarised in Table 85 and Table 86.  Data on the age of onset of 
epilepsy were missing in seven (2.4%) of 291 cases overall; five of these had previously 
sought medical help, of whom four remained under follow-up.  There was no significant 
difference between cases who had previously presented and those who had not in age on 
the prevalence date (Mann-Whitney U 4424.5, z = -0.791; p=0.43), or in age at first onset 
of seizures (Mann-Whitney U 3635.0, z = -1.801; p=0.072).  Similarly, among cases who 
had previously presented to medical services there was no significant difference between 
those remaining under follow-up and those no longer under follow-up in terms of age on 
the prevalence date (Mann-Whitney U 6541.0, z = -0.616; p = 0.538), or age at first onset 
of seizures (Mann-Whitney U 5620.5, z = -1.844; p = 0.065). 
Data were available on the interval between onset of seizures and presentation to medical 
services in 225 (88.9%) of 253 cases.  Ninety-six (42.7%) of these had presented within a 
year of seizure onset (forty-four females, fifty-two males), with a further twenty (8.9%) 
presenting between one and two years of seizure onset (eleven females, nine males).  For 
the 109 (48.4%) of 225 cases that presented more than two years after the onset of 
seizures, the mean and median times from onset of seizures to presentation to medical 
services were 9.83 and 7.0 years respectively (Table 84, Figure 32).  There was no 
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significant difference in time to presentation between males and females presenting at 
more than two years after seizure onset (Mann-Whitney U=1418.5, z=-0.369; p=0.712). 
Of the 253 cases that had previously sought medical attention (121 female, 132 male), 156 
(61.9%) had presented to a government health facility at district level, 108 (42.9%) had 
presented to a government hospital (either Mawenzi hospital in Moshi, Kibong’oto 
National Hospital in the neighbouring Siha district, or Muhimbili National Hospital in Dar 
es Salaam), and seventy-nine (31.4%) had presented to one of the large mission hospitals 
in the area, usually KCMC in Moshi, or Machame Hospital within the Hai district (Table 87).  
One hundred and seven (42.3%) of 253 cases reported seeking help from at least two 
different sources when initially presenting for advice and treatment (Figure 33). 
Of the 174 cases remaining under follow-up at the time of the study, 113 (64.9%) were 
receiving help from one of the government facilities within the district (Table 88).  The 
plurality of treatment seeking when first presenting was not replicated in cases who 
remained under follow-up, with 162 (93.1%) of 174 cases stating that they consistently 
attended one service in particular for treatment.  Of the remainder, eleven (6.3%) said 
that they regularly attended two different services for treatment, and one (0.6%) regularly 
attended three different services (Figure 33). 
8.3.2 Diagnosis 
Data on previous diagnosis were available for 250 (99.2%) of 252 cases who had 
previously sought medical help for their seizures, including 172 (198.9%) of the 174 who 
remained under follow-up (Table 89).  Of all cases seeking medical help for their seizures, 
eighty-five (34.0%) 250 said that they had been told they had epilepsy.  The proportion of 
cases which remained under follow-up who clearly recalled having been given a diagnosis 
was 40.1%, compared to 20.5% of those who were not under any kind of follow-up by the 




 Female (n=136) Male (n=155) Total (n=291) 
n (%) n (%) n (%) 
Medical help sought previously 121 89.0% 132 85.2% 253 86.9% 
Under follow-up at time of study 91 66.9% 83 53.5% 174 59.8% 
Table 83: Presentation and follow-up for epilepsy 
 
 
 Time to presentation (years) 
 n (%) Median Min Max IQR 
Female 51 (46.8) 7.00 2 49 10 
Male 58 (53.2) 7.50 2 36 10 
Combined 109 (100.0) 7.00 2 49 11 




 Age on prevalence date (years) 
 n Median  Min Max IQR 
Medical help sought previously 253 30 15 81 22 
No medical help sought 38 34 15 85 23 
Total 291 30 15 85 21 
Under follow-up 174 29 15 81 22 
Not under follow-up 79 33 15 71 56 
Total 253 30 15 81 22 
Table 85: Age distributions of treatment groups 
 
 
 Age of onset of epilepsy (years) 
 n Median  Min Max IQR 
Medical help sought previously 248 12 0 70 18 
No medical help sought 36 16 0 81 24 
Total 284 13 0 81 20 
Under follow-up 171 11 0 70 15 
Not under follow-up 77 16 0 63 25 
Total 248 12 0 70 18 





Figure 32: Time to presentation at 2+ years from seizure onset 
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 Female (n=120) Male (n=132) Total (n=252) 
n (%) n (%) n (%) 
Govt. district health facility 82 (68.3%) 74 (56.1%) 156 (61.9%) 
Govt. hospital 56 (46.7%) 52 (39.4%) 108 (42.9%) 
Mission hospital 37 (30.8%) 42 (31.8%) 79 (31.4%) 
Private pharmacy 12 (10.0%) 13 (9.8%) 25 (9.9%) 
Family/friends/other 7 (5.8%) 7 (5.3%) 14 (5.6%) 
N.B. percentage columns total more than 100.0% as categories not exclusive 
 
Table 87: Site(s) of initial presentation 
 
Source of follow-up 
Female (n=91) Male (n=83) Total (n=174) 
n (%) n (%) n (%) 
Govt. district health facility 65 (71.4%) 48 (57.8%) 113 (64.9%) 
Govt. hospital 13 (14.3%) 15 (18.1%) 28 (16.1%) 
Mission hospital 13 (14.3%) 14 (16.9%) 27 (15.5%) 
Private pharmacy 5 (5.5%) 8 (9.6%) 13 (7.5%) 
Family/friends/other 2 (2.2%) 3 (3.6%) 5 (2.9%) 
N.B. percentage columns total more than 100.0% as categories not exclusive 
 




Figure 33: Number of services attended 
264 
 
 Under follow-up 
Total (n=250) Yes (n=172) No (n=78) 
n (%) n (%) n (%) 
None given 62 (36.0%) 41 (52.6%) 103 (41.2%) 
Kifafa/epilepsy 69 (40.1%) 16 (20.5%) 85 (34.0%) 
Other 23 (13.4%) 16 (20.5%) 39 (15.6%) 
Degedege/febrile seizures 9 (5.2%) 3 (3.8%) 12 (4.8%) 
Unable to recall/unsure 9 (5.2%) 2 (2.6%) 11 (4.4%) 
Total 172 (100.0%) 78 (100.0%) 250 (100.0%) 




8.3.3 Drug treatment for epilepsy in Hai 
All but one of the 174 cases who remained under follow-up at the time of the study stated 
that they were regularly taking AED treatment (59.5% of all cases).  Of these, 147 (85.0%) 
were using one AED, and twenty-six (15.0%) were regularly using two AEDs in 
combination.  One case (female, aged thirty years) was maintained on oral haloperidol 
and diazepam along with AED treatment for a diagnosis of epilepsy with psychosis. 
The most commonly prescribed AEDs were PB and PHT.  Phenobarbitone was prescribed 
for 112 (76.2%) of 147 cases on mono-therapy and twenty-three (88.5%) of twenty-six 
cases on dual therapy (78.0% of treated cases overall); PHT was prescribed for seven 
(4.8%) of 147 cases on mono-therapy and twenty-one (80.8%) of twenty-six cases on dual 
therapy (16.2% of cases overall).  Other AEDs encountered were CBZ and SV.  
Carbamazepine was used in sixteen (10.9%) cases of mono-therapy and in six (23.1%) 
cases of dual therapy (12.7% of cases overall).  Sodium valproate was used along with CBZ 
in two (7.7%) cases of dual therapy (1.2% of cases overall).  The patterns of mono- and 
dual therapy with AEDs are illustrated in Figure 35 and Figure 36.  In twelve cases that 
were using mono-therapy the AED being used could not be clearly identified (Figure 34).  
One case (male, aged fifty years) had been given a diagnosis of epilepsy with psychosis.  
He remained under treatment at district level, but an AED regime of PB and PHT, with 
previously good seizure control, had been discontinued in favour of a monthly depot 
injection with flupenthixol; at the time of initial assessment by the study he was suffering 




Figure 34: Difficulties in identifying AEDs and doses in the HDSS. 
Clockwise from top left: mislabelled AEDs in government dispensary; improvised container containing unmarked tablets; 




Figure 35: Prescribing pattern in AED mono-therapy 
 
 
Figure 36: Prescribing pattern in AED dual therapy 
n=147 
(85.0% of all cases 
on AED treatment) 
n=26 
(15.0% of all cases 
on AED treatment) 
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8.3.4 Compliance, adequacy and affordability of AEDs in Hai 
Data on self-reported compliance were available in 168 (97.1%) of 173 cases using 
AED therapy at the time of initial assessment (Table 90).  One hundred and twenty-
two of these (72.6%) reported good compliance, saying that they took their 
medication either daily or only occasionally forgot.  A further forty-six (27.4%) cases 
were either irregular in their use of AEDs or reported significant problems in 
obtaining a regular supply of drugs.  Four cases reported using AEDs reactively, taking 
them only after a seizure had occurred. 
Data on the affordability of AEDs were available for 147 (85.0%) of the 173 cases on 
treatment (Table 91).  Fifty-one of these (34.7%) stated that their AEDs were 
provided free by the health facility they were attending, while twenty-six (17.7%) 
stated that they struggled to afford their drugs on a regular basis.  The remainder 
(47.6%) stated that their drugs were affordable to them. 
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 Female (n=89) Male (n=79) Total (n=168) 
n (%) n (%) n (%) 
Daily/occasionally forgets 63 (70.8%) 59 (74.7%) 122 (72.6%) 
Irregular/not compliant 26 (29.2%) 20 (25.3%) 46 (27.4%) 
Total 89 (100.0%) 79 (100.0%) 168 (100.0%) 
Table 90: AED compliance (self-reported) 
 
 
 Female (n=74) Male (n=73) Total (n=147) 
n (%) n (%) n (%) 
Provided free 30 (40.5%) 21 (28.8%) 51 (34.7%) 
Able to afford 31 (41.9%) 39 (53.4%) 70 (47.6%) 
Unable to afford regularly 13 (17.6%) 13 (17.8%) 26 (17.7%) 
Total 74 (100.0%) 73 (100.0%) 147 (100.0%) 




 Female (n=91) Male (n=82) Total (n=173) 
n (% ) n (%) n (%) 
Yes 52 (57.1%) 47 (57.3%) 99 (57.2%) 
No 21 (23.1%) 20 (24.4%) 41 (23.7%) 
Unknown 18 (19.8%) 15 (18.3%) 33 (19.1%) 
Total 91 (100.0%) 82 (100.0%) 173 (100.0%) 
Table 92: Adequacy of AED doses in all cases on treatment 
 
 
 Female (n=63) Male (n=59) Total (n=122) 
n (%) n (%) n (%) 
Yes 39 (61.9%) 38 (64.4%) 77 (63.1%) 
No 16 (25.4%) 14 (23.7%) 30 (24.6%) 
Unknown 8 (12.7%) 7 (11.9%) 15 (12.3%) 
Total 63 (100.0%) 59 (100.0%) 122 (100.0%) 
Table 93: Adequacy of AED doses in cases reporting regular compliance 
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8.3.5 Adverse effects of AEDs 
Data on side-effects from AED treatment were available in 159 (91.9%) of 173 treated 
cases, with 134 (84.3%) of these reporting no adverse effects.  In the twenty-five 
individuals that did report side effects, the most commonly reported problem was 
tiredness, identified by seventeen cases: thirteen who were using PB mono-therapy, 
three using PB and PHT, and one using an unidentified drug.  Other adverse effects 
reported included five cases who complained of dizziness (four on PB mono-therapy, 
one on an unidentified drug), headache (two cases, both using PB), rash (one case 
using CBZ and SV), memory problems (one case using PB), and unspecified 
behavioural disturbance (one case using PB). 
8.3.6 Seizure frequency in treated and untreated cases 
The majority of cases had little or no seizure control, with only twenty-one (12.1%) of 
173 cases taking AEDs reporting to be seizure-free on their treatment (7.2% of all 
cases).  The proportional frequencies of seizures in the 173 cases using AEDS are 
summarized in Table 94, and the cumulative percentage of seizure frequency in all 
cases with uncontrolled seizures is illustrated in Figure 37.
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 Female (n=91) Male (n=82) Total (n=173) 
n (%) n (%) n (%) 
Daily - several/day 0 (0.0%) 1 (1.2%) 1 (0.6%) 
Seizure(s) most days 1 (1.1%) 3 (3.7%) 4 (2.3%) 
Weekly - several/week 11 (12.1%) 5 (6.1%) 16 (9.2%) 
Seizure(s) most weeks 14 (15.4%) 11 (13.4%) 25 (14.5%) 
Seizure(s) most months 24 (26.4%) 30 (36.6%) 54 (31.2%) 
≥1 in past year 28 (30.8%) 20 (24.4%) 48 (27.7%) 
≥1 in past 5 years 5 (5.5%) 0 (0.0%) 5 (2.9%) 
Seizure-free 8 (8.8%) 12 (14.6%) 20 (11.6%) 
Total 91 (100.0%) 82 (100.0%) 173 (100.0%) 








8.3.7 Previous treatment 
Of the seventy-nine individuals who had previously sought help but who were not 
receiving any treatment at the time of assessment, sixty-four (82.1%) reported having 
previously received treatment of some description, although the majority of these (thirty-
eight cases; 59.4%) were unable to recall the identity or nature of drugs with which they 
had previously been treated.  Thirteen cases (20.3%) had previously received PB, one case 
(1.6%) had received PHT, another case had received CBZ, and four cases (6.3%) had 
previously been treated with a combination of PB and PHT.  Seven cases (10.9%) described 
prior treatment with anti-malarial or antipyretic drugs when presenting with convulsive 
episodes. 
Data on the reason for discontinuation of previous treatment were available for fifty-four 
(84.4%) of the sixty-four previously treated cases: twelve (22.2%) said they had been given 
an acute prescription only, with no advice that treatment should be continued in the long-
term; eleven (20.4%) did not pursue further treatment after a lack of initial efficacy; four 
(7.4%) reported that they had stopped taking treatment when seizures initially went into 
remission but had not recommenced treatment when seizures had subsequently relapsed; 
seven (13.0%) said they stopped due to initial side-effects; seven (13.0%) were unable to 
afford continued treatment; two (9.3%) said that further treatment had not been readily 
available.  The remaining eleven (20.4%) cases described a range of reasons for stopping 
treatment that related to various social circumstances, often relating to the death of a 
relative or other benefactor that had been supplying treatment.  Instances of local 
healthcare workers who had been supplying treatment leaving their posts and treatment 




8.3.8 Epilepsy treatment gap 
At the time of initial assessment 122 (41.9%) of 291 cases reported using AEDs with good 
compliance, although thirty (24.6%) of these were identified as using sub-therapeutic 
doses of AEDs.  We therefore identified ninety-two (31.4%) out of 291 cases that could be 
considered as being adequately and appropriately treated with AEDs at the time of the 
study.  Based on these data, a conservative estimate of the ETG in the adult HDSS 
population based on self-reported AED use is therefore 68.6% (95% CI 63.0 to 73.7).  Given 
that 92.8% of all cases were suffering from active seizures (including 87.9% of cases using 
AEDs), the true ETG may be higher still. 
8.3.9 Traditional treatment for epilepsy 
Data on the use of traditional healers and traditional treatments were available from 276 
(94.8%) of 291 cases of whom 133 (48.2%) reported having used traditional treatment of 
some description.  Of the thirty-nine cases who denied having previously sought medical 
help for their seizures, twenty-two (64.7%) said they had used traditional treatment.  Of 
the 133 cases who had attended traditional healers, ninety (67.7%) were able to recall 
details of the diagnosis they had been given: no diagnosis was given in thirty-three cases 
(36.7%), a supernatural explanation for the seizures was used in twenty-three cases 
(25.6%), thirteen cases (14.4%) were diagnosed as ‘degedege’, and ten cases (11.1%) were 
diagnosed as ‘kifafa’.  A further eleven cases (12.2%) described a range of other 
explanations relating to physical or emotional causes.  Of the 121 cases who answered a 
question on their opinion of the efficacy of traditional treatment, 106 (87.6%) said that 
they had derived no benefit from their treatment.  Eighty-five people provided an 
estimate of the total they or their family had spent on traditional treatment, and this was 
often considerable: twenty (23.5%) cases claimed to have spent in excess of 100,000 
Tanzanian shillings, with one individual claiming to have spent over two million Tanzanian 
Shillings (c.700 GBP/1,500 USD).  Modes of treatment employed by traditional healers that 
we encountered included inhalations, purgatives, wearing of amulets and talismen, 









8.3.10 Analyses of treatment groups: presentation to medical services 
Univariable analyses were performed to identify demographic, clinical and social 
predictors of ever having presented to medical services (Table 95).  Cases who were less 
likely to have presented to medical services previously were those who were Muslim (OR 
0.20, 95% CI 0.20 to 0.90; p=0.023), and cases who drank alcohol (OR 0.36, 95% CI 0.17 to 
0.77; p=0.006); cases who had completed their primary education, compared with those 
with either no or incomplete primary education, were more likely to have presented to 
medical services (OR 2.89, 95% CI 1.28 to 6.53; p=0.008).  No other significant uni-variable 
associations with presentation to medical services were identified. 
A binary logistic regression model was constructed to further examine the influence of 
these predictors and to look for any confounding effects.  The adjusted ORs for all 
variables entered into the model are summarised in Table 96, and the final model is 
summarised in Table 97.  Of note, the positive association with having completed primary 
education was replicated in the final model (OR 2.55, 95% CI 1.09 to 5.98; p=0.032), as 
was the negative association with drinking alcohol (OR 0.32 95% CI 0.13 to 0.80; p=0.014).  
In addition, two further associations with seeking medical treatment were suggested by 
the final model: a positive association with the presence of an aura as part of the seizure 
manifestation (OR 2.83, 95% CI 1.12 to 7.12; p=0.028), and a negative association with the 
use of traditional medicine (OR 0.36, 95% CI 0.16 to 0.85; p=0.020).  Thirty-six (12.4%) of 
291 cases were excluded from the regression analysis due to missing data. 
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Variable OR 95% CI p-value 
Demographic features 
Male sex 0.71 0.36 to 1.43 0.334 
Tribe other than Chagga 0.79 0.34 to 1.85 0.583 
Muslim religion (vs. Christian) 0.43 0.20 to 0.90 0.023 
Cases identified via screening (vs. Key Informants) 1.09 0.51 to 2.31 0.829 
Clinical associations 
Seizure-associated injuries 1.13 0.41 to 3.11 0.818 
Cognitive impairment present 0.81 0.39 to 1.67 0.568 
Motor impairment present 0.59 0.26 to 1.34 0.200 
Family history of epilepsy 0.93 0.39 to 2.25 0.876 
Aura present 2.05 0.96 to 4.41 0.061 
Automatisms present 0.98 0.44 to 2.19 0.961 
Daytime seizures (vs. nocturnal only) 1.70 0.75 to 3.87 0.200 
Social factors 
Any education (vs. no education) 1.38 0.58 to 3.27 0.466 
Completed 1o education (vs. none/incomplete) 2.89 1.28 to 6.53 0.008 
Literate 1.21 0.58 to 2.53 0.612 
Use of traditional treatment/healers 0.49 0.23 to 1.04 0.058 
Drinks alcohol 0.36 0.17 to 0.77 0.006 





B S.E. Sig. Adj. OR* 
95% C.I. 
Variable Lower Upper 
Demographic features       
Male sex 0.00 0.45 1.000 1.00 0.42 2.41 
Tribe other than Chagga 0.04 0.63 0.953 1.04 0.30 3.55 
Muslim religion (vs. Christian) -0.87 0.55 0.112 0.42 0.14 1.23 
Cases identified via screening (vs. Key Informants) 0.41 0.47 0.387 1.51 0.60 3.82 
Clinical associations       
Seizure-related injuries 0.58 0.65 0.369 1.79 0.50 6.33 
Cognitive impairment present 0.16 0.61 0.790 1.18 0.36 3.90 
Motor impairment present -1.02 0.64 0.109 0.36 0.10 1.25 
Family history of epilepsy -0.18 0.57 0.757 0.84 0.27 2.56 
Aura present 1.24 0.53 0.020 3.47 1.22 9.85 
Automatisms present -0.06 0.53 0.905 0.94 0.33 2.66 
Daytime seizures (vs. nocturnal only) 0.31 0.57 0.588 1.37 0.44 4.20 
Social factors       
Any education (vs. no education) -0.19 0.64 0.767 0.83 0.24 2.91 
Completed 1
o
 education (vs. none/incomplete) 1.48 0.61 0.015 4.39 1.33 14.54 
Literate -0.91 0.69 0.183 0.40 0.11 1.54 
Traditional treatment/healers -0.99 0.47 0.034 0.37 0.15 0.93 
Drinks alcohol -1.19 0.53 0.026 0.30 0.11 0.87 
*adjusted for variables in Table 95 





B S.E. Sig. Adj. OR* 
95% C.I. 
Variable Lower Upper 
Drinks alcohol -1.13 0.46 0.014 0.32 0.13 0.80 
Completed primary education (vs. none/incomplete) 0.94 0.44 0.032 2.55 1.09 5.98 
Aura present 1.04 0.47 0.028 2.83 1.12 7.12 
Use of traditional treatment/healers -1.01 0.44 0.020 0.36 0.16 0.85 
Goodness of fit (Hosmer & Lemeshow)=0.87 *adjusted for variables in Table 95 




8.3.11 Analysis of treatment groups: cases remaining under follow-up 
The same set of uni-variable predictor variables were used to compare cases who had 
previously presented to medical services and remained under follow-up at the time of the 
study (n=174) with those who were no longer under follow-up (n=79).  Within these two 
groups the cases who were less likely to remain under follow-up were males (OR 0.56, 
95% CI 0.32 to 0.96; p=0.035) and those who drank alcohol (OR 0.26, 95% CI 0.13 to 0.53; 
p<0.001); cases with any level of education compared with non were more likely to 
remain under follow-up (OR 2.62, 95% CI 1.38 to 4.99; p=0.003).  An additional variable of 
whether patients recalled having previously being given a diagnosis consistent with 
epilepsy was also included for these groups, and this was also positively associated with 
remaining under follow-up (OR 2.58, 95% CI 1.42 to 4.69; p=0.002).  All variables examined 
are summarised in Table 98. 
A binary logistic regression model was again used to examine for any confounding effects, 
and initial and final models are summarised in Table 99 and Table 100.  In the final model 
two protective factors were reproduced as significant associations: ever having received a 
diagnosis of epilepsy (OR 3.09, 95% CI 1.56 to 6.15; p=0.001) and having any level of 
education (OR 2.46, 95% CI 1.20 to 5.05; p=0.014).  The negative association with alcohol 
use was also retained (OR 0.32, 95% CI 0.15 to 0.68; p=0.004), although the negative 
association with being male was not.  Twenty-nine (11.5%) of 253 cases who had ever 
presented to medical services were excluded from regression analysis due to missing data. 
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Variable OR 95% CI p-value 
Demographic features 
Male sex 0.56 0.32 to 0.96 0.035 
Tribal group other than Chagga 0.91 0.46 to 1.81 0.787 
Muslim religion (vs. Christian) 0.81 0.41 to 1.60 0.540 
Patients identified by screening (vs. Key Informants) 1.04 0.56 to 1.89 0.890 
Clinical associations 
Seizure-associated injuries 0.64 0.26 to 1.56 0.320 
Cognitive impairment present 0.73 0.41 to 1.30 0.287 
Motor impairment present 0.60 0.30 to 1.21 0.151 
Family history of epilepsy 1.26 0.61 to 2.60 0.534 
Aura present 1.11 0.65 to 1.91 0.698 
Automatisms present 0.85 0.46 to 1.58 0.613 
Daytime seizures (vs. nocturnal only) 0.98 0.47 to 2.04 0.947 
Diagnosis of epilepsy given previously 2.58 1.42 to 4.69 0.002 
Social factors 
Any education (vs. no education) 2.62 1.38 to 4.99 0.003 
Completed 1
o
 education (vs. none/incomplete) 1.43 0.83 to 2.48 0.196 
Literate 1.19 0.69 to 2.04 0.534 
Use of traditional treatment/healers 1.17 0.68 to 2.02 0.573 
Drinks alcohol 0.26 0.13 to 0.53 <0.001 








Male sex 0.56 0.34 0.095 0.57 0.29 1.10 
Tribal group other than Chagga 0.04 0.45 0.931 0.96 0.40 2.33 
Muslim religion (vs. Christian) 0.46 0.44 0.303 0.63 0.27 1.51 
Cases identified by screening (vs. KIs) 0.20 0.37 0.601 1.22 0.59 2.52 
Clinical associations 
Seizure-related injuries 0.21 0.53 0.698 0.81 0.29 2.30 
Cognitive impairment present 0.25 0.45 0.587 0.78 0.32 1.89 
Motor impairment present 0.30 0.49 0.543 0.74 0.29 1.93 
Family history of epilepsy 0.71 0.47 0.130 2.03 0.81 5.04 
Aura present 0.14 0.36 0.770 1.11 0.55 2.23 
Automatisms present 0.24 0.39 0.538 0.79 0.36 1.70 
Daytime seizures (vs. nocturnal only) 0.49 0.51 0.338 0.62 0.23 1.66 
Diagnosis of epilepsy given previously 1.15 0.38 0.002 3.15 1.51 6.57 
Social factors 
Any education (vs. no education) 0.86 0.53 0.104 2.37 0.84 6.69 
Completed 1
o
 education (vs. none) 0.14 0.47 0.764 1.15 0.46 2.88 
Literate 0.32 0.51 0.532 0.73 0.27 1.97 
Use of traditional treatment/healers 0.11 0.34 0.755 0.90 0.47 1.74 
Drinks alcohol 1.14 0.42 0.007 0.32 0.14 0.73 
*adjusted for variable in Table 98 




Variable B S.E. Sig. Adj. OR* 
95% C.I. 
Lower Upper 
Diagnosis of epilepsy previously 1.13 0.35 0.001 3.09 1.56 6.15 
Any education (vs. none) 0.90 0.37 0.014 2.46 1.20 5.05 
Drinks alcohol -1.16 0.40 0.004 0.32 0.15 0.68 
Goodeness of fit (Hosmer & Lemeshow)=0.75 *adjusted for variable in Table 98 




Although we estimate the ETG in adult PWE living in Hai to be approaching 70%, we also 
found that a larger proportion (nearly 90%) had previously presented to local health 
services for advice and treatment at some point.  Cases more likely to present to medical 
services were those who had completed primary education and those experiencing an 
identifiable aura or prodrome prior to their seizures.  Conversely, cases who drank alcohol 
or who had also used traditional healers were less likely to have presented previously.  
While being Muslim, compared with being Christian, correlated with a reduced likelihood 
of seeking medical treatment on uni-variable analysis, this predictor did not appear in the 
final regression model.  Of these factors, lack of education and alcohol use could be 
interpreted either as socio-economic markers that may predict a lower level of 
engagement with services in general, or may be factors that are present more frequently 
as the result of having untreated epilepsy. 
Our findings contrast with those of an in-depth cross-sectional study of the risk factors 
associated with the ETG in 673 PWE in Kilifi, Kenya (Mbuba et al., 2012b).  In this study 
epilepsy-specific factors that were associated with failure to seek treatment were duration 
of epilepsy of ten years or more and the presence of focal-onset seizures, usually with 
secondary generalisation.  The authors postulate that PWE with a long duration of 
epilepsy may have learned to cope with their condition, and that the prodromal 
awareness associated with focal-onset seizures may have made people less likely to seek 
treatment because of stigma.  In Hai there was no association between duration of 
epilepsy and treatment-seeking, and we found that awareness of an aura or prodrome 
was positively associated with seeking treatment.  It is interesting to note that in the 
Kenyan study, holding traditional religious beliefs as opposed to being either Christian or 
Muslim was also associated with failure to seek treatment.  In Hai the only religious 
groups identified on open questioning were Christian and Muslim, with no individuals 
describing themselves as belonging to traditional religions.  It may be that this points to a 
more modern social milieu, in which stigma may be less prominent than in more 
traditional societies, which may in turn moderate the influence of epilepsy-specific factors 
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such as those identified in Kilifi on treatment-seeking behaviours.  Elsewhere in Tanzania, 
both supernatural and more scientific ideas about the causes of epilepsy seem to coexist 
among PWE and their communities (Winkler et al., 2010b), while in Zambia it has been 
identified that PWE are disadvantaged with regards to social and economic matters, and 
social stigma, isolation and lack of knowledge about epilepsy contribute to the fact that 
only a minority of PWE access health facilities (Birbeck, 2000a, Birbeck et al., 2007).  It has 
been proposed that while quantitative approaches such as those employed here may 
identify associations with treatment-seeking behaviour, any deeper understanding of the 
complex influences on the decision to seek care for epilepsy in sub-Saharan communities 
will need to employ broader ethnographic approaches, taking into account not just 
patient- and resource-related factors, but also considering treatment providers and the 
communities in which they work (Kendall-Taylor et al., 2009).  Such an approach would 
certainly seem warranted in Hai, where use of traditional healers is a predictor of not 
seeking biomedical treatment, which mirrors findings from contemporaneous populations 
in Kilifi in Kenya as well as elsewhere in Tanzania (Winkler et al., 2010b, Mbuba et al., 
2012b). 
Among PWE who had previously presented to medical services there was considerable 
attrition from follow-up, with less than 60% of these cases being in regular contact with 
treatment services at the time of the study.  We have shown that receiving a diagnosis of 
epilepsy is a protective factor in terms of remaining under follow-up, suggesting that 
education about epilepsy on the part of both health workers and PWE is a contributory 
factor to defaulting from follow-up; this is a potentially modifiable barrier to treatment, 
but one which must be seen in the context of the general absence of specialist 
neurologists in LMICs (WHO, 2005).  It has been suggested that interventions at a local 
level should address the training of health care workers to diagnose and manage epilepsy, 
to counsel PWE about their diagnoses, and to make appropriate referrals (Mbuba and 
Newton, 2009), and such interventions have been shown to be efficacious in improving 
the diagnosis and management of epilepsy in communities in India, Zimbabwe and 
Ethiopia (Adamolekun et al., 1999, Gourie-Devi et al., 2003, Berhanu et al., 2009).  In Hai, 
where nearly one third of PWE that initially present to treatment services are not 
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retained, targeted educational interventions would also be appropriate.  This suggestion is 
further supported by evidence of plurality of treatment seeking behaviour, with 42.5% of 
those cases initially presenting to services attending two or more different service 
providers while seeking a diagnosis, implying that treatment approaches and availability 
are not uniform among the health facilities in the district. 
With regards to patient factors, presentation to services from the time of onset of seizures 
was delayed by two years or more in nearly half of all those who had previously presented 
(48.4%).  Reasons for this are likely to be multi-factorial and educational interventions 
directly targeting PWE, their carers and their communities to increase awareness and to 
reduce stigma are therefore also warranted.  Support groups for PWE are found in many 
countries, including Tanzania (Mental Health Association of Tanzania, 2012), and 
community-based programmes in African countries that have aimed to increase levels of 
treatment for PWE through education as well as drug supply have reported success, albeit 
contingent on external support and funding (Feksi et al., 1991, Watts, 1989, Berhanu et 
al., 2009). 
The ETG in the Hai population, based on reported use of adequate and appropriate AED 
therapy, was 68.4% (95% CI 63.0 to 73.7).  This is lower than previous estimates of the ETG 
in Tanzania of between 76% and 95.8% (Winkler et al., 2009c, Dent et al., 2005), although 
is in line with more recent systematic reviews of ETG in developing countries worldwide 
(Mbuba et al., 2008, Meyer et al., 2010).  The lower ETG in Hai may be due its proximity to 
the large towns of Arusha and Moshi, where numerous private clinics and non-
governmental healthcare providers are located, and also to a large referral hospital 
(KCMC), where there is a practicing neurologist.  Conversely, we know that there is a high 
degree of stigma associated with epilepsy in this population (Mushi et al., 2010), and more 
stigmatised or marginalised individuals may not have presented to the study.  It can be 
assumed that such individuals would be less likely to be treated, and would therefore 
contribute to the estimate of ETG if they were known. 
The utility of self-reporting in estimating the ETG has recently been called into doubt by a 
study from Kenya (Mbuba et al., 2012b).  The overall concordance between self-reported 
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adherence and detection in blood for the three AEDs known to be prescribed in the study 
population was only 55%, with reported adherence having a sensitivity of only 38.1% and 
specificity of 80.8% when verified through detection of AEDs in blood.  This would suggest 
by extrapolation that the true ETG in Hai may be lower than our estimate of 68.6%.  In our 
cohort, however, a low rate of seizure-freedom was observed, being reported in only 
11.6% of treated cases.  In cases with uncontrolled seizures 68.9% reported seizures on at 
least a monthly basis and 31.9% on a weekly basis.  Retrospective reporting of seizure 
frequency at up to two months has been shown to be consistent between patients and 
carers (Wiebe, 2000), and these rates of high seizure frequency among PWE in Hai would 
suggest that the true level of adequate treatment may be much lower, and the true ETG 
therefore higher. 
Phenobarbital was the most commonly prescribed AED, being used by 78% of all treated 
cases.  The majority of cases using AEDs (84.3%) did not report any side-effects, and none 
complained of serious side-effects leading to withdrawal of treatment.  This finding 
corresponds with observational studies conducted in resource-poor settings, including 
SSA, which have consistently demonstrated efficacy and tolerability of PB in everyday 
clinical use (Nimaga et al., 2002, Feksi et al., 1991, Sykes, 2002).  The Hai cohort is now 
under follow-up, allowing for prospective evaluation of treatment outcomes, including 
adherence, tolerability and efficacy. 
Finally, nearly half (48.2%) of all PWE reported that they had used traditional medicines or 
healers for their epilepsy.  The use of traditional healers has been identified in a number 
of studies examining access to treatment for epilepsy in LMICs, including SSA.  Their 
influence remains uncertain, with some data suggesting that access to a traditional healer 
is a positive predictor of subsequent of concurrent access to biomedical treatment (Quet 
et al., 2011), while observational data have cited a preference for traditional healers as a 
reason for not attending an epilepsy clinic (Berhanu et al., 2009).  In Hai attendance at a 
traditional healer was associated with a reduced likelihood of presenting to biomedical 
services (OR 0.44; 95% CI 0.16 to 0.85).  What is clear is that traditional healers will 
provide culturally acceptable explanations for seizures, and may represent a source of 
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psycho-social support for PWE and their families that is embedded in the community 
(Baskind and Birbeck, 2005a, Winkler et al., 2010b, Kendall-Taylor et al., 2009).  
Intervention strategies that incorporate this group of individuals represent an enticing but 
challenging prospect (Mbuba and Newton, 2009). 
8.5 Summary and conclusions 
The ETG in adult PWE living in the HDSS is in line with estimates from other countries in 
SSA, and in LMICs in general.  A combination of clinical, socio-economic and cultural 
factors are associated with the likelihood of seeking treatment.  Presentation to medical 
services is delayed by two years or more in a considerable proportion of patients, and 
interventions to increase awareness and reduce stigma may serve to encourage PWE to 
seek treatment sooner.  Having presented to services, retention under follow-up is 
correlated with a higher educational level of the patient and with having received a 
diagnosis of epilepsy.  This latter factor is potentially modifiable through educational 
interventions targeting healthcare workers.  PB is widely available, is the most commonly 
prescribed drug locally, and appears to be well tolerated in this patient group. 
In conclusion, we suggest that low-cost educational interventions targeting both patients 
and health care workers would serve to reduce the ETG in the HDSS and without recourse 
to additional external human or material resources.  Such efforts should be informed by 
detailed and nuanced characterisation of the various factors influencing treatment 
seeking and delivery of care for PWE in this population.  Having established a well-
characterised prevalent cohort of adult PWE to which we have access for the purposes of 
clinical follow-up and further study, we are now in a position to pursue these ends.  A 
deeper understanding of these issues in the HDSS population will serve to benefit PWE 
locally as well as elewhere in Tanzania, and in SSA in general. 
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Chapter 9.  Summary and recommendations 
9.1 Introduction 
The data presented here are derived from one of the largest community-based 
epidemiological studies of epilepsy to be conducted in SSA to date and the largest to date 
in Tanzania.  It is also one of only a handful of studies from SSA to correlate clinical data 
with investigation findings in the context of a cross-sectional prevalent cohort of patients.  
As such, we hope that these findings will provide valuable insights to those involved in the 
care of PWE and to those planning further epidemiological, clinical or operational research 
of epilepsy in this region. 
The size of the study coupled with limitations in human and material resources meant that 
a number of pragmatic decisions were taken as field work progressed that are reflected in 
the scope and strength of some of the final data. 
9.2 Pilot study and screening questionnaire 
The chief limitations of the pre-census pilot work were the small numbers included and 
the paucity of clinical information available regarding epilepsy cases included in the pilot.  
Accepting this, the screening questionnaire as a whole had a sensitivity of 100% and a 
specificity of 54.5%.  The reason that this apparently low specificity did not lead to a much 
higher response rate to census-based screening in the Hai population is not clear, and 
further investigation of this would be informative for any future work seeking to replicate 
the methods used here. 
Due to limited time and resources, no larger field-based validation was possible prior to 
the population census and screening.  Such an exercise would have allowed us to further 
explore the performance and utility of the screening questionnaire which in turn would 
have allowed for more precision during analysis of and adjustment of the final prevalence 
estimates.  Field-based validation would also have allowed us to test the utility of 
statistical modelling of a reduced number of questions that suggested a sensitivity of 
100% while maintaining a specificity of 86.4%.  As it stood, however, prior to the census 
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we were confident that the screening instrument was sensitive and culturally acceptable 
within our study population.  We hope that the post-hoc analysis of how the screening 
questionnaire performed in the field will be of value in the design and planning of any 
further community-based surveys of epilepsy in SSA, particularly in a Kiswahili-speaking 
population.  Future work may also benefit from further exploration of the screening 
instrument in a given social context by way of psychometric and linguistic methods to 
provide measures of internal consistency and construct validity. 
9.3 Prevalence and nature of epilepsy in Hai 
Only epilepsy with convulsive seizures was detected during this study, and while this 
renders strict comparisons with studies that have reported on all epilepsy types difficult, 
active convulsive epilepsy would appear to have a lower prevalence in this part of 
Tanzania than elsewhere in SSA.  We suggest that this should be interpreted as indicating 
that previously reported high prevalence rates for epilepsy in SSA cannot be generalised, 
either within Tanzania, or to the region as a whole.  Recent large scale multi-site studies 
that have been published since the completion of the research presented here support 
this assertion, having found considerable variation in prevalence in different regions that 
cannot be ascribed to methodology alone (Ngugi et al., 2013b).  It should be stressed that 
these studies have pragmatically chosen from the outset to screen only for active 
convulsive epilepsy, recognising the difficulties inherent in detecting other seizure types in 
community-based screening studies. 
The high proportion of focal-onset epilepsy among people with ACE living in the HDSS is 
suggestive of a considerable burden of acquired brain pathology in this patient 
population.  Aetiological factors or associations suggested by this study include perinatal 
complications and febrile seizures in childhood: findings which are consistent with 
contemporary and historical studies from elsewhere in SSA.  Neurocysticercosis, while 
present in this population, does not appear to represent a major aetiological burden with 
regards to epilepsy.  The role of family history is unclear, that of HIV is unknown, and both 
warrant further investigation. 
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The prevalence of absence seizures or of focal seizures associated with pure motor activity 
or sensory phenomena only, without secondary generalisation, remains unknown in this 
population.  While further study of these clinical entities is warranted, our experience 
suggests that alternative methodologies should be used, and any community-based 
screening approaches to this problem should be developed and piloted on a smaller scale, 
with complete case ascertainment within a sampling frame rather than a population-wide 
approach.  This would echo the original development work behind the screening 
questionnaire used here, performed in Ecuador in the 1980s (Placencia et al., 1992a, 
Placencia et al., 1992d). 
The contribution of dissociative or non-epileptic attacks to our prevalence estimate is also 
unclear.  While we have validated our case-finding as best we can, it may be that answers 
to this question emerge as the cohort is followed up prospectively.  While this entity is 
known to account for up to 15% of cases of apparently refractory epilepsy seen in clinic 
settings in HICs (Devinsky, 1999), there are presently no data of which we are aware 
specifically examining this issue in an African setting. 
The findings of febrile seizures, perinatal complications and evidence of structural brain 
disease as predictors of epilepsy in the Hai population point to a considerable burden of 
acquired epilepsy.  By implication, improvements in obstetric care and in the recognition 
and management of febrile seizures in childhood in this population may lead to a 





Cysticercosis and NCC appear to be present in Hai, although with a low endemicity.  While 
the utility of serological testing with antibody EITB for cysticercosis is not proven in this 
epidemiological context, the presence of NCC needs to be considered in the assessment 
and management of any individual presenting with new-onset epilepsy or seizures, 
particularly in adulthood. The conditions for the ongoing transmission of human and 
porcine cysticercosis appear to be present in the district, although few households keep 
pigs, and these are generally not free-ranging.  Although these aspects have not been 
formally studied here, a clear understanding of the social and environmental factors that 
distinguish Hai from other areas of Tanzania and SSA where NCC is more highly endemic 
may help to target public health initiatives to reduce the burden of acquired epilepsy. 
9.5 The social burden of epilepsy in Hai 
Epilepsy is associated with adverse socio-economic outcomes in Hai, indicating that the 
burden of epilepsy extends beyond the morbidity and costs associated with the medical 
aspects of the disease.  These aspects should be further explored through more detailed 
comparison with a control population without epilepsy, utilising appropriate techniques 
such as psychometric measures and focus-group discussions.  The degree to which 
reduced educational attainment and economic productivity pertains to the physical 
burden of disease or to enacted stigma also warrants further investigation. 
Over one quarter of PWE living in Hai have suffered burns as a result of their epilepsy, and 





The ETG in adult PWE living in the HDSS is in line with estimates from other countries in 
SSA, and in LMICs in general.  A combination of clinical and socio-economic and cultural 
factors appear to be associated with the likelihood of seeking treatment.  Presentation to 
medical services is delayed by two years or more in a considerable proportion of patients 
and interventions to increase awareness and reduce stigma may serve to encourage PWE 
to seek treatment sooner.  Having presented to services, retention under follow-up 
appears to correlate with educational level of the patient and with having received a 
diagnosis of epilepsy.  This latter factor is potentially modifiable through educational 
interventions targeting healthcare workers.  While phenobarbitone is widely available, is 
the most commonly prescribed drug locally, and appears to be well tolerated in this 
patient group, recent systematic work suggests that this and other AEDs remain in limited 
supply and at increased cost in LMICs, including Tanzania (Cameron et al., 2012). 
9.6 Conclusions 
W suggest that low-cost educational interventions targeting both patients and health care 
workers would serve to reduce the ETG in the HDSS without recourse to additional 
external human or material resources.  Such efforts should be informed by detailed and 
nuanced characterisation of the various factors influencing treatment seeking and delivery 
of care for PWE in this population, utilising both quantitative and qualitative techniques.  
Having established a well-characterised prevalent cohort of adult PWE to which we have 
access for the purposes of clinical follow-up and further study, we are now in a position to 
pursue these ends.  A deeper understanding of these issues in the HDSS population will 












Appendix II: Patient information leaflets and consent forms 
(English and Kiswahili) 
 
Study of epilepsy in the Hai District, Kilimanjaro – patient information 
You have been invited to take part in a research project studying people with epilepsy in the Hai district.  Before you decide, it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read this information carefully, and to discuss it with 
your friends and relatives.  Please ask us if there is anything that is not clear, or if you would like more information. 
What is the purpose of the research and what will it involve? 
There have been many studies throughout the world to see how common epilepsy is.  It is thought that it may be more common in sub-Saharan 
Africa, including Tanzania, than in other parts of the world.  This is not certain, however, and more information is needed.  What we do know is 
that there are good treatments for epilepsy, but that many people who have the condition do not know about it, or are not getting any treatment.  
We hope that by carrying out this study there will be direct benefits to people with epilepsy in the Hai District.  
Why have I been chosen? 
You have been chosen because you live in Hai, and because you have epilepsy. 
Do I have to take part? 
It is your choice whether to take part.  If you do decide to, we will ask you to sign a consent form, although you will still  be free to withdraw at any 
time and without giving a reason.  If you do not want to take part in the study, the research team will still be happy to offer you advice on how to 
manage your condition. 
What will happen to me if I take part? 
You will be asked questions by the research doctor about your medical history, occupation, etc.  The doctor will then carry out a physical 
examination, which may include having a trace of your heart beat made with wires that are attached to your chest with sticky pads (ECG).  This is 
not dangerous and it does not hurt.  You will also be invited to come to Kilimanjaro Christian Medical Centre in Moshi to undergo a CT head scan 
(special X-ray), and a recording of your brain’s electrical activity (EEG).  This is a little like an ECG, except the wires are attached to your head using 
tape.  It does not hurt, is completely safe, and takes around 15 minutes.  The study will pay for all the transport costs and hospital costs.  We will 
also take a blood sample from you that will be analysed to see if you have been exposed to infections that may cause epilepsy.  The sample will 
also be stored to be analysed in the future as part of a study to look at how epilepsy might be inherited. 
A file will be opened at the hospital under your name if you do not have one already, and you will be able to use this at any time in the future, 
should you need to.  The results of all these tests will be stored in your hospital file. 








































































Appendix IX: Epilepsy screening questionnaire 
 
1.  Have you ever had attacks of shaking of the arms or legs which you could not control?  
Je, ulishawahi kupatwa na hali ya kutetemeka mikono au miguu, ghafla bila sababu yeyote, 
ambayo hukuweza kuizuia? 
2.  Have you ever had attacks in which you fall suddenly, without any reason, changing colour in 
the palms, lips or face?  
Je, ulishawahi kupatwa na hali ambayo ilikufanya uanguke, ghafla bila sababu yeyote, kubadilika 
rangi na kuwa mweupe kwenye viganja, midomo na usoni?? 
3.  Have you ever lost consciousness? 
Je, ulishawahi kupoteza fahamu? 
4.  Have you ever had attacks in which you fall with loss of consciousness?  
Je, ulishawahi kupatwa na hali ambayo ilisababisha uanguke na kupoteza fahamu, ghafla bila 
sababu yeyote? 
5.  Have you ever had attacks in which you fall and bite your tongue?  
Je, ulishawahi kupatwa na hali iliyokusababisha uanguke ghafla bila sababu yeyote, na 
kuuma/kung’ata ulimi wako? 
6.  Have you ever had attacks in which you fall and lose control of your bladder?  
Je, ulishawahi kupatwa na hali ambayo ilikufanya uanguke ghafla bila sababu yeyote na kutoa 
mkojo? 
7.  Have you ever had brief attacks of shaking or trembling in one arm or leg or in the face?  
Je, ulishawahi kupatwa na hali ya muda mfupi ya kutetemeka au kutikisika mkono au mguu 
mmoja au kwenye uso? 
8. Have you ever had attacks in which you lose contact with the surroundings and experience 
abnormal smells?  
Je, ulishawahi kupatwa na hali ambayo ilikufanya upoteze ufahamu wa mahali ulipo na kusikia 
harufu zisizo za kawaida?  
9.  Have you ever been told that you have or have had epilepsy or epileptic fits?  
Je, ulishawahi kuelezwa kuwa una au ulishawahi kuwa na kifafa au kuanguka kifafa, au 
degedege, au kiumangungu? 
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Appendix X: Geographic distribution of cases and case finding (by village) 
 



















Bomang’ombe Umasaini Masama Masama Kusini Urban 7004 6.8 19.8 16 0.81 2.83 
Foo Upland Machame Machame Kaskazini Rural 2699 2.6 7.6 7 0.92 2.59 
Isuki Upland Masama Masama Magharibi Rural 1195 1.2 3.4 1 0.29 0.84 
Kawaya Umasaini Masama Masama Kusini Rural 1570 1.5 4.4 2 0.45 2.80 
KIA Lowland Masama Masama Kusini Rural 923 0.9 2.6 1 0.38 2.82 
Kikavu Chini Lowland Lyamungo Lyamungo Machame Kusini Rural 2197 2.1 6.2 8 1.29 2.82 
Kilanya Upland Lyamungo Machame Mashariki Rural 1175 1.1 3.3 3 0.91 2.55 
Kimashuku Lowland Lyamungo Lyamungo Machame Kusini Urban 1761 1.7 5 1 0.2 2.84 
Kware Lowland Masama Masama Kusini Rural 2164 2.1 6.1 6 0.98 2.82 
Kwasadala Lowland Masama Masama Kusini Urban 2090 2 5.9 15 2.55 2.82 
Kwatito Lowland Lyamungo Lyamungo Machame Kusini Urban 667 0.7 1.9 1 0.53 2.85 
Kyeeri Upland Machame Machame Magharibi Rural 1963 1.9 5.5 1 0.18 0.51 
Kyuu Upland Masama Masama Magharibi Rural 1162 1.1 3.3 7 2.12 6.02 
Lemira Kati Lowland Masama Masama Magharibi Rural 1079 1.1 3 2 0.66 2.78 
Lengoi Lowland Lyamungo Lyamungo Machame Kusini Rural 1134 1.1 3.2 6 1.88 2.82 























Lukani Upland Masama Masama Magharibi Rural 865 0.8 2.4 4 1.67 4.62 
Lyamungo  Kati Upland Lyamungo Machame Mashariki Rural 1514 1.5 4.3 0 0 0.00 
Lyamungo Side Upland Lyamungo Machame Mashariki Rural 1328 1.3 3.7 3 0.81 2.26 
Mamba Upland Machame Machame Uroki Rural 1349 1.3 3.8 3 0.79 2.22 
Mashua Upland Masama Masama Magharibi Rural 1766 1.7 5 1 0.2 0.57 
Mbatakero Lowland Lyamungo Lyamungo Machame Kusini Rural 386 0.4 1.1 1 0.92 2.85 
Mboreni Upland Masama Masama Masariki Rural 889 0.9 2.5 0 0 0.00 
Mbosho Upland Masama Masama Magharibi Rural 1186 1.2 3.3 5 1.52 4.22 
Mbweera Upland Masama Masama Masariki Rural 2291 2.2 6.5 8 1.23 3.49 
Mijongweni Lowland Lyamungo Lyamungo Machame Kusini Rural 2407 2.3 6.8 3 0.44 2.83 
Mkalama Umasaini Masama Masama Kusini Rural 1787 1.7 5 3 0.6 2.80 
Mtaa Wa 
Shabaha 
Umasaini Masama Masama Kusini Rural 542 0.5 1.5 0 0 2.77 
Mtakuja Umasaini Masama Masama Kusini Rural 897 0.9 2.5 2 0.79 2.79 
Mudio Upland Masama Masama Masariki Rural 3610 3.5 10.2 8 0.78 2.22 
Mulama Upland Lyamungo Machame Mashariki Rural 1122 1.1 3.2 7 2.19 6.24 






















Muroma Upland Masama Masama Magharibi Rural 1260 1.2 3.6 1 0.28 0.79 
Ng’ira Upland Masama Masama Masariki Rural 1486 1.4 4.2 4 0.95 2.83 
Ng’uni Upland Masama Masama Magharibi Rural 1607 1.6 4.5 6 1.33 3.73 
Ngosero Lowland Lyamungo Lyamungo Machame Kusini Rural 534 0.5 1.5 0 0 0.00 
Nkuu Ndoo Upland Lyamungo Machame Mashariki Rural 1363 1.3 3.8 3 0.79 2.20 
Nkuu Sinde Upland Lyamungo Machame Mashariki Rural 1457 1.4 4.1 2 0.49 1.37 
Nkwansera Upland Masama Masama Magharibi Rural 1409 1.4 4 4 1 2.84 
Nronga Upland Machame Machame Magharibi Rural 1593 1.6 4.5 9 2 5.65 
Nshara Upland Machame Machame Kaskazini Rural 5153 5 14.5 15 1.03 2.91 
Nkuu Ndoo Upland Lyamungo Machame Mashariki Rural 1363 1.3 3.8 3 0.79 2.20 
Nkuu Sinde Upland Lyamungo Machame Mashariki Rural 1457 1.4 4.1 2 0.49 1.37 
Nkwansera Upland Masama Masama Magharibi Rural 1409 1.4 4 4 1 2.84 
Nronga Upland Machame Machame Magharibi Rural 1593 1.6 4.5 9 2 5.65 
Nshara Upland Machame Machame Kaskazini Rural 5153 5 14.5 15 1.03 2.91 
Roo Upland Masama Masama Masariki Rural 3405 3.3 9.6 14 1.46 4.11 
Rundugai Umasaini Masama Masama Kusini Rural 4170 4.1 11.8 14 1.19 2.83 
Saawe Upland Masama Masama Masariki Rural 1722 1.7 4.9 4 0.82 2.32 






















Shari Upland Machame Machame Uroki Rural 2428 2.4 6.9 11 1.59 4.53 
Shiri Mgungani Lowland Lyamungo Lyamungo Machame Kusini Urban 1831 1.8 5.2 9 1.74 2.84 
Shiri Njoro Lowland Lyamungo Lyamungo Machame Kusini Urban 1951 1.9 5.5 10 1.82 2.82 
Sonu Upland Masama Masama Masariki Rural 1991 1.9 5.6 5 0.89 2.51 
Tella Upland Lyamungo Machame Mashariki Rural 1573 1.5 4.4 6 1.36 3.81 
Tindigani Umasaini Masama Masama Kusini Rural 644 0.6 1.8 2 1.1 2.80 
Uduru Upland Machame Machame Kaskazini Rural 1488 1.4 4.2 3 0.71 2.02 
Urori Upland Lyamungo Machame Mashariki Rural 1539 1.5 4.3 2 0.47 1.30 
Usari Upland Lyamungo Machame Mashariki Rural 1323 1.3 3.7 3 0.81 2.27 
Uswaa Upland Machame Machame Uroki Rural 2165 2.1 6.1 7 1.15 3.23 
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